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Arthritogenic alphaviruses such as Ross River virus (RRV) and chikungunya virus 
are mosquito-borne viruses that cause epidemics of debilitating myositis and polyarthritis 
in humans in various areas around the world. Studies conducted in a mouse model of RRV-
induced disease have demonstrated a critical role for the inflammatory response in the 
development of disease. In particular, the host complement system contributes significantly 
to damage within target tissues through activation of CR3-bearing inflammatory cells. 
However, the precise mechanism and ligands leading to complement activation and disease 
following RRV infection are not known. In these studies, we have identified critical roles 
for the host innate immune protein mannose binding lectin (MBL) and the viral N-linked 
glycans in mediating complement activation and disease following RRV infection.  Using 
mice deficient in MBL, we demonstrated that the MBL activation pathway of the host 
complement system is the primary pathway required for complement activation and disease 
following infection. MBL recognizes and binds to terminal carbohydrates, such as mannose 
found on glycosylated viral proteins or on infected cells. The RRV E2 envelope 
glycoprotein contains two N-linked glycosylation sites that are glycosylated with a 
combination of high mannose and complex glycans when replicating in mammalian cells. 
We hypothesized that MBL recognizes the E2 N-linked glycans to activate the complement 
system, leading to disease. Using a panel of RRV mutants lacking one or more envelope 
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glycans, we have found that the RRV E2 N-linked glycans contribute to MBL binding to 
RRV infected cells and development of disease. Viruses lacking either E2 N-linked 
glycosylation sites cause reduced disease in mice, while a virus lacking both sites causes 
very mild disease. In addition, the role of the E2 glycans is independent of replication 
within host tissues and recruitment of inflammatory cells. Rather, the E2 glycans were 
required for MBL deposition and complement activation within target tissues in vivo. 
These results suggest that interactions between the viral N-linked glycans and the MBL 
pathway play a central role in development of severe alphavirus-induced arthritis and may 
be an effective target for therapeutic treatment in patients infected with RRV.  
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Alphavirus classification.  
The alphavirus genus is part of the Togaviridae family of enveloped viruses that 
have a single stranded positive sense RNA genome. The Togavirus family is divided into 
two groups, the alphaviruses and the rubiviruses, and the family was initially named for 
their members’ cloak-like appearance under the electron microscope; the word “Toga” is 
Latin for “cloak”. To date, over forty alphaviruses have been identified, many of which 
have been associated with human disease, and can be found on all continents of the globe 
and in a wide range of hosts (78). Rubella virus is the only rubivirus to date, and is an 
important childhood human pathogen. The two genus of Togaviridae are further defined 
by their similar genomic organization with the four nonstructural genes at the 5’ end of 
the genome followed by the structural genes whose expression is driven from a 
subgenomic promoter in the latter third at the 3’ end of the genome. While alphaviruses 
and rubiviruses share similar genome organization and virion structure, they differ 
significantly in replication strategies, types of disease they cause, as well as how they are 
transmitted. Rubella virus is transmitted human to human through aerosol droplets and 
causes a flu-like disease that is characterized by an extensive rash (101), whereas 
alphaviruses are transmitted by arthropod vectors from small mammals to humans and 
are associated with arthritis/myositis or encephalitis (78).  
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Of the forty alphaviruses that have been described, twenty-nine cause human 
disease and are classified into seven distinct antigenic and genetic groups (reviewed in 
(78, 242)). These groups have been classified based on sequence similarity within the E1 
glycoprotein as well as cross-reactivity of sera and members of each complex generally 
share similar disease characteristics (175). The Semliki Forest (SF) complex includes 
many of the arthritic alphaviruses such as the namesake Semliki Forest virus (SFV), Ross 
River virus (RRV), chikungunya virus (CHIKV), and O’nyong nyong virus (ONNV). 
The VEE and EEE complexes encompasses encephalitic viruses such as Venezuelan 
equine encephalitis virus (VEEV), eastern equine encephalitis virus (EEEV), and the 
WEE antigenic complex includes viruses that are associated with both arthritic and 
encephalitic viruses such as Sindbis virus (SINV), and western equine encephalitis virus 
(WEEV). Many aspects of alphavirus biology have been elucidated using two prototype 
alphaviruses: SINV of the WEE antigenic complex and SFV of the SF antigenic complex. 
While there are some differences between these viruses and the other alphaviruses such 
as RRV and CHIKV, the basic biology of replication and structure learned in SINV and 
SFV studies applies to the replication all alphaviruses.  
Of note, alphaviruses were originally categorized with the Flaviviridae family of 
viruses as Group A and B arboviruses, respectively, based upon similarities in 
transmission and disease (125). However, once viruses from both groups were sequenced, 
it became clear that the genome organization was too different to classify them together. 
However, since the disease and transmission of alphaviruses and flaviviruses are similar, 
it has been useful to compare and contrast aspects of disease pathogenesis and interaction 
with both mosquito and mammalian host proteins between the two groups of viruses.  
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Geographic distribution and epidemics. 
Alphaviruses have a global distribution and can be found on all continents. While 
not all alphaviruses are associated with disease pathology, the ones that do cause disease 
are roughly separated into two general groups: the Old World and the New World 
alphaviruses. This grouping is based both on the type of disease associated with each 
virus and geographic location. The Old World alphaviruses are found mostly in Africa, 
Asia, and Oceania and tend to cause polyarthritis and arthralgia in humans. New World 
alphaviruses are found in the Americas and are more closely associated with encephalitis.  
The New World viruses include EEEV, WEEV, and VEEV, and cause 
encephalitis in humans and horses in various regions around the Americas. EEEV has 
been found in parts of eastern North America, as well as parts of Central America and is 
particularly virulent in humans, causing up to 70% mortality in symptomatic cases, and 
the horse fatality rate is 80-90% (42, 206). WEEV is found in western parts of the North 
America and South America, and is reportedly aerosol transmitted as well as mosquito-
borne and has a 10% human fatality rate (78, 180). VEEV has been identified in the 
tropical regions of South America and epizootic outbreaks have involved over 75, 000 
people (185).  
Old world alphaviruses, including CHIKV, RRV, SINV, and ONNV, are present 
throughout parts of Africa and Oceania and are associated with large-scale outbreaks of 
arthritis, arthralgia, myalgia, and rash. CHIKV was first isolated in modern day Tanzania, 
and is currently found throughout India, Southeast Asia, and sub-Saharan Africa, and 
most recently has been associated with epidemic in areas surrounding the Indian Ocean 
that affected upwards of 6 million people (27). ONNV has been found in regions in East 
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Africa and caused an epidemic of rash and fever involving 2 million people in 1959 (247). 
RRV is found in Oceania, and is endemic within many areas of Australia and throughout 
Papua New Guinea and the surrounding islands (86). Outbreaks of RRV-induced disease 
have occurred on coastal areas of Western Australia, in the southern states of New South 
Wales and Victoria, as well as within Papua New Guinea, Fiji, and the Cook and 
Solomon Islands affecting over 50, 000 people. SINV exhibits a broad geographic 
distribution and can be found in Northern Europe, Africa, Southeast Asia, and Oceania 
(78).  
The worldwide distribution of alphaviruses that are associated with human disease 
and the ability to cause periodic and explosive outbreaks involving millions of people 
highlight the importance of understanding how these viruses cause disease in order to 
design a vaccine, develop therapeutics, as well as develop appropriate measures to 
prevent infection and future epidemics.  
 
Transmission of alphaviruses. 
Alphaviruses are generally maintained in an enzootic cycle where the viruses 
transmit between their arthropod vectors and a reservoir host organism, usually birds, 
small mammals, or primates. The reservoir hosts vary for the different alphaviruses, but 
generally support high levels of viral replication and viremia that allow for infection of 
the competent arthropod species. The arthropods, typically mosquitoes, become 
persistently infected with the virus, and are capable of transmitting virus through their 
saliva 2-7 days after initial infection (206). Aedes and Culex species are the primary 
enzootic vectors for most alphaviruses, and certain species of Aedes such as Ae. aegypti 
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and Ae. albopictus, as well as the Anopheles mosquitoes can act as additional vectors 
during epidemics (reviewed in (242)).  
Human disease typically occurs through a spillover effect when humans come 
into contact with the infected mosquito or arthropod. Seasonal outbreaks of alphavirus-
induced disease have been noted and are well documented with RRV in Australia, and 
alphaviruses can also enter into an urban epidemic cycle where viruses can transmit 
between humans and the mosquitoes without a reservoir host. This is thought to have 
occurred in nearly every large-scale epidemic of alphavirus-induced disease.  
The factors that affect the emergence of disease to bring on an epidemic can be 
both environmental and genetic. Climatic events, such as unusually heavy rainfall, can 
alter the mosquito vector host range and bring epidemic mosquito vectors into endemic 
regions (240). Genetic changes within the virus genome also play a role in the epidemic 
potential of the virus. The evolution rate of alphaviruses is approximately 1 x 104 
bases/year, which is slower than some other RNA viruses due to the fact that alphaviruses 
are maintained in two disparate hosts (241). Alphaviruses can acquire changes in the 
genome that confer an ability to replicate within an additional mosquito vector or allow 
for more efficient replication within a host organism. Such a change was observed during 
the most recent CHIKV epidemic where a mutation in the E1 glycoprotein allowed for 
spread of the virus from an additional mosquito vector, Ae. albopictus (227).  
 
Clinical disease and pathology of arthritic alphaviruses: Ross River virus.  
Reports of seasonal epidemics of joint swelling and rashes began as early as 1928 
in Australia, but the etiological agent was not identified as RRV until about 1959 (46). 
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There had been additional epidemics noted prior to 1959 throughout the Northern 
Territory, Queensland, and Papua New Guinea during the Second World War, but it was 
not until an epidemic in Murray Valley in Southeast Australia in 1956 that researchers 
began to suspect that the disease was caused by an arbovirus. CHIKV had recently been 
associated with an outbreak of acute virus polyarthritis in Tanganyika (Tanzania) in 
Africa that shared some similarities with the Australian epidemic. The Australian patient 
sera were assayed for cross-reactivity to other group A arbovirus including SFV and 
CHIKV. While some cross-reactivity was observed, Shope and Anderson concluding that 
the outbreak in Australia was due to a yet undescribed group A arbovirus (214). Doherty 
et al then isolated a virus from a pool of trapped Aedes vigilax mosquitoes by the Ross 
River in Northern Queensland, which reacted strongly with patient sera (46). The virus 
isolated was formally named Ross River virus, and the strain isolated was dubbed T48 
(Townsville and mosquito pool 48). T48 is the type strain of RRV and is the strain used 
in the laboratory to study RRV.  
 The largest outbreak of RRV occurred in 1979-1980 when RRV spread to islands 
in the South Pacific, including Fiji, Samoa, and the Cook Islands. An estimated 50, 000 
people throughout the region were infected and presented with arthritis and/or arthralgia. 
RRV was isolated from several patients by several different research groups (1, 191, 225) 
confirming that the epidemic was associated with RRV. The sudden outbreak of infection 
in the region is thought to be due to high levels of viremia in many of the affected 
individuals evaluated (191), and RRV transmission throughout the region was likely 
sustained through a human-mosquito-human transmission cycle.  
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 Annual seasonal outbreaks of RRV-induced disease occur in Australia, most 
notably in Queensland, resulting in about 5000 reported cases of RRV-associated 
polyarthritis each year (86). Incidence of infection correlates with the presence of the 
mosquito vector and most of the infections reported occur in the late summer-early fall. 
The reservoir hosts for RRV are thought to be marsupials such as wallabies and 
kangaroos as well as fruit bats (86).  RRV has been isolated from about 42 different types 
of mosquito but is transmitted to humans primarily Ae. vigilax and Ae. camptorhynchus 
on the coast, and Culex annulirostris in the inland areas (194).  
The incubation period for RRV in humans is thought to be about 7 to 9 days 
following infection by mosquito bite (56). Joint pain and arthritis affecting the ankles, 
wrist, fingers, and knees are the most common symptom in RRV-induced disease in 
humans, and patients have also reported pain in the back, neck, and elbows (86). Myalgia 
is another common symptom reported in patients, and about half of infected patients 
develop a macropapular rash that can cover the torso and limbs. Many patients develop a 
fever, and experience fatigue and malaise that can last for several weeks to months. Less 
common symptoms of RRV-disease include headache, splenomegaly, hematuria, 
photophobia, and sore throat. The disease symptoms can generally last up to three weeks, 
with the joint pain and swelling most severe in the first week, and many patients are 
incapacitated by the debilitating pain and are unable to work during that time. 
Furthermore, many patients continue to have chronic joint pain and arthritic symptoms 
for several months after initial infection (86).  
Analysis of synovial aspirates from RRV-infected patients revealed the presence 
of inflammatory cells within affected joints. In particular, monocytes, macrophages and 
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natural killer (NK) cells were found in the synovial fluid, and the NK cells had equivalent 
cytotoxic activity as those derived from the periphery (91). Activated macrophages 
within the synovium were observed (32, 57), and subsequent studies in mouse models of 
RRV-induced disease demonstrate that the activated macrophages play a critical role in 
development of clinical disease signs (135). In contrast to other arthritic diseases where 
disease is driven in part by immune complexes with antigen, the presence of immune 
complexes was not observed within the synovium of affected joints from RRV-infected 
patients (57, 58).  
 
Clinical disease and pathology of arthritic alphaviruses: Chikungunya virus. 
Chikungunya virus (CHIKV) was first isolated from a patient in Tanganyika, 
which is present day Tanzania, in the early 1950s (188), however it is very likely that the 
epidemics of disease had occurred prior to its identification, and were mistakenly 
attributed to dengue virus (29). The word “chikungunya” means “that which bends up” in 
the Makonde language, and is thought to describe the debilitating symptoms associated 
with virus infection (188).  
 There had been periodic outbreaks of disease between the 1950s and the early 
2000s (221), but it wasn’t until a large-scale epidemic of disease that lasted from 2004 to 
2011 that public health officials and researchers recognized the virus as a significant 
public health threat. The epidemic began in 2004 in Africa and spread to neighboring 
countries and islands in the Indian Ocean. Notably, the virus infected two-thirds of the 
population of the French island La Reunion, and ultimately is estimated to have infected 
over 6 million people during the epidemic (221). While the majority of transmission 
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events occurred in the areas surrounding the Indian Ocean such as India, Sri Lanka, and 
many countries in Southeast Asia, the virus was detected in patients in over 40 countries 
around the world, including the United States and Australia (27). Importantly, sustained 
local transmission of CHIKV between residents who had not visited affected areas 
occurred in regions of Italy and France that were previously free of the virus (181), 
raising fears that the virus may be able to spread to other countries such as United States.   
 A major factor in the ability of CHIKV to re-emerge in such an explosive manner 
is thought to be due to the presence of a single mutation in the E1 glycoprotein at position 
226 (227). This mutation, a change from an alanine to a valine, allowed for more efficient 
entry and replication within an additional mosquito species, Aedes albopictus (227). 
Interestingly, a change at this same amino acid in SFV that confers cholesterol 
independence has been associated with enhanced viral fusion with mosquito cells leading 
to more efficient replication within the mosquito (4, 230). The Ae. albopictus mosquito is 
an aggressive species that lives in urban areas in close proximity to humans and has a 
worldwide distribution. Thus, a natural mutation at E1 226 that allows for efficient 
replication within Ae. albopictus has allowed CHIKV to spread rapidly throughout the 
regions where the mosquito vector was present.  
The onset of CHIKV-induced disease can occur immediately following the 
incubation period that lasts on average 2-4 days. The disease is characterized by 
polyarthritis along with severe arthralgia and myalgia affecting multiple joints, and is 
often accompanied by a high fever (19, 27, 188). Other common symptoms include 
photophobia, headaches, and a rash. The polyarthritis is a prominent feature of the 
disease and up to 95% of patients develop painful symmetrical swelling in multiple joints 
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(19). While many of the main symptoms subside about 1-2 weeks following onset, a 
subset of patients may experience chronic arthralgia for months to years (18). The basis 
for the chronic arthralgia is has been proposed to be due to viral persistence. Indeed, 
CHIKV antigen has been detected in muscle biopsies from patients up to 18 months post 
infection (100), and viral RNA is detectable within joints of mice in a mouse model of 
CHIKV infection up to 3 weeks post infection (159). Similar to RRV, the pathology of 
CHIKV is associated with inflammation into the joints and muscle. Monocytes, 
macrophages, CD4+ T cells, and high levels of NK cells are found within synovial 
aspirates from CHIKV patients (100), and elevated levels of pro-inflammatory cytokines 
such as IL-1β and IL-6 have been associated with severity of clinical disease (166).  
 
In general, the current therapies for CHIKV and RRV-induced disease as well as 
other arthritic alphavirus diseases are merely palliative. Most patients are simply 
administered nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and aspirin and 
are advised to rest and engage in physical therapy (86, 221). Given the potential long-
term treatment due to the prolonged nature of the disease, long-term use of NSAIDs is 
not ideal, and development of alternative therapeutics is needed.  
 
1.2. Molecular biology of alphaviruses.  
Genome organization and structure of alphaviruses.  
The genome of alphaviruses is encoded on a capped, positive sense RNA that is 
about 11.5kb in length with a poly adenylated tail and can be translated similar to host 
mRNA (219). The four nonstructural proteins (nsP1, nsP2, nsP3, and nsP4) are encoded 
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at the 5’ end of the genome, and once translated, make up the replicase complex that 
allows for both positive and minus strand genome synthesis. The structural proteins 
(capsid, E3, E2, 6K, and E1) that compose the virion particle are encoded on a 
subgenomic mRNA that is transcribed and translated from the minus strand genomic 
template. The alphavirus genome also has a 5’ UTR and a 3’ UTR that contain virulence 
determinants and are required for efficient genome replication and translation (59, 84, 
245).  
The structure of the alphavirus virion has been determined through cryo-electron 
microscopy (EM) and X-ray reconstructions of SFV, SINV, and CHIKV (87, 88, 133, 
162, 174, 234-236). The virion is approximately 70nm in diameter, and is composed of a 
nucleocapsid core that contains a single copy of genomic RNA, and an outer layer that is 
comprised of a lipid bi-layer derived from the host membrane and an exterior 
glycoprotein shell. The glycoprotein shell on each virion has 240 copies of E1 and E2 
that are organized into of 80 trimeric E1-E2 heterodimers, with E1 lying parallel to the 
lipid bi-layer and E2 protruding to the surface to form spikes. The E2 glycoprotein is 
thought to mediate receptor interaction on the surface of host cells and the E1 
glycoprotein mediates fusion of the virus to the host cell (113).  
 
Overview of the lifecycle of alphaviruses.  
The lifecycle of alphaviruses are outlined in Figure 1.1 and is described in detail 
in subsequent sections. Briefly, alphaviruses enter host cells through receptor-mediated 
endocytosis, and release the viral RNA genome into the cytoplasm following fusion of 
the virus membranes with host membranes in the endosome. Since the alphavirus genome 
	   12	  
is a positive sense, capped RNA, it can be immediately translated by host translational 
machinery. The nonstructural polyprotein forms the viral replicase complex, which 
mediates minus-strand RNA synthesis. From the minus-strand template, additional copies 
of positive strand RNA are generated and either translated or packaged into virions. 
Synthesis of the viral structural proteins from the subgenomic RNA leads to synthesis of 
the capsid protein, which will go on to form the nucleocapsid, and the viral glycoproteins 
are translocated into the ER and then the Golgi, where they undergo post-translational 
modification including glycosylation. The glycoproteins are cleaved in the Golgi, and are 
transported to the plasma membrane. Interactions between the viral glycoproteins and the 
nucleocapsid drive viral budding and egress from the host cell plasma membrane to the 
extracellular milieu.  
 
Entry of alphaviruses into host cells.  
Entry of alphaviruses into host cells is thought to primarily occur through 
receptor-mediated endocytosis through engagement of the alphavirus protein E2 on the 
virion with receptors and attachment factors, although direct fusion of virus with host 
membranes has been proposed (49). While several putative receptors have been identified 
for some alphaviruses, there does not appear to be any one single receptor that mediates 
entry for all alphaviruses. Rather, since alphaviruses can infect a broad range of hosts and 
cell types, the prevailing trend is that alphaviruses can use a diverse set of receptors that 
vary according to cell type and host.   
A ubiquitously expressed membrane laminin receptor was first identified as a 
putative SINV mammalian receptor into BHK-21 cells, and for VEEV into mosquito 
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cells (140, 238). However, the laminin receptor does not appear to mediate entry into all 
types of host cells, such as the chick embryo fibroblasts (238), suggesting either that 
alphaviruses can use multiple receptors or that laminin acts more as an attachment 
receptor rather than a true receptor. Additional host factors have been identified as 
attachment factors that aid entry into particular cell types. Klimstra et al. showed that 
certain members of innate immune receptors called C-type lectins (CLRs) such as DC-
SIGN and L-SIGN, mediate entry of mosquito-derived SINV into dendritic cells (120). 
The type IV α1β1 collagen receptor has been proposed to be a putative receptor for RRV 
(128), as RRV bound specifically to α1β1-coated ELISA plates. However, RRV entry 
into α1-knockout MEFs was not completely abolished, and further supports the overall 
hypothesis that alphavirus can use multiple receptors and attachment factors to gain entry 
into cells. More recently, the ubiquitously expressed divalent metal ion transporter 
NRAMP was identified as a receptor for SINV into both insect (dNRAMP) and 
mammalian cells (NRAMP2) through an RNAi screen in Drosophila cells (190). 
Interestingly, the usage of NRAMP2 was specific to SINV as RRV entry into mammalian 
cells was not dependent on NRAMP2. Thus, the alphavirus receptor is still elusive.  
Of note, heparan sulfate (HS) is also thought to be an attachment receptor for 
alphaviruses, and mutations that confer binding to HS modulate virulence in some 
alphaviruses (67, 195). Passage of alphaviruses in cell culture have led to rapid 
acquisition of mutations in E2 that can introduce basic amino acid residues and alter the 
charge of the glycoprotein, leading to an increase in positive charge within E2 and higher 
efficiency and tighter binding to HS molecules on the cell surface (121).  
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Receptor engagement induces a conformational change in E1 and E2 that allow 
for internalization into the host cell through clathrin-mediated endocytosis (43). 
Subsequent acidification of the endosome destabilizes the E2 and E1 heterodimer and 
exposes the fusion peptide on the distal end of E1 (3, 130). The fusion peptide inserts into 
the host cell membrane and leads to E1 trimerization and subsequent formation of the 
fusion pore by bringing the viral membrane and host membranes together (reviewed in 
(125)). The nucleocapsid is released into the cytoplasm, where it disassociates and 
releases the viral RNA.  Since alphavirus genomic RNA is a capped positive strand RNA, 
it can be translated directly by the host translation machinery. The nonstructural proteins 
are synthesized as a single polyprotein either as nsP123 or nsP1234. The production of 
nsP1234 is a result of read-through of the opal stop codon at the end of nsP3 that occurs 
about 10-20% of the time (219). Many alphaviruses including SINV, RRV, VEEV, 
EEEV, and WEEV contain the opal codon (219). The polyprotein P123 and the viral 
RNA dependent RNA polymerase, nsP4, acts as a replication complex to initiate minus 
strand synthesis of the viral RNA. The polyprotein is then cleaved into mature nsP1, nsP2, 
and nsP3, and these proteins, along with nsP4 can act to generate many copies of the 
positive strand viral RNA for packaging and further replication (125).  
 
Roles of the alphavirus nonstructural proteins. 
While the formal roles of most of the alphavirus nonstructural proteins (nsPs) are 
involved in some aspect of genome replication, nearly all of nsPs are likely to be 
involved modification of the host response in one way or another to modulate infection 
and viral pathogenesis.  
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The alphavirus nsP1 has multiple functions in viral replication. First, it mediates 
association of the viral replicase complex with cell membranes through palmitoylation 
groups on the protein (171). Furthermore, nsP1 acts as a methyltransferase and 
guanylytransferase to cap the viral genomic and subgenomic RNAs (152, 153). 
Eukaryotic mRNAs contain a 5’ cap structure, which is a guanine nucleotide that has 
been methylated at the 7-position (m7G). The 5’ cap has multiple functions in mRNA 
stability and export from the nucleus, as well as promoting translation of the mRNA 
transcript. In order to be efficiently translated from host cells, most viruses also have a 
mechanism to cap their mRNA. Furthermore, cytoplasmic RNA innate immune sensors, 
such as RIG-I, recognize RNA motifs like 5’ triphosphates that are hidden from detection 
by the 5’ cap structure (139). Thus, the capping capacity of nsP1 acts to ensure efficient 
translation of the viral RNAs and serves to evade detection by cytoplasmic RNA sensors. 
Indeed, mutations that affect the capping ability of nsP1 in SINV and RRV induce more 
type I IFN compared to a wild-type virus in a RIG-I/MDA5 dependent manner (38).  
The nsP2 protein is the largest of the alphavirus nonstructural proteins and also 
has multiple functions. The N-terminus of the protein is an RNA helicase that unwinds 
RNA, an NTPase, and a 5’ triphophatase, and the C-terminus of the protein is papain-like 
protease that cleaves the viral nonstructural polyprotein (45, 73, 85, 184, 218, 231). In old 
world alphaviruses, nsP2 is thought to mediate host translational shutoff as a mechanism 
to prevent activation of the type I IFN system (69, 70).   
The function of the alphavirus nsP3 protein has been elusive for a number of 
years. It has an essential role in viral RNA synthesis, and the N-terminus is pretty well 
conserved throughout the different alphaviruses, however, the C-terminus is 
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hypervariable and heavily phosphorylated (125).  A recent study identified a putative role 
for the conserved SH3 domain within the C-terminus of nsP3 and appears to interact with 
amphiphysins and may act to regulate endocytosis and membrane trafficking (165). 
However, the overall role of the protein remains unknown.  
Finally, the nsP4 protein is the RNA dependent RNA polymerase, and is the 
critical for replication. The nsP4 protein may interact with other nsPs through the N-
terminus domain, but the functional consequences of these interactions are currently 
unknown (125, 213).  
 
Synthesis of the alphavirus glycoproteins and viral budding. 
 The structural proteins are encoded on the subgenomic 26S mRNA, which is 
produced at roughly three times the amount of genomic 49S RNA (178). The capsid 
protein is translated first and immediately is cleaved from the polyprotein as it leaves the 
ribosome by the autoprotease activity that resides in the C-terminus (5, 81). Translation 
of the pE2 polyprotein follows capsid protein and contains E3 and E2. The cleavage of 
capsid protein from pE2 allows for the N-terminus of pE2 to translocate across the ER 
membrane, and signal sequences within E2 and 6K allow for 6K and E1, respectively, 
translocation across the membrane (125). Once in the ER lumen, pE2 and E1 undergo 
post-translational modifications. N-linked glycans are added to possible N-linked 
glycosylation sites on pE2 and E1 (discussed in more detail in following sections)(207), 
and palmitoylation occurs on pE2, E1, 6K (17). Maturation of the glycoproteins occurs in 
the Golgi where furin cleaves pE2 to generate E3 and E2 (40). Release of E2 from pE2 
allows for E2 and E1 to form heterodimers and further N-linked oligosaccharide 
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processing occurs. E2 and E1 and then transported through the Golgi together as 
heterodimers, and finally to the plasma membrane by cytoplasmic vesicles (182, 258). 
Once at the plasma membrane, the mature E2-E1 heterodimers trimerize to form the 
glycoprotein spikes and subsequent interaction with the nucleocapsid to inititiate viral 
budding and egress from the host cell (125, 234, 235) The alphavirus glycoprotein spike 
is composed of three E1-E2 heterodimers and is easily visualized on the virion surface by 
cryo-EM.  
Immediately following cleavage from pE2, the capsid protein begins to form the 
nucleocapsid. Capsid dimers form around the viral RNA and the protein interacts with the 
RNA through packaging signals in the viral RNA located within nsP1(244).  To initiate 
budding, the nucleocapsid cores assemble and cluster at the plasma membrane. The 
mature glycoprotein E2-E1 trimer spikes are present on the surface of the plasma 
membrane and the interaction between the cytoplasmic tail of E2 and a hydrophobic 
pocket on capsid promotes formation of the virion and drives viral egress.  
 
1.3. Alphavirus-induced disease. 
Alphavirus pathogenesis models.   
The diseases associated with alphavirus infections generally fall into two 
categories: encephalitic and arthritic. New World alphaviruses are more commonly 
associated with encephalitis and Old World alphaviruses with arthritis. Details of 
alphavirus pathogenesis have been elucidated primarily through the use of mouse models. 
Natural virus isolates associated with clinical disease have been identified through 
isolation either from infected patients or from mosquitoes located around sites of disease 
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outbreaks (78). Many of these isolates have been passaged through suckling mice to 
produce virus capable of efficient replication within the mouse. While both inbred and 
outbred strains of mice have been used to model alphavirus pathogenesis, the C57BL/6 
line of inbred mouse is susceptible to alphavirus infection, and has been used extensively 
in many labs. Virus injected subcutaneously into the rear footpad is thought to first come 
into contact with Langerhans cells and dermal fibroblasts that are resident in the skin 
(141). Since infection of humans occurs by a mosquito bite, it is likely that some of the 
first cells that are infected are dendritic cells, and several host factors such as DC-SIGN 
and L-SIGN, as well as other unknown factors are thought to facilitate this interaction 
(120, 209). The virus replicates locally within the synovial fibroblasts in the ankle and is 
likely spread to the popliteal draining lymph node by infected dendritic cells (141). Once 
in the draining lymph node, the virus seeds a serum viremia and is able to spread 
throughout the host, infecting the various target tissues that are specific for the different 
groups of viruses. Virus is cleared through several mechanisms involving both innate and 
adaptive arms of the immune system. Activation of the type I interferon (IFN) system is 
critical in early control of virus replication for most alphaviruses (197, 202, 245, 248), 
and there is evidence for T cells as well and B cells and antibody in clearance of virus 
within tissues (22, 131).  
 
Encephalitic alphaviruses. 
The pathogenesis of encephalitic alphaviruses such as VEEV, WEEV, EEEV 
have been studied using a combination of young and adult mouse models, and 
recapitulate many neurologic disease symptoms that are observed in human disease (39). 
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While SINV infection in humans leads to arthralgia, SINV infection in mice causes an 
encephalitic disease that has been used to model acute encephalomyelitis, and studies 
from both SINV and VEEV have gained some insight into the mechanisms of disease 
following infection with neurovirulent viruses. Infection of adult mice with wild-type 
strains of VEEV and some strains of SINV causes a lethal neurologic disease (39, 93). 
Virus is thought to enter into the brain from the periphery through transient opening of 
the blood-brain barrier (BBB) (201). The opening of the BBB allows for viral infection of 
neurons and other cell types within the brain, leading to activation of pro-inflammatory 
cytokine response, and subsequent infiltration of inflammatory cells into the brain and 
CNS, leading to development of neurologic disease and eventually, death (203, 204).  
 
Arthritic alphavirus pathogenesis: Ross River virus. 
There have been several mouse models used to study arthritic alphavirus 
pathogenesis. Early studies of RRV pathogenesis used a young mouse model ranging 
from newborn mice to mice 10 days old where mice succumbed to viral infection (155). 
Non-lethal models of disease using older mice have been developed, and the most recent 
mouse model established to study RRV-induced disease was described by Morrison et al. 
(161), and is the mouse model used throughout this dissertation. Twenty-four day old 
C57BL/6 mice are subcutaneously infected with 1000 plaque forming units (PFU) of 
RRV T48 (RR64) in the left rear footpad, and go on to develop disease that is 
characterized primarily by hind-limb dysfunction.   
The initial events following RRV infection are similar other alphaviruses outlined 
above. While virus can be detected in the liver, spleen, brain, heart, and spinal cord, RRV 
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replicates to the highest titers in the skeletal muscle and ankle joints (161). Peak viral titer 
within these tissues occurs at 24-48 hours post infection, and steadily declines throughout 
the course of disease, and is virtually undetectable by plaque assay by 10 days post 
infection (dpi) (161). While peak viral titer occurs within the first 2 days of infection, 
infected mice do not start to exhibit clinical disease signs until about 5 dpi (161). Mice 
begin to show signs of hind limb weakness and altered gait at 5 dpi as determined by a 
grip test (161). By 7 dpi, infected mice begin to lose the ability to grip with their hind 
limbs and a subset of mice display the inability to right. Peak disease severity occurs 
from 10-12 dpi where most infected mice are dragging their hind limbs and are unable to 
right themselves. However, by about 14 dpi mice are beginning to recover and regain use 
of their hind limbs, and then by 21 dpi the infected mice have recovered and are 
indistinguishable from uninfected mice (161).  
 Histopathological analyses of the target tissues within infected mice have shown 
that the disease signs observed in the mice correlate with the induction of the host 
inflammatory response rather than viral titer (135, 161). Inflammatory immune cells such 
as macrophages, monocytes, neutrophils, and eosinophils along with CD8+ and CD4+ T 
cells, B cells and NK cells begin to infiltrate into the tissues starting at about 5 dpi and 
reach peak inflammation by 10 dpi. The infiltration of these cells into tissues is thought to 
mediate tissue damage, and in particular the inflammatory macrophages have a critical 
role in damage within the skeletal muscle. Injection of macrophage-cytotoxic agents such 
as silica, carrageenan, and liposome-covered clodronate dramatically reduced disease 
symptoms in RRV-infected mice (134, 135). Furthermore, macrophage-derived 
inflammatory cytokines and products have been implicated in RRV-pathogenesis. 
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Monocyte chemotactic protein (MCP-1; CCL2) is involved in macrophage recruitment 
and chemotaxis of other immune cells, and inhibition of MCP-1 by administration of 
bindarit into mice abrogated RRV-induced disease by significantly reducing the numbers 
of CD11b+ cells recruited into the skeletal muscle (193).  Another cytokine, macrophage 
migration inhibitory factor (MIF), which acts as a powerful pro-inflammatory cytokine 
that regulates multiple aspects of the host inflammatory response (28), has an important 
role in regulating the infiltration of immune cells into target tissues following RRV 
infection (94). MIF-/- mice show reduced disease and tissue damage following RRV 
infection compared to WT mice, and correlated with a reduction in inflammation in the 
skeletal muscle rather than altering viral titer (94). Finally, arginase I, which is produced 
by alternatively activated macrophages and neutrophils, thwarts clearance of RRV from 
skeletal muscle and ankle joints, and allows for sustained replication and disease at later 
time points (216).  
 All of these studies indicate a critical role for the host inflammatory response in 
mediating RRV-induced disease. However, there are gaps in our understanding regarding 
the underlying mechanisms of how the inflammatory response is initiated and/or 
regulated following RRV infection. Furthermore, the specific RRV ligands that activate 
the inflammatory response have not been identified, thus many aspects of RRV 
pathogenesis remain unknown and understudied.  
 
Arthritic alphavirus pathogenesis: chikungunya virus. 
Development of appropriate CHIKV mouse models have been hampered 
somewhat by the lack of a mouse adapted CHIKV that spreads systemically from the site 
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of infection to replicate in distal tissues. However, several models using two different 
human isolates from the most recent CHIKV epidemic have been described. A young 
mouse model where 14 day old C57BL/6 mice and infected with a CHIKV isolate from 
Sri Lanka exhibits swelling, arthritis, tenosynovitis, and myositis in the injected foot, and 
shares many pathologic characteristics with the human CHIKV disease (159). Similar to 
RRV, CHIKV infection results in inflammation within the joints and skeletal muscle, 
although swelling of the joints occurs following CHIKV infection but is absent during the 
mouse model of RRV-induced disease. Pronounced swelling of the ankles occurs at 2-3 
dpi and 6-7 dpi in the CHIKV mouse model. Analysis of the inflammatory cells 
infiltrating into the leg reveals that NK cells and neutrophils are the predominant 
infiltrating cell types at 5 dpi, although a heterogenous mix of NK cells, neutrophils, 
monocytes/macrophages and CD8+/CD4+ T cells were observed at 7 dpi (159). An older 
mouse model, where both feet of mice are injected with a CHIKV isolate from La 
Reunion Island, demonstrate similar disease characteristics as the young mouse model, 
albeit less pronounced, but may be more amenable to vaccination and therapeutic studies 
(68). Studies using a neonatal mouse model demonstrated the importance of type I IFN in 
protection from lethal CHIKV infection (202), further highlighting the critical role of the 
innate immune system in protection from alphavirus infection.  
 
1.4. The host complement system.  
The innate immune system is generally considered to be the first line of defense 
against invading pathogens and is critical in host protection. The host complement system 
is a branch of innate immunity that has many diverse functions including pathogen 
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recognition, signaling, initiation of inflammation, and direct pathogen lysis. The 
complement system is truly a “system” as there are well over thirty extracellular and cell-
associated proteins that help orchestrate the immune response to a given pathogen. A 
general schematic of the complement system is shown in Figure 1.2.  
Activation of complement is thought to occur through three main pathways: 
classical, lectin, and alternative pathways. Regardless of which pathway activates 
complement, the critical step in complement activation is cleavage of the C3 protein, 
which is central to the complement system (reviewed in (183)). Cleavage of C3 requires 
formation of the C3 convertases that are generated on target pathogens or cells following 
activation through either the classical or the lectin pathway. Cleavage of C3 results first 
in the generation of C3a and C3b, and C3b becomes covalently attached to the target 
surface through recognition of the reactive thioester group that is exposed upon cleavage 
on C3b and carbohydrate groups on the target surface. Interestingly, the specificity of the 
C3 thioester group for carbohydrates, and in particular terminal sugars on 
polysaccharides may have biological relevance since glycosylation on pathogens and 
stressed/infected cells can be different than healthy uninfected cells, and could be an 
additional safety guard to protect host cells from excessive complement activation (199). 
C3a is released and acts as a chemoattractant and anaphylatoxin to aid in activation of 
other arms of the immune response.  
The C3b deposition on the target cell leads to formation of additional C3 
convertases allowing for rapid accumulation of C3b on the surface of the cell. Eventually, 
the C5 convertase is formed (C4b2b3b) to cleave C5 into C5a and C5b. C5b can then 
interact with C6 and C7 to begin the membrane attack complex. The C5bC6C7 complex 
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inserts into the target membrane, allowing for C8 and then C9 to become part of the 
complex and generates a lytic pore called the membrane attack complex (MAC) that 
lyses the target cell. C5a is an additional anaphylatoxin that is released upon cleavage and 
acts on neutrophils and monocytes to induce rapid phagocytosis of opsonized targets. 
In addition to the first C3 cleavage event that generates C3a and C3b, C3b is 
further cleaved by factor I in complex with CR1 that inactivates C3b, but generates iC3b 
and C3c, C3dg and eventually C3f and C3d, which all have biological functions in 
complement to aid in pathogen clearance (183). Perhaps the most effective cleavage 
product is iC3b. The iC3b cleavage product acts to opsonize the target cell and interacts 
with several complement receptors on phagocytic cells to promote phagocytosis and 
leukocyte signaling (183, 233, 251). Interactions with complement receptors such as CR3 
and CR4 lead to enhanced phagocytosis of iC3b-opsonized cells and can trigger signaling 
downstream from both of the receptors (50, 183). CR3-mediated signaling within 
phagocytic cells, such as monocytes/macrophages and neutrophils, can act to initiate and 
enhance cytotoxic effector functions of the cells (173, 232).  
 
The role of complement in alphavirus pathogenesis. 
 The role of the complement system in alphavirus infection is either protective or 
pathologic role depending on the virus. Complement has a protective role in mouse 
models of SINV and VEEV infections, but is pathologic in RRV infection (23, 97, 99, 
158).  
 The role of complement following SINV infection is generally thought to be 
protective. Mice depleted for complement by cobra venom factor administration, which 
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consumes and depletes C3, had elevated levels of SINV in serum and in the brains 
compared to untreated infected controls (97, 98). Interestingly, inflammation in the brains 
of the complement depleted mice was increased compared to controls, and correlated 
with prolonged disease signs, suggesting that complement may also regulate 
inflammation (97). Analysis of the mechanisms of viral control by complement revealed 
that both the classical and alternative pathways were activated upon SINV infection even 
in the absence of virus-specific antibodies (99). Furthermore, mice genetically deficient 
in C5 displayed enhanced susceptibility to SINV infection, suggesting that formation of 
the MAC by complement is very important for control of serum viremia and infection 
within the tissues (96). Interestingly, despite the increase in viral titer with the CNS and 
serum, the C3 depleted mice did not show any enhanced mortality and actually had 
prolonged survival compared to undepleted mice (97), suggesting that there may be some 
pathology associated with presence of C3. The role of the lectin pathway has not been 
evaluated in the context of SINV infection.  
 In the context of VEEV infection, the complement system plays a role in host 
protection (23). Using a non-lethal model of VEEV infection where mice are infected 
with an attenuated strain of VEEV, V3533, Brooke et al. demonstrated that C3-/- mice are 
more susceptible to V3533 compared to WT mice (23). C3-/- mice displayed enhanced 
weight loss, and morbidity compared to WT mice in response to VEEV infection, and 
increased disease correlated with elevated levels of virus in the CNS and the periphery 
and increased inflammation with the brain. Furthermore, the role of complement in 
limiting viral replication and disease appeared to be most important in preventing spread 
of virus into the CNS from the periphery as C3-/- and WT mice inoculated with VEEV 
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directly into the brain showed no difference in mortality. Furthermore, C5-/- mice 
displayed wild-type kinetics and severity of disease, indicating that formation of the 
MAC was not required for limiting viral spread by complement. Instead, it is likely that 
other effector mechanisms involving C3 cleavage products have a key role in protection 
from VEEV infection.  
 The pathology and disease associated with RRV infection in humans and mice is 
primarily mediated by the host inflammatory response. Studies by Morrison et al. 
demonstrated that the complement system is activated following RRV infection (158). 
RRV-infected mice exhibited elevated levels of circulating C3 in the serum compared to 
mock-infected mice, and also had increased amounts of C3 cleavage products in the 
quadriceps muscle and ankle joints (158). In addition, human patients with RRV-induced 
polyarthritis had elevated levels of C3a, indicative of complement activation, within the 
synovial fluid compared to patients with the non-inflammatory arthritis disease 
osteoarthritis. Furthermore, the authors demonstrated that complement activation has a 
critical role in mediating damage and disease within target tissues. Mice deficient in C3, 
which is the central component of the complement system, developed a mild disease 
compared to wild-type mice. Interestingly, viral burden and localization of viral 
replication within the tissues was not affected by the presence or absence of C3, 
suggesting that complement regulated some aspect of inflammation. However, 
histopathologic analysis of both quadriceps muscle and ankle joints indicated the 
presence of inflammatory cells within the tissues, and flow cytometric quantification and 
characterization of the inflammatory cells within the muscle showed that complement did 
not affect the numbers or types of infiltrating inflammatory cells. Furthermore, disease in 
	   27	  
C5-deficient mice did not differ significantly from WT mice, indicating that formation of 
MAC is not required for disease (Morrison TE and Heise MT, unpublished data).  
 Follow-up studies evaluating the role of other complement proteins in mediating 
RRV-induced disease demonstrated that complement receptor 3 (CR3, CD11b/CD18, 
Mac-1, amb2) contributes to disease (160). CR3 is present on multiple types of immune 
cells, including monocytes, macrophages, neutrophils, DCs, and T cells, and interacts 
with the C3 cleavage factor iC3b (259). Mice deficient in CR3/CD11b exhibited reduced 
RRV-induced disease compared to WT mice, and many aspects of the disease in 
CR3/CD11b-/- were similar to the disease observed in C3-/- mice. Viral burden and the 
amount of inflammatory cells within the tissues were equivalent between CR3/CD11b-/- 
and WT mice, while disease and tissue damage were reduced in CD11b-/- mice.  
Ligation of CR3 by iC3b can induce signaling within CR3-bearing cells in a Syk-
PI3K mediated pathway and can serve to activate pro-inflammatory effector programs 
within the cells (50, 132, 157). Interestingly, expression of a subset of pro-inflammatory 
genes was dependent on both CR3 and C3 following RRV infection (160). The 
calgranulin proteins S100A8 and S100A9 are secreted as heterodimers from activated 
leukocytes, and have been implicated in the pathogenesis of inflammatory arthritis (172). 
Both of these genes are highly expressed in the inflamed quadriceps muscle following 
RRV infection, and their expression is dependent upon both CR3 and C3 (160). While 
further investigation is needed to determine if there is a role for these proteins during 
RRV infection, their complement-dependent expression suggests that the role that 
complement may have in RRV pathogenesis is at the level of activation of pro-
inflammatory effector programs in CR3-bearing cells.  
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 Taken together, these data indicate the complement system can play both a 
protective and a pathologic role following alphavirus infection. In SINV and VEEV 
infection, complement appears to be required to neutralize the viruses and help clear virus 
from the serum, thus limiting spread of the virus into additional tissues. In contrast, 
following RRV infection, the complement system does not neutralize the virus, but rather 
contributes to development of disease through activation of CR3-bearing inflammatory 
cells resulting in the inflammatory tissue destruction and disease. It is not currently clear 
why complement is protective in certain alphavirus infection but pathologic in another, 
but further exploration into the mechanisms of complement activation and identification 
of viral ligands may provide some insight into these processes.  
 
Complement activation pathways. 
There are three main activation pathways of complement: the classical, lectin, and 
alternative pathways. The classical and lectin pathways converge as activation through 
either pathway leads to the formation of the C3 convertase C4b2b. The classical 
activation pathway had initially been thought to activate complement only through 
recognition of IgM and IgG in antibody-antigen immune complexes by the initiator 
molecule C1q, but recent work has demonstrated that C1q can bind to a number of self 
and non-self ligands in addition to immunoglobulins (64, 123). Surface binding of C1q to 
a ligand results in activation of C1r and C1s proteases, and C1s cleaves C4 and C2 to 
generate the C3 convertase C4b2b (183); the classical pathway and lectin pathways are 
indistinguishable at this point. The alternative pathway is initiated through binding of 
factor B (fB) protease to spontaneously hydrolyzed C3 (C3H2O). Subsequent cleavage of 
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C3 within the fB-C3 complex by Factor D generates the alternative C3 convertase, 
C3bBb, which cleaves C3 and activates the complement cascade.  
 
The lectin activation pathway of complement. 
The lectin activation pathway of complement is mediated through the serum 
proteins mannose binding lectin (MBL) and ficolins (L-, M-, and H-ficolin) that act as 
pattern recognition receptors (PRRs). Both MBL and the ficolins contain a collagen-like 
domain in the N-terminus that mediates oligomerization of the structural subunits to form 
higher order structures required for functional complement activation. MBL has a 
carbohydrate recognition domain (CRD) in the C-terminus, whereas ficolins have a 
fibrinogen-like domain that acts in a similar manner to the CRD of MBL (63). The ever-
expanding list of MBL ligands will be discussed in further detail in following sections, 
and the ficolins have been shown to bind to terminal N-acetylglucosamine (GlcNAc) on 
glycosylated proteins on bacteria as well as apoptotic cells (124, 147, 255). MBL, L-
ficolin, and H-ficolin are produced in the liver and circulate within the serum, where as 
M-ficolin is produced by monocytes and granulocytes (63).  
The MBL-associated serine proteases (MASPs) circulate throughout the body in 
association with the ficolins and MBL. There are three MASP proteins (MASP-1, -2, -3), 
however, only MASP-2 has been shown to be able to form the C3 convertase C4b2b to 
activate the complement cascade (192, 226). Interestingly, MASP-1 and MASP-3 have 
been shown to mediate cleavage of Factor D, which is required for activation of 
complement through the alternative pathway (9). Once the PRRs have been engaged 
through the CRD, a conformational change occurs, and allows for the serine proteases to 
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be able to cleave C4 and C2 to generate the C3 convertase C4b2b, cleavage of C3 and 
complement activation.  
Of note, collectin-11 (CL-11) was recently identified as an additional serum 
protein that circulates in association with MASP-1 and/or MASP-3 (83). CL-11 bound to 
several microbial and fungal species including Escherichia coli, Pseudomonas 
aeruginosa, and Candida albicans. Furthermore, CL-11 bound to influenza A virus and 
was able to partially inhibit the entry of virus into cells at high concentrations. The ability 
of CL-11 to activate complement has not yet been demonstrated, but given the microbial 
substrates, association with MASP-1 and/or MASP-3, and levels circulating in serum, it 
is likely that CL-11 will join the complement system as a PRR.  
 
Mannose binding lectin (MBL): structure and ligands. 
MBL was identified as a serum protein that could recognize and bind to 
carbohydrate structures (187), and was subsequently found to be able to activate the 
complement system (105). MBL is produced in primarily in the liver of several 
vertebrates, and has been associated with complement activation in most organisms (48, 
156). There are two human MBL genes, Mbl1 and Mbl2, but only Mbl2 encodes the 
functional MBL protein that activates the complement system. Mice and rats have two 
isoforms of MBL, termed MBL-A and MBL-C, and both appear to be capable of 
activating the complement system, although they have different circulating levels in 
resting animals (138). MBL is an acute phase protein, meaning that the expression and 
production of MBL is elevated following infection or stress (53), and further highlights 
the important role of MBL in host defense.  
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The Mbl2 gene on chromosome 10 encodes the human MBL protein, and the 
functional protein is composed of multimers of the 32 kDa MBL polypeptide. Each 
polypeptide has a calcium-dependent carbohydrate recognition domain (CRD) at the C-
terminus, and a collagenous region that forms into a triple helix with other two 
polypeptides to make up one structural subunit of MBL. Each structural subunit 
maintains a fixed 45Å distance between the three CRDs which allows for binding to the 
carbohydrate ligands (211). While each subunit can bind to the carbohydrate ligands, the 
affinity is relatively low, the oligomerized multimers of MBL are able to bind to larger 
arrays of carbohydrates thus increasing the affinity of binding and allows for activation of 
complement (106). The importance of 45Å spacing of the CRDs is to allow for specific 
binding to certain sugars, namely the hydroxyl groups in the hexose structure in N-
acetylglucosamine, mannose, glucose, and fucose (102). These sugars are commonly the 
terminal carbohydrate residue on microbial glycoproteins and not commonly found on 
mammalian glycoproteins, which favor terminal galactose and sialic acid. The CRDs of 
MBL do not bind to the hexose structure in galactose or sialic acid therefore preventing 
binding and activation of complement, which further adds to the specificity of 
recognition (243).  
MBL was originally thought to recognize terminal sugars present on microbial 
glycosylated proteins, but more recently, several studies have shown that MBL can also 
bind to sugars on self-antigens such as DNA, RNA, phospholipids, and other altered self-
proteins to help mediate phagocytic clearance of apoptotic or necrotic cells (119, 167, 
168, 220).  The presentation of certain self-antigens, such as DNA and RNA, to MBL 
present in circulation may be an additional mechanism that is used to alert the innate 
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immune system to stress and possible infection. MBL is thought to bind to the pentose 
sugars present on free DNA and RNA from either apoptotic or necrotic cells to help 
facilitate phagocytic clearance (168). Similarly, binding of MBL N-acetylglucosamine on 
phospholipids may also serve to enhance recognition and clearance of apoptotic cells 
(119, 126). Thus, MBL has an important role in recognition of pathogens as well as 




The levels of circulating MBL in healthy human adults varies substantially 
between individuals and across the population due to several polymorphisms and 
mutations that affect the structure and expression of MBL (reviewed in (47)). The human 
MBL2 gene is encoded on chromosome 10 and is composed of four exons: exon 1 and 2 
encode the collagenous region of the MBL protein required for oligmerization, exon 3 
encodes the neck region, and exon 4 encodes the carbohydrate recognition domain. There 
are several mutations that lie within exon 1 (R52C, G54D, and G57E) that all lead to a 
functional deficiency of MBL (137, 143, 222). The mutation at codons 52 (D variant) 
affects the oligomerization of MBL and prevents formation of the higher order structures 
that are required for complement activation through MBL. The mutations at codons 54 (B 
variant) and 57 (C variant) lead to distortion of the collagenous helix and prevent high 
affinity binding to carbohydrate arrays by MBL. There are also several polymorphisms 
that alter the level of expression of MBL. The polymorphisms are located in the promoter 
of the gene at -550, -221, and +4 (144, 145). Together with the structural mutations, the 
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promoter polymorphisms lead to extreme variation within the human populations and 
serum levels of MBL range from nearly undetectable to 10 µg/ml (47).  
The importance of MBL in mediating host protection from a number of bacterial 
and viral pathogens has been demonstrated by several studies that have evaluated the 
susceptibility of patients who are functionally deficient in MBL to certain pathogens. 
Sumiya et al found that children with recurrent bacterial infections had genetically lower 
levels of MBL compared to healthy children (222), and several studies have shown 
enhanced susceptibility to certain viral infections including heptatitis B virus and HIV 
(25, 52).  
 
Role of MBL in sterile inflammatory diseases. 
Since MBL can bind to both self-antigens such as DNA and phospholipids as well 
as the glycosylated proteins of pathogens, it is not surprising that MBL, like complement, 
can be a double edged sword: required for protection from a number of different 
pathogens, but can also lead to autoimmunity. Indeed, MBL has been associated with 
pathology in sterile inflammatory diseases such as ischemic reperfusion injury (IRI), and 
has been implicated in rheumatoid arthritis (RA).  
 Ischemic reperfusion injury occurs after blood flow is restored to tissues and 
organs after a period of deprivation. The pathology of disease is characterized by 
induction of a pro-inflammatory state within the affected tissue and subsequent 
inflammation that leads to eventual apoptosis, necrosis, and possible permanent tissue 
damage (76). The complement system has long been known to be involved in 
development of myocardial IRI through chemotaxis of leukocytes into the tissue (76, 95), 
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and more recently, the lectin pathway has been shown to have a critical role in mediating 
complement activation following reperfusion (reviewed in (76)). Early in vitro studies 
demonstrated that the oxidative stress induced by IRI on endothelial cells initiated MBL 
and subsequent C3 deposition, likely through altered glycosylation of host proteins on the 
cells (34, 35). Subsequent studies in myocardial, gastrointestinal, and renal reperfusion 
injury animal models using either antibodies to deplete MBL, or MBL-A-/- MBL-C-/- 
(MBL-DKO) and MASP-2-/- mice further demonstrated that MBL and the lectin pathway 
regulated complement activation and subsequent inflammation and damage within the 
reperfused tissues (112, 205, 237).  
 Rheumatoid arthritis is an autoimmune disease that is characterized by chronic 
inflammation within the joints of affected individuals. Autoantibodies are thought to 
contribute to disease in part through activation of the complement system, but several 
studies have evaluated the lectin pathway in disease susceptibility and severity in cohorts 
of RA patients. However, the results from these studies are conflicting as different studies 
found a correlation of low MBL levels in RA patients with both protection and pathology 
(80, 109, 110, 198, 228). Thus, the role of MBL in inflammatory arthritis has not been 
established and remains unclear.  
 
Role of MBL in viral infection: Flaviviruses. 
Flaviviruses such as West Nile virus (WNV) and dengue virus (DENV) are 
mosquito-borne viruses that are a significant cause of disease in humans. The innate 
immune response is critical for host protection from these viruses, and the complement 
system has been demonstrated to play an important role in protection (reviewed in (8)). 
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Mice deficient in C3 are highly susceptible to WNV infection due to a defect in the 
development of a robust adaptive immune response. Neutralizing antibody responses as 
well as CD8+ T cell responses were reduced in C3-/- mice, leading to higher viral titers 
within the CNS of infected mice (149, 150). MBL deficient mice were also more 
susceptible to WNV infection, and MBL deficient serum showed reduced neutralization 
of insect derived virus (61, 62).  
MBL has also been reported to bind to and neutralize DENV, even in the absence 
of complement activation (61), and levels of MBL within human serum directly 
correlated with neutralization of both mosquito and mammalian-derived DENV2 (7), 
suggesting that MBL has a protective role in DENV infection. However, several studies 
analyzing the role of MBL in determining disease severity in DENV-infected patients 
have yielded conflicting results. One study was unable to correlate low levels of MBL 
with patient progression from dengue fever (DF) to the more severe disease dengue 
hemorrhagic fever (DHF), yet other studies found that high levels of MBL were 
associated with DHF, and low levels of MBL protected DHF patients from 
thrombocytopenia (2, 33, 164). From these studies, it is currently unclear the role of MBL 
in determining DENV severity, although experimental evidence suggests that MBL 
contributes to neutralization of DENV and is thus likely to have a protective role 
following DENV infection.  
 
Role of MBL in viral infection: other viruses. 
MBL is thought to contribute to protection from infection by the human 
immunodeficiency virus (HIV). The HIV gp120 glycoprotein is heavily glycosylated 
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with N-linked glycans, and several groups have demonstrated that MBL can bind to both 
lab strains as well as primary isolates of HIV (54, 200). MBL binding to HIV is reported 
to be important in direct neutralization of the virus by preventing binding to host cells, 
although studies differ on the extent of neutralization (54, 254). 
MBL has also been shown to contribute to host protection of several other viral 
infections such as herpes simplex virus-2 (HSV-2), Ebola virus, and SARS-coronavirus 
(65, 107, 111, 257). MBL was found to bind to HSV-2 virions in an ELISA assay, and 
MBL-DKO mice exhibited enhanced viral titer within the liver compared to WT mice 
(65).  Furthermore, serum levels of MBL in asymptomatic HSV-2 patients were elevated 
compared to symptomatic patients and those with recurrent infections, suggesting that 
higher levels of MBL contribute to suppression of virus in human infection (65, 208).  
 MBL can also mediate direct neutralization of virus infection through blocking of 
virus receptor interactions with the host cell. Spear and colleagues have found that MBL 
blocks the interaction between the Ebola and Marburg glycoproteins and the host C-type 
lectin DC-SIGN, which binds to the viral glycoproteins, resulting in reduced infectivity 
into cells (111). In addition, MBL contributed to complement dependent neutralization of 
Ebola and Marburg viruses, and administration of high doses of MBL were able to 
protect mice from a lethal challenge with Ebola virus (111, 154), indicating a protective 
role for MBL in filovirus infection. MBL also been shown to bind to SARS-CoV in vitro, 
and was found to inhibit the virus by specifically binding to the N-linked glycan on the 
tip of the spike protein to block interactions with DC-SIGN (107, 257). Furthermore, 
enhanced susceptibility to SARS-CoV was found in patients with genotypes conferring 
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lower levels of MBL compared to patients with genotypes leading to higher amounts of 
circulating MBL (107).   
 
1.5. The viral N-linked glycans. 
Glycosylation is an important post-translational modification.  
Glycosylation and other forms of post-translational modifications on proteins 
have an important, yet understudied and perhaps underappreciated role in protein 
structure, function, and regulation. On a broader scale, glycosylation of proteins is critical 
to development and function of many organisms, as mutations or deletions of the 
glycosyltransferases required for proper glycosylation frequently result in deleterious 
phenotypes and the inability to glycosylate is lethal (reviewed in (229)). Furthermore, 
differential glycosylation of proteins can introduce a remarkable amount of variation and 
diversity to the form and function of any given protein, thus adding another layer of 
complexity to our already complex and beautiful world.  
The term “glycosylation” used in this dissertation refers to the addition of an 
oligosaccharide, also called a glycan, to a protein at designated sites within the protein by 
enzymes in the ER and the Golgi. There are generally two types of glycosylation on 
polypeptides: N-linked and O-linked glycosylation. Asparagine (N)-linked glycosylation 
is the additional of oligosaccharide at a specific site on the polyprotein indicated by the 
following sequeon: N-(X)-S/T where X is any amino acid except for proline. About two-
thirds of all proteins contain N-linked glycosylation sequences, and about two-thirds of 
those proteins are actually glycosylated at the indicated site (reviewed in (229)). N-linked 
glycosylation begins in the lumen of the ER where a base glycan that consists of a N-
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aceytlglucosamine (GlcNAc) core and branches of terminal mannose residues is 
convalently linked to the polyprotein, and is further processed by glycosidases and 
glycosyltransferases in the Golgi. O-linked glycosylation is commonly found on 
glycoproteins termed mucins and proteins that are secreted into the mucosa. O-linked 
glycosylation is characterized by the addition of GlcNAc to serine/threonine residues in 
the Golgi and does not appear to have any specific sequence that identifies putative sites.  
  The biological functions of glycans can be broadly categorized into the following 
roles: structural role, where glycans are required for proper folding of proteins; a role in 
mediating cell-intrinsic interactions where glycans mediate interactions within the cell 
organism with glycan-binding proteins; and cell-extrinsic roles which involve the 
interactions between foreign organisms such as bacteria, viruses, and fungi. The presence 
of glycans can protect the protein from proteases, antibodies, or premature interactions 
during synthesis and trafficking. HIV is a notable example where the heavy glycosylation 
of gp120 can act as a glycan shield, protecting the virus from antibody-mediated 
neutralization. The cell-extrinsic role of glycans involves recognition and interaction 
between the glycans and glycan-binding proteins on pathogens and other foreign 
molecules. These interactions have a major impact on infectious disease, especially since 
these interactions are required for pathogen entry into a host cell, recognition of a 
pathogen by the immune system, or affect some other aspect of disease.  
 
N-linked glycosylation. 
As the polyprotein is synthesized and translocated into the ER, a base glycan is 
covalently added at putative N-linked sites by the oligosaccharidetransferase (229). The 
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base glycan is a fourteen-sugar oligomannose composed of glucose (Glc3), mannose 
(Man9), and N-aceytlglucosamine (GlcNAc2). As the protein moves through the ER and 
the Golgi, the glycan gets trimmed by glucosidases and mannosidases and then modified 
by various transferases that add different sugar groups (galactose, GlnNAc, sialic acid) 
onto the glycan to generate the final glycan structure (215). There are three main types of 
glycans that are produced: complex, high mannose, and hybrid. While there is a 
staggering amount of diversity within the three types of glycans, there are defining 
characteristic of each type. Complex glycans are characterized by the presence of 
terminal sialic acid residues; high mannose (also can be called oligomannose) glycans 
have terminal mannose residues; and hybrid glycans have a combination of terminal 
mannose and sialic acid residues.  
Complex glycans can have extensive branching that allows for additional glycan 
diversity, and the different branching and terminal carbohydrates modifications are 
dictated in a tissue-specific and cell-lineage dependent manner. The ability to produce 
complex glycans is due to the presence of specific glycosidases and transferases that are 
able to trim down the base glycan, and rebuild with different sugars.  
High mannose glycans are more typically found on glycosylated proteins 
produced from invertebrates. While the base glycan is the same glycan as the one found 
on proteins produced in vertebrate cells, invertebrates do not produce certain glycosidases 
and transferases and thus are unable to produce complex or hybrid glycans. Glycosylation 
in bacteria is quite distinct, but plays a similar role in bacterial protein function, 
interactions, and ultimately pathogenesis.  
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Innate immune recognition of N-linked glycans. 
 Given that bacteria, viruses, parasites, and fungi use glycosylation to modify their 
proteins either for proper folding or interaction with host proteins, it is not surprising that 
there are several different innate immune receptors that recognize non-self or altered 
glycans to activate the immune system. Several Toll-like receptors (TLRs) such as TLR4 
and TLR2 recognize glycoproteins to activate TLR signaling pathways resulting in 
initiation of pro-inflammatory programs and activation of adaptive immunity. TLR4 
recognizes lipopolysaccharide on bacterial cell walls, and has been shown to recognize 
glycoproteins from many different viruses as well, including respiratory syncytial virus 
and MMTV (reviewed in (117)). TLR2 recognizes components of viral glycoproteins as 
well to stimulate innate immunity (reviewed in (6, 117)). However, to date, viral N-
linked glycans present on viral glycoproteins have not been shown to be directly engage 
TLRs, although given their location on the glycoprotein, it is plausible that they might.  
As discussed above, PRRs that activate the complement system such as MBL and 
ficolin also recognize terminal sugar moities. Furthermore, members of the C-type lectin 
family of innate immune proteins are carbohydrate-binding proteins, and act as receptors 
and initiate signaling within myeloid cells (reviewed in (189)). C-type lectins such as 
DC-SIGN, L-SIGN, SIGN-R1, Dectin-2, Langerin, and mannose receptor recognize high 
mannose glycans on bacteria, viruses and fungi to modulate the host response (71). 
Indeed, there have been several studies that demonstrate both protective and pathologic 
roles for C-type lectins during viral infection. Capture of MBL-opsonsized influenza 
virus by SIGN-R1 in lymph nodes contribute to development of a protective humoral 
response by B cells (74). In contrast, another C-type lectin, CLEC5A, has been reported 
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to contribute to the pathogenesis of flaviviruses such as DENV and Japanese encephalitis 
virus through induction of pro-inflammatory cytokines and inflammasome activation (30, 
31, 250). With regard to alphaviruses, DC-SIGN and L-SIGN have reported to be 
attachment factors that mediate entry of mosquito-derived virus into dendritic cells (120). 
The role other members of the C-type lectin family in alphavirus pathogenesis have not 
been evaluated.  
MBL has been shown to directly bind to the N-linked glycans of several viruses 
discussed in earlier sections. Mosquito-derived WNV and DENV are neutralized by MBL 
in part through recognition of the high mannose N-linked glycans on the viral E protein 
on virions leading to complement activation (61). The high mannose and complex 
glycans on HIV gp120 mediate binding and neutralization by MBL both on the virus and 
on the infected cell (90), and a single N-linked glycan on the tip of the SARS-CoV spike 
protein was required for the interaction between the virus and MBL (257). Importantly, 
all of the described interactions between viruses and MBL indicate that the interaction 
between viral N-linked glycans and MBL leads to a protective response following viral 
infection.  
 
The alphavirus N-linked glycans.  
Alphaviruses have three to four N-linked glycosylation sites on the envelope 
glycoproteins. RRV and CHIKV have two E2 N-linked glycans, and one E1 N-linked 
glycan, whereas SINV has two glycans on E2 and two on E1 (219). The functions of 
these N-linked glycans appears to differ between the viruses in terms of viability and 
effects on pathogenesis.  
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The positions of the SINV and RRV glycans have been mapped by cryo-EM 
analysis of the structure of the glycoprotein spike (174). Since E1 lies parallel to the 
virion surface, the E1 glycans are located roughly in between, but below, the E2 
glycoprotein spike (174). The glycans at E2 N200 (RRV) and E2 N196 (SINV) are 
located at the tip of the E2 glycoprotein spike, with the SINV glycan on the top of the 
“petal” structure, and the RRV glycan on the bottom (174). The locations of the glycans 
at E2 N262 (RRV) and E2 N318 (SINV) differ slightly. In SINV, the glycan is closer to 
the lipid bilayer whereas the RRV glycan is in between the glycoprotein spikes. The 
positions of the E2 glycans on the glycoprotein spike, especially the E2 N200 (RRV) and 
E2 N196 (SINV) located on the tip of the spike, make the N-linked glycans attractive 
candidates to interact with host carbohydrate binding proteins.  
The oligosaccharide content and type of glycan present at each of the viral 
glycosylation sites is dependent on the host cell. The glycan composition at each site has 
been determined for both RRV and SINV and is summarized in Table 1.1 (148, 210). 
EndoH and PNGase digestion of mutant viruses that lack the glycosylation sites revealed 
that the RRV E1 N141 and E2 N262 glycans are predominantly complex 
oligosaccharides while replicating in mammalian cells, whereas the E2 N200 glycan is 
high mannose (210). EndoH cleaves glycans in between high mannose branches and the 
GlcNAc core, and PNGase cleaves between GlcNac and the asparagine. Thus, EndoH 
sensitive glycans are high mannose or hybrid, and EndoH resistant glycans are complex. 
In mosquito cells, all of the RRV glycans were either high mannose or hybrid glycans, as 
expected (210).  
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The composition of oligosaccharides for the SINV glycans were determined by 
analysis of purification of the E1 and E2 glycoproteins from virus grown in the presence 
of radiolabeled sugars (148). For SINV replicating in vertebrate cells, the glycans at E1 
N139 and E2 N196 are predominantly complex glycans, whereas the glycan at E1 N245 
can be either a high mannose or complex glycan and the E2 N318 glycan is 
predominantly a high mannose oligosaccharide (26, 148). The differences in 
oligosaccharide composition between the glycans on the same virus when replicating in 
mammalian cells are generally attributed to the availability of the glycan to glycosidases 
and glycosyltransferases as the protein moves through the Golgi. Since the base glycan 
has terminal mannose branches, it is plausible for any given glycan to be inaccessible to a 
particular glycosylation enzyme due to protein structure and folding (104).  
Given the ligand specificity for many carbohydrate-binding proteins such as MBL 
and many of the C-type lectins, the high mannose and complex glycans on the alphavirus 
glycoproteins represent possible ligands to interact with host proteins and activate innate 
immunity. Furthermore, since the E2 glycans are located at the tip of the glycoprotein 
spike, it is possible that interactions between the glycans and host proteins may modulate 
alphavirus pathogenesis and disease.   
 
Role of alphavirus glycans in pathogenesis. 
To date, the only published studies of the role of the alphavirus N-linked glycans 
in disease pathogenesis is in the context of SINV infection. Knight et al. used previously 
described mutants of SINV TE12 that have the glycosylation sites mutated from 
asparagine to a glutamine at each site and evaluated the effect of loss of each glycan in 
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cells and in a mouse model of SINV encephalomyelitis (122). Loss of either of the E1 
glycans generally reduced infectivity and replication within BHK-21 cells and 
consequently, virulence in mice compared to SINV WT. Interestingly, loss of either of 
the E2 glycans had the opposite effect and had increased replication within BHK-21 cells, 
virulence in mice, and delayed clearance from the CNS. This increased replication was 
due to enhanced binding of the E2 glycan mutants to HS compared to SINV WT (122). 
Since sialic acid is negatively charged, removal of the glycan likely allowed for tighter 
binding to the negatively charged HS, thus enhancing infectivity and disease. RRV T48 
does not efficiently bind to HS (92), and so it is unclear if loss of the RRV glycans would 
lead to enhanced disease.  
The alphavirus N-linked glycans also interface with the host immune system. In 
particular, the RRV E2 glycans have been shown to be important in induction of type I 
IFN production from dendritic cells (210).  Mosquito cell derived RRV, which has high 
mannose and hybrid glycans, failed to induce type I IFN from myeloid dendritic cells 
compared to mammalian cell derived virus (209). One of the differences between 
mammalian and mosquito-derived virus is differential glycosylation of proteins, 
suggesting a possibility that the N-linked glycans may play a role in type I IFN induction.  
Indeed, infection of mDCs with RRV mutants that lack both E2 N-linked glycosylation 
sites show reduced type I IFN production compared to RRV WT without altering 
infectivity into the cells (210). Interestingly, it appeared that the presence of both of the 
E2 glycans were required for type I IFN induction from mDCs, and suggests that perhaps 
the combination of a high mannose and a complex glycan presented together that activate 
the innate immune response.  
	   45	  
The studies described above indicate that the alphavirus N-linked glycans can 
interact with host proteins, and in the case of RRV, the glycans can modulate the innate 
immune response and are therefore likely to have an impact on disease pathogenesis. 
However, to date, the role of the N-linked glycans in RRV pathogenesis have not been 
evaluated.  
 
1.6. Dissertation Objectives. 
 The objectives of this dissertation are to identify additional host and viral factors 
that contribute to arthritic alphavirus pathogenesis. The host inflammatory response is 
critical in the development of RRV-induced disease and some host factors that are 
important in mediating disease have been identified. Inflammatory macrophage and 
macrophage products are central in mediating damage within the skeletal muscle leading 
to disease (94, 134, 135, 193). Furthermore, the host complement system has a critical 
role in RRV pathogenesis through activation of CR3-bearing inflammatory cells that 
infiltrate into the skeletal muscle and joints following infection (158, 160). However, it is 
unknown how the complement system is activated following RRV infection.  
 The complement system is activated through three main pathways: the classical, 
the lectin, and the alternative pathways. Given that the complement system plays a 
critical role in RRV pathogenesis, we first sought to determine which pathway of 
complement was required for RRV-induced disease. We evaluated the role of each of the 
three main pathways using mice deficient in the various initiator molecules in RRV 
pathogenesis, and found that the MBL pathway of complement was essential to 
development of disease. We characterized RRV-induced disease in MBL-deficient mice, 
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and found that MBL was required for complement activation and subsequent disease 
following RRV infection, indicating a previously undescribed pathologic role for MBL in 
viral infection (79). Furthermore, analysis of samples from RRV patients showed a 
correlation between higher levels of circulating MBL and severity of disease (79).  
 Given the ligand specificity of MBL for carbohydrates that can be found on N-
linked glycans, we next investigated whether viral N-linked glycans were required for 
RRV-induced disease through activation of the host complement system. Indeed, the 
RRV E2 N-linked glycans were required for development of RRV-induced disease, as a 
virus that lacks both E2 glycans caused mild RRV-induced disease in mice compared to a 
wild-type virus and is similar to the RRV-induced disease observed in MBL and 
complement deficient mice. Consistent with our hypothesis that the E2 glycans mediates 
disease through activation of the lectin pathway of complement, the E2 glycans were 
required for MBL deposition onto infected cells and within infected tissues, leading to 
decreased complement activation and C3 deposition. Together, these studies provide a 
model of RRV pathogenesis where the RRV E2 glycans activate the complement system 
through MBL to cause disease.  
The results of this dissertation identify a critical role for the both MBL and the 
RRV E2 N-linked glycans in mediating severe RRV-induced disease through activation 
of the host complement system. Furthermore, these studies describe novel roles for both 
MBL and the alphavirus N-linked glycans in mediating pathology and disease in viral 
infection, and are among the first sets of studies to explore and evaluate the role of 
interaction between host carbohydrate binding proteins of the innate immune system and 
the viral N-linked glycans.  
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Aims: 
1. Does the mannose-binding lectin pathway of complement contribute to severe 
RRV-induced disease? 
2. Do the RRV E2 N-linked glycans contribute to severe RRV-induced disease? 
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Figure 1.1: Life cycle of alphaviruses. 
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Figure 1.1: Life cycle of alphaviruses. 
Details of each step are discussed within the text. N-linked glycans are represented as red 
and green diamonds. C: capsid; ER: endoplasmic reticulum. Figure adapted from Li et al 
and Jose et al with permissions from Nature Publishing Group and Future Medicine, 
respectively (113, 133).  
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Figure 1.2: The host complement system.  
Cartoon schematic of the three main activation pathways of the host complement system. 
Additional details of ligands and stepwise discussion of the complement cascade are 
outlined in the text. Briefly, the classical pathway (top left) is activated though C1q 
recognition of antibodies in immune complexes; the lectin pathway (top middle) is 
activated through MBL and ficolin recognition of carbohydrates; and the alternative 
pathway (top right) is activated through spontaneous cleavage of C3. Activation through 
the classical and lectin pathways results in formation of the classical C3 convertase 
C4b2b (middle left), and activation through the alternative pathway produces the 
alternative C3 convertase BbC3b (middle right). The C3 convertases cleave C3 into C3a, 
C3b, and subsequently C3b is cleaved by factor I to generate iC3b. Effector functions of 
each of the cleavage products are outlined at the bottom, and are discussed in greater 
detail in the text.  
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Table 1.1: N-linked glycans on alphaviruses.  
 
Virus Glycan position Cell type Type of Glycan Ref. 
RRV E2 N200 Mammalian high mannose (210) 
 E2 N262 Mammalian complex (210) 
 E1 N141 Mammalian complex (210) 
 E2 N200 Mosquito high mannose/paucimannose (210) 
 E2 N262 Mosquito high mannose/paucimannose (210) 
 E1 N141 Mosquito high mannose/paucimannose (210) 
     
SINV E2 N196 Mammalian complex (26, 148) 
 E2 N318 Mammalian high mannose (26, 148) 
 E1 N139 Mammalian complex (148) 






CHAPTER TWO: 	  
MANNOSE BINDING LECTIN IS REQUIRED FOR ALPHAVIRUS-INDUCED 
ARTHRITIS/MYOSITIS  
 
2.1 Summary  
Mosquito-borne alphaviruses such as chikungunya virus and Ross River virus 
(RRV) are emerging pathogens capable of causing large-scale epidemics of virus-induced 
arthritis and myositis. The pathology of RRV-induced disease in both humans and mice is 
associated with induction of the host inflammatory response within the muscle and joints, 
and prior studies have demonstrated that the host complement system contributes to 
development of disease. In this study, we have used a mouse model of RRV-induced 
disease to identify and characterize which complement activation pathways mediate 
disease progression after infection, and we have identified the mannose binding lectin 
(MBL) pathway, but not the classical or alternative complement activation pathways, as 
essential for development of RRV-induced disease.  MBL deposition was enhanced in 
RRV infected muscle tissue from wild type mice and RRV infected MBL deficient mice 
exhibited reduced disease, tissue damage, and complement deposition compared to wild-
type mice.  In contrast, mice deficient for key components of the classical or alternative 
complement activation pathways still developed severe RRV-induced disease.  Further 
characterization of MBL deficient mice demonstrated that similar to C3-/- mice, viral 	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replication and inflammatory cell recruitment were equivalent to wild type animals, 
suggesting that RRV-mediated induction of complement dependent immune pathology is 
largely MBL dependent.  Consistent with these findings, human patients diagnosed with 
RRV disease had elevated serum MBL levels compared to healthy controls, and MBL 
levels in the serum and synovial fluid correlated with severity of disease. These findings 
demonstrate a role for MBL in promoting RRV-induced disease in both mice and humans 
and suggest that the MBL pathway of complement activation may be an effective target 




Arthritogenic alphaviruses, such as Ross River virus (RRV) and chikungunya 
virus (CHIKV), are mosquito-borne viruses that cause severe polyarthritis and myositis in 
humans. RRV causes annual disease outbreaks in Australia and has caused sporadic 
epidemics of debilitating polyarthritis, including one outbreak involving over 60,000 
people in Oceania (86). RRV is transmitted to humans primarily by the Aedes and Culex 
species of mosquitoes that generally populate marsh areas, and CHIKV transmission has 
been traditionally mediated by the urban Aedes aegypti, though the virus has recently 
adapted for efficient transmission by the widely distributed Aedes albopictus species 
(227), leading to an increased risk for CHIKV spread into new areas, as illustrated by 
recent outbreaks in Italy and southern France (181). The expansion of CHIKV into an 
additional mosquito vector and the subsequent epidemic has highlighted the ability of the 
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arthritic alphaviruses to move into new geographic areas and cause large-scale outbreaks 
of acute and persistent arthralgia and myalgia in humans.  
RRV-induced arthritic disease presents predominantly as painful stiffness, 
inflammation, and swelling in peripheral joints that can last months after initial infection 
and the host inflammatory response is thought to play a major role in disease 
pathogenesis. Inflammatory monocytes constitute the bulk of leukocytes isolated in 
synovial aspirates from RRV-infected patients (55, 91), and macrophage-cytotoxic drugs 
have been shown to drastically reduce disease progression and severity in mice (134, 
135). In addition, mice lacking C3, the central complement factor that is essential for 
complement activation, exhibit reduced RRV-induced disease and tissue destruction 
(158), implicating a role for complement in development of the disease. Consistent with 
studies in mice, synovial aspirates from patients with RRV-induced arthritis have been 
shown to contain increased levels of the C3 cleavage product C3a (158). Although 
macrophage recruitment to infected tissues is markedly increased after RRV infection, 
the role played by complement is independent of inflammatory cell recruitment. Rather, 
tissue destruction and disease progression requires complement receptor 3 (CR3), 
suggesting that complement interactions with CR3 on inflammatory cells promote tissue 
destruction in RRV-infected tissues (160). However, it is currently unclear how the 
complement system is activated following RRV infection.  
There are three main activation pathways of the complement cascade; the 
classical, alternative, and lectin dependent pathways, that all converge on factor C3 and 
lead to activation of complement effector functions (reviewed in (183)). The classical 
pathway is initiated by C1q interactions with antigen-bound complexes of IgG and IgM, 
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and the proteases C1r and C1s cleave C4 and C2 to generate the C3 convertase C4b2b. 
Binding of factor B (fB) and spontaneously hydrolyzed C3 initiates the alternative 
pathway, and fB binding to C3b leads to formation of the alternative C3 convertase 
C3bBb that can amplify complement activation. In the lectin pathway, mannose binding 
lectin (MBL) or the ficolins bind to carbohydrate moieties on foreign bodies, such as 
viruses, or to host cells and apoptotic cells, and the MBL-associated serine proteases 
(MASPs) cleave C4 and C2 to form the C3 convertase C4b2b. Cleavage and processing 
of C3 by the C3 convertases produce several C3-derived components that are potent 
activators of the immune system. One such component is iC3b, which is a ligand for 
several complement receptors, such as CR3. Binding of iC3b to CR3 on cells such as 
monocytes/macrophages, neutrophils, and NK cells, results in activation of these cells, 
leading to enhanced phagocytosis and cytotoxic activity against iC3b-opsonized cells 
(183). 
MBL is a soluble C-type lectin that can initiate the complement cascade through 
binding of the carbohydrate recognition domains (CRD) to cell-surface sugars expressed 
on bacteria and viruses and some endogenous host ligands (reviewed in (223)). The 
complement system is notorious for having both a protective and pathologic role and 
frequently leads to additional tissue injury and damage once activated. Similarly, MBL 
appears to be able to have the ability to protect as well as harm the host cells. In the 
context of sterile inflammatory diseases such as myocardial and gastrointestinal ischemic 
reperfusion injury, MBL and the lectin pathway mediate development of disease through 
complement-mediated regulation of pro-inflammatory cytokines and inflammation, 
leading to exacerbated pathology and tissue injury (89, 112, 205, 237). In contrast to the 
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pathologic role of MBL in sterile inflammatory diseases, MBL is thought to primarily 
play a protective role in response to infectious pathogens. MBL has been shown to be 
essential for host protection from many different viral and bacterial infections either 
through direct binding to pathogens or by limiting spread through complement effector 
functions. MBL has been shown to bind directly to many different viruses, including 
human immunodeficiency virus (HIV), Ebola virus, and arboviruses such as dengue virus 
and West Nile virus (WNV), and MBL can either directly neutralize these viruses 
through activation of complement or interfere with their binding to host cells (reviewed 
in (217)). Furthermore, studies using mice deficient in both MBL genes (MBL-A-/- and 
MBL-C-/-; MBL-DKO) have revealed that MBL can have a protective role during WNV 
and herpes simplex virus infections (61, 62, 65).  Though MBL neutralizes flaviviruses, 
such as WNV and dengue virus (61), and plays a protective role during WNV infection 
(62), these same studies found no detectable interactions between MBL and alphaviruses, 
suggesting that MBL does not play a protective role during alphavirus infection.  
However, the role of MBL role in the pathogenesis of alphavirus-induced 
arthritis/myositis has not been evaluated.   
The goal of this study was to further assess the role of the host complement 
system in the pathogenesis of alphavirus-induced inflammatory disease and to determine 
which complement activation pathways are required for virus-induced disease. In a 
mouse model of RRV-induced arthritis and myositis, mice deficient in either the classical 
or alternative pathways developed severe disease, while mice deficient in both genes of 
MBL (MBL-DKO) were resistant to disease, suggesting that MBL plays a major role in 
RRV-induced disease. Similar to previous findings with C3-/- mice (158), RRV-infected 
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MBL-DKO mice had similar levels of viral burden and inflammation compared to wild-
type (WT) but exhibited significantly less complement deposition, tissue damage, and 
disease. Further analysis found that MBL levels are enhanced in RRV infected tissues 
and that MBL binds to RRV infected cells, suggesting that RRV infection leads to MBL 
deposition and subsequent complement activation.  Importantly, studies in human 
patients suffering from RRV-induced disease found that levels of MBL were elevated in 
the serum of RRV-infected patients compared to healthy controls. In addition, serum and 
synovial fluid MBL levels correlated with the severity of RRV disease, while no 
differences were observed in classical or alternative pathway activation, suggesting that 
MBL contributes to RRV-induced disease in human populations. 
 
2.3 Materials and Methods 
Ethics Statement. Some of the studies described in this manuscript did involve human 
samples.  For human serum samples, all serum samples had been submitted for diagnostic 
testing with written and oral informed patient consent at CIDMLS, Westmead Hospital 
and The Royal Melbourne Hospital (Melbourne, Australia). Samples were de-identified 
by the testing laboratory before being used in the research project. Synovial samples were 
collected from adult patients (age range, 30–45 years) residing in the Murray-Goulburn 
Valley (Victoria, Australia) who had acute cases of RRV-induced polyarthritis in 
accordance with human subjects protocols approved by the Royal Melbourne Hospital 
Human Ethics Committee.  All individuals received and completed written informed 
consent forms prior to collection of materials.  Mouse studies were performed in strict 
accordance with the recommendations in the Guide for the Care and Use of Laboratory 
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Animals of the National Institutes of Health.  All mouse studies were performed at the 
University of North Carolina (Animal Welfare Assurance # A3410-01) using protocols 
approved by the UNC Institutional Animal Care and Use Committee (IACUC).  All 
studies were performed in a manner designed to minimize pain and suffering in infected 
animals, and any animals that exhibited severe disease signs was euthanized immediately 
in accordance with IACUC approved endpoints. 
 
Viruses and cells. The viral stocks used in this study were generated from the infectious 
clone of the T48 strain of RRV (pRR64), kindly provided by Richard Kuhn (Purdue 
University) as described in (161). Briefly, viral RNA was generated through in vitro 
transcription of SacI-linearized pRR64 using the mMessage mMachine SP6 kit (Ambion) 
and electroportated into BHK-21 cells (ATCC). Viral titer was determined by plaque 
assay on BHK-21 cells.  BHK-21 cells were grown in α-MEM (Gibco) supplemented 
with 10% donor calf serum (DCS), 10% tryptose phosphate, L-glutamine, penicillin, and 
streptomycin. C2C12 cells were grown in DMEM (Gibco) supplemented with 20% fetal 
bovine serum (FBS), L-glutamine, penicillin, and streptomycin prior to differentiating. 
To differeniate cells into myotubes, confluent C2C12 cells were maintained in DMEM 
supplemented with 2% horse serum, L-glutamine, penicillin, and streptomycin.  
 
Mice. All mice used in this study were maintained and bred in house at the University of 
North Carolina (UNC) in accordance with UNC Institutional Animal Care and Use 
Committee guidelines. C57BL/6 and MBL-DKO mice were purchased from The Jackson 
Laboratories (Bar Harbor, ME); C1q-/- mice were a generous gift from Dr. Marina Botto 
	   60	  
(Imperial College London, UK); fB-/- mice were generously provided by Dr. Charles 
Jennette (UNC). While RRV is classified as a biosafety level-2 agent, due to the exotic 
nature of the virus, all animal studies were performed in a biosafety level-3 facility. 
Twenty-four day old mice were inoculated with 103 PFU of RRV in diluent (phosphate 
buffered saline supplemented with 1% DCS) into the left rear footpad. Mice were 
weighed daily and assigned a clinical score based on hind limb weakness and altered gait 
on the following scale: 0= no disease; 1=mild loss of hind limb grip; 2=moderate loss of 
hind limb grip; 3=severe loss of hind limb grip; 4= no hind limb grip and mild inability to 
right; 5=no hind limb grip and complete inability to right; 6=moribund.  
 
Viral burden analysis. Mice were infected with RRV as described above, and at 
indicated times post infection mice were sacrificed, perfused with 1X PBS, and indicated 
tissues were dissected out, weighed, and homogenized with glass beads in diluent. Viral 
titer within infected tissues were determined by plaque assay on BHK-21 cells from 
tissue homogenates. 
 
In situ hybridization. Mice were infected with RRV as described above, and at indicated 
times post infection mice were sacrificed, perfused with 4% paraformaldehyde (PFA), pH 
7.3. Tissues were paraffin embedded and 5µm sections were generated and in situ 
hybridization was performed as previously described (161) using an RRV-specific or 
EBER-specific 35S-labeled RNA probe.  
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Histological analysis. At desired times post infection, mice were sacrificed and perfused 
with 4% paraformaldehyde (PFA), pH 7.3. Tissues were paraffin embedded and 5µm 
sections were generated and stained with hematoxylin and eosin (H&E) to examine tissue 
pathology and inflammation. Sections were visualized by bright field light microscopy 
(Olympus BX61).  
 
Evans blue dye uptake analysis. At 10 days post infection mice were injected with 1% 
Evans blue dye in PBS into the peritoneal cavity (50µl/10g mouse weight). At 6 hours 
post injection, mice were sacrificed and perfused with 4% PFA. Quadriceps muscle 
tissues were embedded in optimal cutting temperature compound (OCT) and frozen in an 
isopentane histobath, 5µm sections were generated, mounted with ProLong Gold with 
DAPI (Invitrogen) and sections were analyzed by fluorescence microscopy (Olympus 
BX61).  
 
Immunohistochemistry. At 7 dpi, mice were sacrificed and perfused with 4% PFA. 
Quadriceps muscles were removed, paraffin embedded, and 5µm sections were generated. 
Sections were deparaffinized in xylene, rehydrated through an ethanol gradient, and 
probed with a goat anti-mouse C3 polyclonal antibody (1:500 Cappel) using the 
Vectastain ABC-AP kit (Vector Labs, CA) and Vector Blue Alkaline phosphatase 
substrate kit (Vector Labs, CA) according to the manufacturers’ instructions. Sections 
were counterstained with Gill’s hematoxylin.  
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Immunoblot analysis. At indicated times post infection, mock-infected and RRV-
infected mice were sacrificed, and perfused with 1X PBS. Quadriceps muscles were 
removed and homogenized in radioimmunoprecipitation lysis buffer (RIPA; 50µM Tris 
pH 8.0, 150mM NaCl; 1% NP-40, 0.5% deoxycholate, 0.1% SDS and 1X complete 
protease inhibitor cocktail (Roche)) by glass beads. Protein concentration was determined 
by Bradford protein assay and 25-30µg of protein was run onto a 10% SDS-PAGE gel. 
Protein was transferred onto a PVDF membrane, and membranes were blocked in 5% 
milk, 0.1% Tween-20 in PBS. Membranes were probed with goat anti-mouse MBL-A 
(1:1000 R&D Systems), goat anti-mouse MBL-C (1:1000 R&D Systems), goat anti-
mouse C3 polyclonal antibody (1:1000 Cappel), mouse anti-RRV (1:1000 ATCC), or 
goat anti-mouse actin polyclonal antibody (1:500 SCBT), washed with PBS containing 
0.1% Tween-20 and incubated with rabbit anti-goat antibody or sheep anti-mouse 
antibody conjugated to horseradish peroxidase (1: 10, 000 Sigma). Membranes were 
washed again and protein visualized by ECL (Amersham) according to manufacturer’s 
instructions. Densitometry was performed using ImageJ software (NIH).  
 
MBL deposition onto C2C12 cells. Differentiated C2C12 cells were either mock-
infected or infected at an approximate MOI of 20 with RRV. At 24 hpi, culture medium 
was removed and cells were incubated in differentiation medium containing either 10% 
serum from WT or MBL-DKO mice for an additional 30 minutes. Cells were washed and 
harvested in RIPA lysis buffer, and cell lysates were analyzed by immunoblot analysis.  
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Enzyme Linked Immunosorbent Assay (ELISA).  High binding ELISA plates were 
coated overnight at 4°C with either 10µg/ml mannan (Sigma Aldrich, St. Louis, MO), 5 x 
106 PFU of either mammalian (BHK-21 cells) or mosquito (C6/36 cells) derived virus, or 
mock supernatant from either BHK-21 or C6/36 cells in 1X carbonate buffer. Wells were 
washed with three times with 1X PBS, and subsequently incubated for one hour at room 
temperature in serum from WT mice at 1:20 dilution in gelatin veronal buffer with 
calcium and magnesium (Sigma Aldrich, St. Louis, MO). Wells were washed three times 
with 1X PBS, and incubated in primary antibody against either mouse MBL-C (1:100 
R&D Systems) or against RRV (1:200 ATCC). Wells were washed three times with 1X 
PBS + 0.1% Tween 20 and then incubated in the appropriate HRP-conjugated secondary 
antibody, and developed using TMB substrate (Sigma Aldrich). The OD450nm was 
measured and recorded.  
 
Analysis of infiltrating inflammatory cells by flow cytometry. To determine the 
composition of the inflammatory cell infiltrates within the quadriceps muscle, at 
indicated times post infection mice were sacrificed and perfused with 1X PBS. Both 
quadriceps muscles were removed, minced, and digested with RPMI containing 10% 
fetal bovine serum (FBS), 15mM HEPES, 2.5mg/ml collagenase A (Roche), 1.7mg 
DNase I (Roche) for 2 hours at 37ºC with shaking. Cells were strained through a 40µm 
strainer and washed twice with wash buffer (HBSS containing 1% sodium azide and 1% 
FBS) and total viable cells were determined by trypan blue exclusion. To stain cells for 
flow cytometry, cells were incubated with anti mouse FcγRII/III (2.4G2; BD 
Pharmingen) and stained with combinations of the following antibodies:  fluorescein 
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isothiocyanate (FITC)-conjugated anti-mouse CD3, phycoerythrin (PE)-conjugated anti-
NK1.1, PE-Cy5 anti-CD45 (leukocyte common antigen), PE-Cy7 anti-F4/80, 
Allophycocyanin (APC)-conjugated anti-CD49b, eF450-conjugated anti-CD11b, APC 
anti-major histocompatibility complex class II antigens (MHC II), and eF780-conjugated 
anti-CD45 (B220) (eBiosciences, San Diego, CA), FITC anti-Ly-6G, and PE anti-
SigLecF (BD-Pharmingen, San Diego, CA), and PE-Texas Red-conjugated anti-CD45 
(B220), and PE-Texas Red anti-CD11c (Molecular Bioprobes, Invitrogen). Cells were 
fixed with 2% PFA (pH 7.3) and analyzed on a CyAn flow cytometer (Becton Dickinson), 
and data was analyzed using Summit software.  
 
Gene expression. At 7 dpi following RRV infection, mice were sacrificed and perfused 
with 1X PBS. Quadriceps muscles were removed and homogenized in Trizol (Invitrogen) 
using glass beads. RNA was extracted using Invitrogen PureLink RNA purification kit, 
and mRNA expression of indicated genes was measured by quantitative real-time PCR. 
Raw data values were normalized to 18S rRNA levels.  
 
Patient samples. Convalescent serum samples from five patients presenting with acute, 
serologically confirmed (seroconversion by neutralization, IgM and IgG) RRV-infection 
and thirteen samples from healthy individuals were provided by CIDMLS, Westmead 
Hospital (Sydney, Australia). All serum samples had been submitted for diagnostic 
testing with informed patient consent at CIDMLS, Westmead Hospital and The Royal 
Melbourne Hospital (Melbourne, Australia). Samples were de-identified by the testing 
laboratory before being used in the research project. Needle biopsy was performed to 
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collect synovial fluid samples from adult patients (age range, 30–45 years) residing in the 
Murray-Goulburn Valley (Victoria, Australia) who had acute cases of RRV-induced 
polyarthritis. Samples were collected and prepared aseptically in the laboratories of 
Echuca Hospital (Murray-Goulburn Valley; Victoria, Australia) and The Royal 
Melbourne Hospital and was performed in accordance with The Royal Melbourne 
Hospital Human Ethics Committee. Severe RRV-induced disease was defined as a patient 
presenting with intense swelling, severe joint pain and myalgia affecting both the knee 
joints and joints of the fingers. Mild RRV-induced disease was defined as a patient 
presenting with minor swelling, localized in the knees, and no additional symptoms. For 
osteoarthritis samples, synovial fluid aspirates were obtained from 5 patients with 
osteoarthritis from the John James Hospital (Canberra, Australia). Sample collection was 
performed in accordance with the AustralianCapital Territory Health Community Care 
Human Research Ethics committee. Samples were obtained at the time that knee joint 
arthroplasty was performed, and joints were aspirated before arthrotomy. The diagnosis 
given to patients was primary osteoarthritis with no evidence of an inflammatory 
arthropathy.  These samples were de-identified prior to analysis. 
 Levels of MBL in serum and synovial fluid were determined using a 
commercially available ELISA kit according to the manufacturer’s instructions (R&D 
Systems). Levels of C4a in the synovial fluid was determined using BD OptEIA (BD). 
Bb levels were determined using Microvue Bb Plus (Quidel). The levels of the C1q-C4 
complex were determined as described in (249).  
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Statistical analysis. Clinical scores and percent of starting weight at 10 dpi between C1q-
/-, fB-/-, MBL-DKO, and wild-type mice were analyzed for statistically significant 
differences by Mann-Whitney analysis with multiple comparisons corrections (clinical 
scores; p<0.01 is considered significant), and by one-way ANOVA with Bonferroni’s 
correction (percent of starting weight; p<0.05 is considered significant). Viral burden, 
total number of infiltrating cells, and gene expression data at each time point between 
wild-type and MBL-DKO mice was analyzed for statistically significant differences by 
Mann-Whitney analysis or t-test (p<0.05 is considered significant). Levels of MBL, C4a, 
C1q-C4 complexes, and Bb in serum and synovial fluid from human patients were 
analyzed by Mann-Whitney analysis for statistical significance (p<0.05 is considered 
significant). Statistical analyses were performed using GraphPad Prism 5. 
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2.4 Results  
The MBL pathway is essential for RRV-induced disease and inflammatory tissue 
destruction. 
 Complement activation products are elevated in the synovial fluid of persons 
suffering from RRV-induced arthritis and complement activation is required for virus-
induced arthritis/myositis in a mouse model (158, 160, 161).  Although other 
alphaviruses, such as the neurovirulent Sindbis virus, have been shown to activate 
complement via both the classical and alternative pathways (99), the pathway(s) leading 
to complement activation by arthritic alphaviruses is currently unknown. Therefore, mice 
deficient in key components of the classical (C1q-/-), alternative (factor B, fB-/-), or lectin 
(MBL-A/C-/-, MBL-DKO) pathways were assessed for their susceptibility to RRV-
induced disease. C1q-/-, fB-/-, MBL-DKO, or WT C57BL/6 mice were inoculated with 
RRV in the footpad and assessed for weight loss and scored for hind limb function as 
previously described (161). RRV-infected WT mice showed signs of hind-limb weakness 
by 5 days post infection (dpi) and developed severe hind-limb weakness by 7 dpi through 
10 dpi (Figure 2.1). RRV causes disease independently of B cells and antibody (161), 
suggesting that the classical pathway does not contribute to disease during RRV infection. 
Consistent with this, C1q-/- mice exhibited severe disease signs and hind-limb weakness 
similar to WT animals (Figure 2.1A). Likewise, fB-/- mice developed severe RRV-
induced disease (Figure 2.1A), demonstrating that the alternative pathway of complement 
activation is not required for RRV-induced disease, though it is important to note that 
RRV-infected fB-/- mice tended to develop more severe disease compared to WT mice, 
suggesting that the alternative pathway is activated and may actually play a protective 
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role during RRV infection.  In contrast to C1q-/- and fB-/- mice, MBL-DKO mice infected 
with RRV developed mild hind-limb weakness and exhibited reduced weight loss 
compared to WT mice (Figure 2.1, A and B). Mock-infected WT and MBL-DKO mice 
did not differ in weight gain and showed no signs of disease throughout the course of 
infection (data not shown). While we cannot rule out a minor contribution of the classical 
and alternative activation pathways or activation of the lectin pathway through ficolins in 
development of RRV disease, this data demonstrates that the lectin pathway initiated by 
MBL plays an essential role in driving RRV-induced disease. 
 
MBL contributes to damage within quadriceps muscle.  
Following infection of WT C57BL/6 mice, RRV replicates to high levels within 
both the joints and skeletal muscle and elicits an inflammatory infiltrate into these tissues 
(161).  Following the onset of inflammatory cell infiltration, wild type mice develop 
severe destructive myositis, which is a major aspect of virus-induced disease in this 
mouse model, and we have previously shown that muscle cell killing and disease is 
dependent upon both C3 activation and CR3 (158, 160).  Therefore, to confirm the role of 
MBL in driving RRV-induced disease, inflammatory pathology was assessed within the 
quadriceps muscles of RRV-infected fB-/-, C1q-/-, MBL-DKO, or WT mice by H&E 
staining of paraffin embedded sections. At 10 dpi, a time point of peak RRV disease, we 
observed similar inflammation and tissue pathology in fB-/-, C1q-/-, and WT mice (Figure 
2.2A). Inflammatory cells are present in the quadriceps muscles of infected mice from all 
strains, as indicated by the solid arrowheads. We observed tissue damage in the 
quadriceps muscles in fB-/-, C1q-/-, and WT mice as evidenced by the degeneration of the 
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fibrous architecture of the skeletal muscle. In contrast, RRV infected MBL-DKO mice 
maintained the architecture of the skeletal muscle with very little tissue damage, despite 
the presence of inflammatory cells (Figure 2.2A), which was strikingly similar to 
previous results demonstrating an essential role for C3 in RRV-induced disease (158). To 
confirm that MBL-DKO mice have decreased tissue damage following RRV infection 
compared to WT mice, we used Evans Blue dye (EBD) uptake to detect areas of damage. 
Consistent with the clinical scores and histological analyses at 10 dpi, RRV-infected WT 
mice had abundant EBD positive muscle fibers within the quadriceps muscle whereas 
EBD positive cells were rare in RRV-infected MBL-DKO mice (Figure 2.2B), further 
demonstrating that MBL is required for the induction of tissue damage during RRV-
induced disease. 
 
RRV infection induces MBL deposition onto tissues and cells.  
 To determine if MBL is deposited onto tissues following RRV infection, we 
evaluated tissue homogenates of quadriceps muscle from RRV-infected WT mice at 7 dpi 
for levels of MBL by immunoblot analysis. We observed an increase in the amount of 
MBL in the quadriceps muscle of infected mice compared to that of mock-infected mice 
(Figure 2.3A), indicating that RRV infection results in elevated amounts of MBL within 
target tissues.  Given the enhanced MBL within RRV infected muscle tissue, we next 
evaluated whether MBL would directly bind to RRV or RRV infected cells.  Studies with 
two other alphaviruses, CHIKV and Sindbis virus, found no evidence for interactions 
with MBL, while mosquito derived West Nile virus was efficiently bound and neutralized 
by MBL (61). Consistent with these findings, we were unable to detect direct binding 
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between MBL and either mammalian cell or mosquito cell derived RRV virions by 
ELISA (Figure 2.4A-B) and we also found no evidence for MBL-mediated neutralization 
of RRV (Figure 2.4C). Given the lack of detectable interactions between MBL and the 
RRV virion, we assessed whether MBL bound to RRV-infected cells. Differentiated 
C2C12 murine skeletal muscle cells were infected with RRV for 24 hours and then 
incubated with medium containing either C57BL/6 wild-type serum or MBL-DKO serum 
for 30 minutes. Cell lysates were harvested and analyzed for presence of MBL-C by 
immunoblot analysis. As shown in Figure 2.3B, the amount of MBL-C deposition was 
enhanced in cells infected with RRV compared to mock infected cells, indicating that 
RRV infection results in increased MBL binding to cells. No deposition of MBL was 
detected onto cells incubated with MBL-DKO serum, indicating the specificity of 
detection.  Therefore, though MBL does not appear to interact with the RRV virion, RRV 
infection does lead to MBL deposition on infected cells.    
 
Complement deposition and activation is reduced in RRV-infected MBL-DKO compared 
to WT mice. 
MBL, but not the alternatively or classical complement activation pathways, was 
required for RRV-induced disease and tissue pathology (Figures 2.1 and 2.2), and the 
phenotype in MBL-DKO mice is strikingly similar to C3-/- mice, suggesting that MBL 
plays a major role in driving complement activation during RRV infection.  Therefore, 
we directly assessed whether MBL was required for RRV-dependent complement 
deposition.  Western blot analysis of skeletal muscle from wild type or MBL-DKO mice 
indicated that C3 levels, including the α and β chains of C3 were present at reduced 
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levels in the skeletal muscle of RRV infected MBL-DKO mice compared to wild type 
mice (Figure 2.5). However, since inflammatory macrophages produce C3 (20), western 
blot analysis was not able to clearly differentiate between complement deposition within 
the tissue and de novo production of complement by the infiltrating inflammatory cells in 
both wild type and MBL-DKO animals. Therefore, we directly assessed the impact of 
MBL deficiency on complement deposition within the RRV infected muscle by 
performing immunohistochemistry on quadriceps muscle from WT and MBL-DKO mice 
using an anti-mouse C3 antibody. Abundant C3 staining localized to damaged skeletal 
muscle at 7 dpi in WT mice while C3 staining was substantially reduced in muscle from 
RRV-infected MBL-DKO mice (Figure 2.6A).  Importantly, we observed comparable C3 
staining between RRV-infected C1q-/-, fB-/-, and WT mice (Figure 2.6B), suggesting that 
neither C1q nor fB are required for C3 deposition on muscle tissue following RRV 
infection. Therefore, these results suggest that MBL is the major mediator of complement 
activation and deposition within RRV infected muscle tissue.   
 
Viral replication is unaffected in the muscle tissue of MBL-DKO mice.  
Prior studies with C3-/- and CR3-/- mice demonstrated that complement activation 
and CR3-dependent signaling is essential for RRV-induced disease and tissue destruction, 
but complement deficiency had no effect on viral burden or tropism. To determine 
whether this was also the case in MBL-DKO mice, we evaluated WT and MBL-DKO 
mice for viral load within the quadriceps muscles, ankle joints, and serum.  As shown in 
Figure 2.7A, MBL-DKO mice exhibited no significant difference in the amount of 
infectious virus in the quadriceps muscle through days 7 and 10 dpi, which represent the 
	   72	  
times when RRV-induced muscle destruction peaks.  Furthermore, analysis of the viral 
distribution within wild type and MBL-DKO animals by in situ hybridization found no 
differences in the localization of RRV specific signal between the two mouse strains. 
(Figure 2.7D).  Therefore, the differences in RRV-induced tissue destruction (Figure 
2.2A-B) or C3 deposition (Figure 2.6) within the RRV infected muscle of MBL-DKO 
mice cannot be explained by differences in viral replication.   
In addition to evaluating viral titers within the skeletal muscle, we also assessed 
viral loads within the serum and ankle joints.  Viral titers within the ankle joints were 
similar between MBL-DKO and WT mice through 7 dpi (Figure 2.7B), though we did 
observe a small, but statistically significant decrease in viral titer within the ankle joints 
of MBL-DKO mice compared to wild type mice at day 10 post infection.  MBL-DKO 
mice had higher amounts of virus in the serum at 1 dpi compared to WT mice (Figure 
2.7C), indicating that MBL may play some role in initial control of viremia. However, 
virus was cleared from the serum of infected animals at similar rates in both WT and 
MBL-DKO mice (Figure 2.7C), suggesting that MBL does not play a major role in serum 
clearance of RRV or direct neutralization of virus in the serum. The impact of this initial 
increase in serum viremia in MBL-DKO mice on downstream disease through antibody 
production is unclear, although it is important to note that both RAG-1-/- and µMT mice 
develop disease similar to WT mice (158), indicating that the antibody response is not 
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MBL deficiency does not affect inflammatory cell recruitment, but alters expression of 
inflammatory mediators within the RRV-infected muscle. 
Prior studies demonstrated that complement activation drives inflammatory tissue 
destruction, but does not regulate inflammatory cell recruitment during RRV infection 
(158). However, as MBL may regulate the host inflammatory response independently of 
its effects on complement activation, we quantified and analyzed the inflammatory cell 
populations within the muscle of WT and MBL-DKO animals at 7 and 10 dpi, which are 
the times of peak inflammation in WT mice (161). Consistent with prior findings in C3-/- 
mice, RRV infected MBL-DKO mice exhibited no statistically significant differences in 
either total number of leukocytes (Figure 2.8A) or the composition of the inflammatory 
infiltrates at either 7 or 10 dpi (Figure 2.8B). Representative flow cytometry plots of the 
various cell types are shown in Figure S2.1. The total numbers of CD4+ T cells, CD8+ T 
cells, and NK cells at both 7 and 10 dpi were not significantly different between RRV-
infected WT and MBL-DKO mice (Figure 2.8B). Given the role of inflammatory 
macrophage in development of RRV-induced disease (135), we compared total numbers 
of cells with staining characteristics of inflammatory macrophages (F4/80+ CD11b+ Gr-
1lo B220-) at both 7 and 10 dpi, and observed no difference at 7 dpi, and interestingly, a 
significant increase in numbers of these cells in RRV-infected MBL-DKO mice at 10 dpi. 
While we cannot rule out the possibility that minor populations of inflammatory cells are 
differentially regulated by MBL, these data suggest that MBL does not affect the major 
populations of inflammatory infiltrates recruited to the skeletal muscle following RRV 
infection.  
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Although inflammatory cell recruitment was largely unaffected by either MBL or 
C3 deficiency (158) we have previously shown CR3 is also required for RRV-induced 
disease and that a subset of inflammatory genes expressed in the inflamed muscle of 
RRV-infected mice are dependent upon both C3 and CR3, including the calgranulins 
S100A8 and S100A9, IL-6 and the enzyme arginase I (ArgI) (160). Therefore, to 
determine if MBL affected expression of these genes in the same manner as C3 and CR3, 
expression levels were assessed in the quadriceps muscle from both WT and MBL-DKO 
mice at 7 dpi.  As shown in Figure 2.9, RRV-infected WT mice exhibited significantly 
higher expression of S100A8 and S100A9 compared to RRV-infected MBL-DKO mice, 
indicating that expression of these genes is also regulated by MBL during RRV infection. 
Interestingly, the S100A8/S100A9 complex has been associated with inflammatory 
arthritis (reviewed in (172)) however, the role of these proteins in RRV disease requires 
further investigation. Expression of TNFα and IL-1β, which were shown to be C3-
independent (160), were also unaffected in MBL-DKO mice (Figure 2.9). Expression of 
IL-6 and Arg I, which we have previously shown to be C3 and CR3-dependent, were 
unaffected in MBL-DKO mice (IL-6) or slightly reduced (Arg I) (Figure 2.9). Expression 
of these genes may reflect residual complement activation in the absence of MBL (Figure 
S3), though this requires further study. Interestingly, expression of IL-10, which is 
largely C3-independent following RRV infection (160), was dependent on MBL and 
suggests that MBL may be interacting with pathways other than the complement system 
to mediate IL-10 expression (Figure 2.9).  
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Levels of MBL are elevated in RRV patients. 
 Prior studies have shown that the C3 cleavage product C3a is elevated in synovial 
fluid of RRV polyarthritis patients (158). To determine if circulating levels of MBL are 
elevated in RRV-infected patients, we compared serum MBL levels from patients during 
convalescence to serum MBL levels in RRV-seronegative controls. As shown in Figure 
2.10A, RRV patients had significantly higher levels of circulating MBL compared to 
healthy controls. Since MBL levels are highly variable in human populations, we also 
assessed serum and synovial fluid MBL levels in a small cohort of patients clinically 
characterized as having severe or mild RRV-induced polyarthritis. MBL levels correlated 
with severity of RRV disease (Figure 2.10B), with higher levels of MBL observed in 
patients classified as having severe disease. Severity of disease also correlated with 
increased levels of C4a in the synovial fluid (Figure 2.10C), which could result from 
complement activation through either the lectin or classical pathway. However, analysis 
of the level of C1q-C4 complexes formed within the synovial fluid, an activation marker 
of the classical pathway (249), showed no difference between patients with severe or 
mild disease (Figure 2.10C), suggesting that the higher C4a levels in severe RRV disease 
was primarily due to activation through the lectin pathway. In addition, we did not 
observe a difference in levels of Bb, an activation marker of the alternative pathway 
(Figure 2.10C), further supporting the hypothesis that the MBL pathway primarily 
mediates complement activation following RRV infection. Importantly, when we 
assessed MBL levels in a cohort of patients suffering from non-inflammatory 
osteoarthritis, we found no evidence for elevated MBL levels (mean MBL levels of 57.8 
± 24.8 ng/ml [n=5 patients with severe osteoarthritis]) compared to MBL levels of 485 ± 
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163.7 ng/ml in patients with severe RRV induced disease and 218.5 ± 82.4 ng/ml within 
the synovial fluid of patients with mild RRV-induced disease, suggesting that elevated 
levels of MBL are not simply the result of arthritis symptoms within the joints.  Although 
additional studies with a larger cohort of patients are required to determine whether MBL 
levels associate with the severity of RRV-induced arthritis, and whether this effect 
reflects a causal role for MBL in human disease, these results, combined with the 
knockout mouse studies strongly suggest that the MBL pathway of complement 
activation plays a major role in the pathogenesis of RRV-induced inflammatory disease.   
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2.5 Discussion 
Alphaviruses such as CHIKV and RRV represent significant emerging disease 
threats that cause large-scale outbreaks of severe chronic and persistent 
arthralgia/myalgia in human populations.  Though alphavirus-induced arthralgia and 
myalgia is often debilitating, the mechanisms by which these viruses cause 
arthritis/arthralgia are not fully understood.  Previous studies have shown that 
inflammatory macrophages play a major role in the pathogenesis of both RRV and 
CHIKV (68, 135), that the host complement cascade is essential for the induction of 
muscle destruction by these inflammatory cells during RRV infection, and that this 
process is dependent on complement receptor 3 (CR3) (158, 160). The data presented 
here demonstrate that RRV infection results in the deposition of MBL within RRV 
infected tissues, and that MBL, but not the alternative or classical complement activation 
pathways, was essential for RRV induced complement activation and subsequent 
inflammatory tissue destruction and disease.  Consistent with this, humans suffering from 
severe RRV disease exhibited increased levels of MBL, but not markers of the classical 
or alternative complement activation pathways in their synovial fluid.  Therefore, these 
studies demonstrate that MBL plays a key role in promoting the pathogenesis of 
alphavirus-induced inflammatory disease, and suggest that MBL may represent a target 
for therapeutic intervention in the treatment of alphavirus-induced arthritis/myositis.  
MBL has generally been associated with a protective role during viral infection, 
either through its ability to neutralize viruses directly or via the downstream activation of 
complement.  In the context of arbovirus infection, MBL contributes to direct 
neutralization of mosquito-derived West Nile virus and both mammalian and mosquito-
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derived dengue virus through interactions between MBL and viral N-linked glycans (7, 
61), and MBL contributes to protection from West Nile virus-induced disease in vivo 
(62). Though the host complement cascade has been shown to play a protective role 
during neurotropic alphavirus infection (23, 98, 99) these processes are dependent upon 
either the classical or alternative complement activation pathways (99).  Furthermore, 
though Fuchs, et al., found that MBL bound and neutralized WNV virions, they found no 
evidence for MBL interactions with two alphaviruses, CHIKV and Sindbis virus (61), 
which is supported by our inability to demonstrate direct binding or neutralization of 
RRV virions by MBL.  Therefore, our findings demonstrate a novel role for MBL in the 
pathogenesis of alphavirus-induced arthritis/myositis and indicate that this pathway, 
which plays a protective role against many viral infections, is actually a major driver of 
RRV-induced tissue pathology and disease.    
In addition to its prominent role in the pathogenesis of RRV-induced disease, the 
complement cascade is linked to a number of host autoimmune inflammatory disorders, 
including rheumatoid arthritis (reviewed in (103)).  However, the role of MBL in these 
processes is less clear.  Though MBL has been shown to contribute to ischemic injury in 
mouse models of cardiac or intestinal reperfusion injury (89, 112, 205, 237), MBL has 
not been directly linked to inflammatory arthritis.  There are conflicting reports 
associating MBL polymorphisms with rheumatoid arthritis in humans (80, 109, 110, 198, 
228), however in mouse models of collagen-induced arthritis, which serves as a model of 
RA, MBL is dispensable for complement activation and arthritis induction (10, 11).  
Therefore, MBL appears to be playing a unique role in the pathogenesis of RRV-induced 
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arthritis/myositis that is not shared with other arthritic syndromes, though further 
comparisons between these different disease states are needed to clarify this issue.    
The studies presented here demonstrate that MBL-dependent complement 
activation promotes RRV-induced disease and raises several questions relating to the 
mechanism of RRV activation of complement, the role of MBL polymorphisms in 
determining disease severity, and the therapeutic potential of MBL inhibition to treat 
RRV-infected patients. The CRD of MBL recognizes terminal carbohydrates, such as 
mannose and glucose, which can be found on glycosylated proteins in bacteria and 
viruses. The RRV glycoproteins contain three N-linked glycosylation sites that are 
glycosylated with a combination of high mannose and complex glycans (210) and may 
serve as ligands for MBL, leading to complement activation. While we did not observe 
direct binding of MBL to virions, we did observe an increase in the amount of MBL 
deposited onto infected tissues and on virally infected cells (Figure 2.3), indicating that 
some aspect of RRV infection induces MBL deposition and complement activation. 
Alphaviruses bud from the plasma membrane of infected cells and the viral glycoproteins 
are prominently exposed on the surface of the cell. Therefore, it is possible that MBL is 
recognizing and binding to viral glycoproteins on infected tissues during viral egress, 
resulting in complement activation directly onto the tissue rather than binding to free 
virus. Alternatively, viral infection may lead to the modification of host cell N-linked 
glycans or other cellular components, thereby promoting MBL deposition and 
complement activation; however, both of these possibilities require further investigation.   
Given the central role of MBL in development of severe RRV-induced disease, 
specific inhibition of the MBL activation pathway of the complement system in RRV-
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patients may be a strategy to alleviate disease. Current therapy involves administration of 
non-steroidal anti-inflammatory drugs, and given the role that complement plays in 
mediating severe RRV-induced disease, treatment with complement inhibitors may 
provide an attractive alternative to nonspecific anti-inflammatory drugs. However, 
prolonged inhibition of the complement system can leave patients susceptible to other 
infectious diseases, especially as treatment of disease symptoms may require several 
months for some individuals (163). Our results suggest that a more focused approach 
targeting MBL may prove effective in limiting RRV-induced arthralgia/myalgia, while 
limiting the general immune suppression associated with complement inhibition. 
Inhibitors targeting the MBL pathway of complement through inhibition of MASP-2 are 
in development (14), and may be useful in treatment of RRV-induced disease in humans.   
In addition to raising the possibility of targeting MBL in the treatment of RRV or 
other alphavirus-induced arthraligias/myalgias, these studies raise the issue of whether 
polymorphisms in MBL affect susceptibility to RRV-induced disease.  Common genetic 
polymorphisms within the promoter region and exon 1 of the human Mbl2 gene lead to 
variations in serum MBL levels or functional deficiency of MBL (reviewed in (51)). 
Human patients with severe RRV disease have higher levels of MBL within the synovial 
fluid and serum; however, it is unclear if levels of MBL are elevated in response to 
severe RRV infection or if naturally higher levels of MBL contribute to the development 
of severe disease. Preliminary analysis of a small cohort of RRV patients does not 
associate Mbl2 polymorphisms with severity of RRV disease (S. Mahalingam, B. Piraino, 
B. Cameron, L. Herrero, and A. Lloyd, unpublished data), however a larger cohort of 
RRV-infected individuals must be analyzed before we can conclude whether MBL 
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polymorphisms associate with RRV-induced disease severity or if up-regulation of MBL 
in response to viral infection contributes to disease pathogenesis in humans.  
 
In summary, the data presented in this study demonstrate the role for MBL in 
promoting severe disease following RRV infection through complement activation and 
subsequent destruction of RRV infected tissue. Numerous studies have shown a 
protective role for MBL and the complement system in response to a diverse set of 
viruses. Our results demonstrate a novel role of MBL following viral infection in which 
MBL contributes to development of severe disease, and these findings suggest that MBL 
may be a therapeutic target for treatment in humans suffering from RRV-induced 
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Figure 2.1: MBL is required for development of severe RRV-induced disease and 
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Figure 2.1 MBL is required for development of severe RRV-induced disease and 
tissue damage.  
(A-B) Twenty-four day old WT C57BL/6 (solid square, n=6), C1q-/- (open square, n=6), 
fB-/- (solid circle, n=5), or MBL-DKO (open circle, n=6) mice were infected with RRV, 
scored for hind limb function based on a scale described in the Materials and Methods 
(A), and assessed for weight loss (B). Each data point represents the arithmetic mean 
±SD and is representative of at least three independent experiments. We performed a 
Mann-Whitney analysis with multiple comparison corrections (p<0.01 was considered 
significant) on clinical scores at 10 dpi and a one-way ANOVA analysis with 
Bonferroni’s correction on percent of starting weight at 10 dpi (p<0.05 was considered 
significant) to determine significance between the various knock-out lines compared to 
WT **p<0.01; *** p<0.001; n.s. not significant. 
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Figure 2.2: MBL is required for development of severe RRV-induced pathology and 
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Figure 2.2 MBL is required for development of severe RRV-induced pathology and 
tissue damage within skeletal muscle.  
(A) Twenty-four day old WT C57BL/6, C1q-/-, fB-/-, or MBL-DKO mice were infected 
with RRV. Tissue pathology and inflammation was examined at 10 dpi by H&E staining 
of paraffin embedded sections of quadriceps muscle. A representative section from each 
knockout strain is shown. A section from RRV-infected C3-/- is shown for comparison.  
(B) To assess damage within the muscle, mock or RRV-infected WT or MBL-DKO mice 
were injected with EBD at 10 dpi, and frozen sections were generated. EBD positive 
muscle fibers were identified by fluorescence microscopy. Representative sections of 
mock- and RRV-infected mice are shown and are representative of two independent 
experiments.  
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Figure 2.3 RRV infection induces MBL deposition onto cells 
(A) To determine if MBL levels are elevated within the quadriceps muscles of RRV-
infected wild-type animals, homogenized quadriceps muscles from either mock- or RRV-
infected WT mice at 7 dpi were analyzed by immunoblot analysis using anti-mouse 
MBL-A, anti-mouse MBL-C, or anti-mouse actin antibodies. Each lane represents an 
individual mouse and is representative of at least three independent experiments. 
Densitometry measurements of bands in immunoblot from three different experiments are 
graphically depicted as arbitrary units normalized to actin (mock n=4; RRV n=9).  
(B) To determine if MBL deposition is enhanced onto RRV-infected cell, differentiated 
C2C12 murine skeletal muscle cells were infected with RRV, and incubated with either 
serum from a WT or MBL-DKO mouse for 30 minutes prior to harvesting. Cells were 
washed, harvested, and lysates were analyzed by immunoblot analysis using anti-mouse 
MBL-C, anti-RRV, or anti-mouse actin antibodies.  
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Figure 2.4 MBL does not bind or neutralize RRV virions. 
(A-B) To determine if MBL could bind to RRV virions directly, a modified sandwich 
ELISA was performed. Wells were coated with mannan (grey bar), mammalian or 
mosquito-derived RRV (solid bar), or mock supernatant (open bar), and were 
subsequently incubated in WT mouse serum as a source of MBL. (A) The amount of 
MBL deposition within the wells was detected by an antibody against mouse MBL-C 
using standard ELISA techniques. (B) The amount of RRV antigen was detected using an 
antibody against the RRV structural proteins. Data is expressed as raw OD450nm values 
normalized to background, and each bar is the arithmetic mean ± SD of three replicates 
and is representative of two independent experiments. 
(C) To determine if RRV could be directly neutralized by complement components 
within serum, 103 PFU of RR64 was incubated with increasing amounts of naïve mouse 
serum from wild-type (solid circle) or MBL-DKO mice (solid square), or heat-inactivated 
wild-type serum (open circle) for 1 hour at 37°C. The number of plaques was determined 
by plaque assay on BHK-21 cells. Each data point represents the arithmetic mean ± SD of 
three replicates and is representative of three independent experiments. 
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Figure 2.5: Complement activation within quadriceps muscle is largely dependent 
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Figure 2.5. Complement activation within quadriceps muscle is largely dependent 
on MBL.  
To determine if complement activation was dependent on MBL, we analyzed 
homogenized quadriceps muscles from either mock- or RRV-infected WT or MBL-DKO 
mice 7 dpi by immunoblot analysis using an anti-mouse C3 or anti-mouse actin antibody. 
C3 cleavage products are indicated with solid arrowheads. Each lane represents an 
individual mouse, and the western blot is representative of three independent experiments  
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Figure 2.6. MBL is required for C3 deposition following RRV-infection.  
(A) C3 deposition was assessed by IHC using an anti-mouse C3 antibody on quadriceps 
muscle sections from either mock- or RRV-infected WT or MBL-DKO mice at 7 dpi. C3 
positive areas are stained in blue. A representative section from each strain is shown and 
is representative of two independent experiments. No signal was observed in sections 
incubated with a control goat IgG antibody. 
(B) To determine if either the classical or alternative complement activation pathways 
contribute to C3 deposition following RRV infection, we performed IHC using an anti-
mouse C3 on quadriceps muscle sections from RRV-infected wild-type, C1q-/-, or fB-/- at 
10 dpi. C3 deposition is shown in red for C1q-/- and the wild-type control, and in blue for 
the fB-/- and wild-type control. 5µm thick paraffin-embedded sections were prepared as 
described in the Materials and Methods, with the following modification:  RRV-infected 
C1q-/- and wild-type sections were developed using Vector Red Alkaline phosphatase 
substrate kit (Vector Labs, CA) instead of Vector Blue Alkaline phosphatase substrate kit. 
A representative section from each strain is shown (n=3 for wild-type mice, n=3 for C1q-
/- mice; n= 3 for wild-type mice, n=3 for fB-/- mice) 
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Figure 2.7: MBL deficiency does not affect viral replication or tropism within 
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Figure 2.7: MBL deficiency does not affect viral replication or tropism within 
infected tissues.  
 
 C.  
 
 D.  
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Figure 2.7 MBL deficiency does not affect viral replication or tropism within 
infected tissues.  
(A-C) Quadriceps muscle (A), ankle joints (B), and serum (C) from RRV-infected WT 
(solid circles, n=3-9/time point) or MBL-DKO (open circles, n=3-8/time point) mice 
were assayed to determine viral titer at various times post infection. Viral titer was 
determined by plaque assay on BHK-21 cells. Each data point represents the viral titer 
from a single animal; data is combined from two independent experiments. *p<0.05 as 
determined by t-test.  
(D) Tropism within the quadriceps muscle tissue was determined by in situ hybridization 
using RRV-specific probe. We did not detect any signal using an EBER-specific probe 
(data not shown). A representative section from each strain is shown (n=3 for both WT 
and MBL-DKO mice) 
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Figure 2.8: MBL deficiency does not affect inflammatory cell recruitment. 
  A.  
 
 B.  
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Figure 2.8 MBL deficiency does not affect inflammatory cell recruitment. 
(A-B) Leukocytes were isolated from the quadriceps muscle of RRV-infected WT (solid 
circles, n=3-5/time point) or MBL-DKO (open circles, n=3-7/time point) mice at 7 or 10 
dpi. Cells were characterized and quantified by flow cytometry using the markers 
described in the materials and methods. Total numbers of leukocytes (A) and specific 
cells types (B) are shown. A single experiment for each time point is shown. *p<0.05 by 
Mann-Whitney analysis.  
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Figure 2.9: MBL deficiency alters expression of inflammatory mediators within the 
RRV infected muscle.  
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Figure 2.9 MBL deficiency alters expression of inflammatory mediators within the 
RRV infected muscle.  
Relative mRNA expression of C3-dependent inflammatory mediators and cytokines 
S100A9, S100A8, Arginase I, and IL-6, and C3-independent cytokines TNFα, IL-1β, and 
IL-10 from quadriceps muscle from RRV-infected WT (solid bar, n=3) or MBL-DKO 
(open bar, n=3) mice by quantitative real-time PCR. Raw data values were normalized to 
18S rRNA levels, log-transformed, and are graphically depicted as fold expression over 
mock-infected mice. Data from a single experiment is shown, but is representative of two 
independent experiments. ***p<0.001; **p<0.005 by t-test.  
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Figure 2.10: Levels of MBL are elevated in RRV patients.  
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Figure 2.10 Levels of MBL are elevated in RRV patients. 
(A) Serum from RRV-infected patients (solid circles, n= 5) or healthy sero-negative 
controls (open circles, n=13) were analyzed by ELISA for MBL levels. Each data point 
represents a single individual, and bar represents the median. *p<0.05 by Mann-Whitney 
analysis.  
(B) MBL levels within serum and synovial fluid from patients clinically characterized 
with either severe RRV-induced disease (solid circles, n=6) or mild RRV-induced disease 
(open circles, n=4) were analyzed by ELISA. Each data point represents a single 
individual, and the bar represents the median. **p<0.01 by Mann-Whitney analysis.  
(C) Levels of C4a (left), C1q-C4 complex (middle) and Bb (right) within the synovial 
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Figure S2.1: Representative flow cytometry plots and gating scheme used to 
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Figure S2.1 Representative flow cytometry plots and gating scheme used to 
characterize inflammatory infiltrates.  
(A) To determine the number of leukocytes, we gated on LCA+ cells. To further 
distinguish between NK cells and T cells, we analyzed expression of NK1.1 and CD3 on 
LCA+ lymphocytes. NK1.1+CD3- were classified as NK cells, and NK1.1-CD3+ cells 
were classified as T cells. T cells were further classified into CD4+ and CD8+ T cells 
based on CD4 and CD8 expression. Percentages displayed on plots represent the 
percentage of cells within the indicated gate. (B) To determine the number of 
inflammatory macrophage, we first gated on LCA+ cells, followed by analysis of CD11b 
and B220 expression. Inflammatory macrophage typically stain CD11b+B220-. We 
distinguished inflammatory macrophage from neutrophils within the CD11b+B220- 
population by analyzing F4/80 and Gr-1/Ly-6G expression; inflammatory macrophage 
were defined as CD11b+B220-F4/80+Gr-1lo. Percentages displayed on plots represent the 








ROSS RIVER VIRUS ENVELOPE N-LINKED GLYCANS CONTRIBUTE TO 
ALPHAVIRUS-INDUCED ARTHRITIS AND MYOSITIS THROUGH 
ACTIVATION OF THE HOST COMPLEMENT SYSTEM.  
 
3.1 Summary 
Mannose binding lectin (MBL) generally plays a protective role during viral infection, 
both through the ability to directly neutralize viruses and its role in activating the host 
complement cascade.  However, in the context of alphavirus-induced arthritis and 
myositis, MBL-mediated complement activation plays a pathologic role by promoting 
virus-induced inflammatory tissue destruction.  To define the mechanisms by which 
MBL contributes to virus-induced disease following Ross River virus (RRV) infection, 
studies were performed to identify specific viral factors were involved in promoting 
MBL-dependent complement activation.  Since MBL recognizes and binds to terminal 
carbohydrates, we hypothesized that one or more of the three N-linked glycosylation sites 
on the RRV envelope glycoproteins acted as ligands for MBL binding and subsequent 
complement activation and disease. Using a panel of RRV mutants lacking one or more 
envelope glycans, we have found that the RRV E2 N-linked glycans were required for 
MBL binding to infected cells and induction of RRV-induced disease.  Animals infected 
with a virus lacking both N-linked glycans on the E2 glycoprotein (E2 N200;262Q) 
exhibited reduced disease, significantly less tissue damage, and decreased MBL binding 	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and complement activation compared to animals infected with the wild type virus.  These 
results demonstrate that interactions between MBL and the viral N-linked glycans play a 
major role in promoting virus induced disease and suggest that targeting these 
interactions may be of benefit in developing potential therapies in the treatment of 
alphavirus-induced arthritis.  
 
3.2 Introduction 
Arthritic alphaviruses such as RRV and chikungunya virus (CHIKV) are 
mosquito-borne viruses that cause outbreaks of debilitating infectious arthritis in many 
regions of the world. These viruses are transmitted to humans primarily by the Aedes and 
Culex species of mosquito and have been found to cause epidemics of disease in both 
urban and rural settings (86). Both RRV and CHIKV share similar disease symptoms that 
are characterized by debilitating polyarthritis and myositis that frequently results in 
painful swelling of the peripheral joints. Studies in both humans and mice have identified 
a critical role for the host inflammatory response in the development of RRV-induced 
arthritis and immunopathology associated with disease (135, 161). In particular, the host 
complement system plays a critical role in development of disease and is thought to act 
not through direct lysis of cells by formation of the terminal complex, but rather through 
activation of CR3-bearing inflammatory cells to mediate direct damage to the inflamed 
tissues (158, 160). Furthermore, we recently demonstrated that the lectin pathway, which 
is one of the three main activation pathways of the complement system, initiated by 
mannose binding lectin (MBL) mediates activation of complement following RRV 
infection and contributes to disease without altering tropism and viral burden (79).  This 
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is in contrast with many other viral systems, such as West Nile virus (WNV), Ebola virus, 
human immunodeficiency virus, and SARS-CoV, where MBL plays a protective role 
during infection, either through direct inhibition of viral infection or via complement 
activation (54, 61, 111, 257).   
MBL-mediated complement activation is initiated by the recognition of terminal 
sugars on glycosylated proteins by the CRD of MBL (reviewed in (223)). Though we 
have previously demonstrated that MBL does not directly bind to free RRV virions, given 
the ligand specificity of MBL, we hypothesized that MBL might interact with the N-
linked glycans on the RRV envelope glycoproteins when they are displayed on the 
surface of infected cells. The alphavirus glycoproteins E1 and E2 contain three to four N-
linked glycosylation sites (Asn - X - Ser/Thr) that are glycosylated with N-linked glycans 
(219). The RRV pE2 and E1 glycoproteins are synthesized and processed through the ER 
and then further processed in the Golgi to generate mature E2-E1 heterodimers. The E2-
E1 heterodimers self-assemble into trimeric spikes at the plasma membrane, and each 
budding alphavirus virion incorporates 80 glycoprotein spikes to make up the viral 
envelope. The E2 glycoprotein is prominently displayed on the surface of the virus and 
on the surface of infected cells, and for most alphaviruses, two of the N-linked glycans 
are located on E2. The positions of the RRV E2 glycans on the glycoprotein spike have 
been mapped: the E2 N200 carbohydrate moiety is located on one side of the tip of the 
protruding E2 “petal”, and the E2 N262 glycan appears to be located between the trimeric 
spikes (174). Thus, the RRV E2 N-linked glycans are surface exposed and are in a key 
position to interact with host proteins. The RRV E2 N-linked glycans are glycosylated 
with a combination of high mannose and complex glycans when produced in mammalian 
	   108	  
cells; the glycan at E2 N200 is either a high mannose or hybrid glycan and the E2 N262 
position is predominantly glycosylated with a complex glycan (210). The role of these N-
linked glycans in arthritic alphavirus pathogenesis to date has not been evaluated.  
 In this study, we have used a panel of mutant viruses that lack one or both of the 
two N-linked glycosylation sites on E2 to demonstrate that the E2 N-linked glycans are 
required for MBL binding to virally infected cells and subsequent induction of virus-
induced disease. While RRV infected cells are readily bound by MBL, this activity was 
lost when the cells were infected with RRV lacking both N-linked glycans on the viral E2 
glycoprotein.  Furthermore, viruses lacking either E2 N-linked glycosylation site cause 
reduced RRV disease in mice, while a virus lacking both sites causes very mild disease. 
Our results supports a model of RRV disease pathogenesis wherein the E2 N-linked 
glycans promote activation of the lectin complement pathway by MBL, resulting in 
activation of CR3-bearing inflammatory cells and subsequent damage within inflamed 
tissues 
 
3.3 Materials and Methods 
Viruses and cells. Wild-type RRV is derived from the infectious clone of RRV T48 
(pRR64), and the E2 N-linked glycan mutants were generated previously by site directed 
mutagenesis of N-linked glycosylation sites in E2 in pRR64 (210). The viral stocks used 
in this study were generated as described in (161). Briefly, viral RNA was generated 
through in vitro transcription of SacI-linearized pRR64 using the mMessage mMachine 
SP6 kit (Ambion) and electroportated into BHK-21 cells (ATCC). Viral titer was 
determined by plaque assay on BHK-21 cells.  BHK-21 cells were grown in α-MEM 
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(Gibco) supplemented with 10% donor calf serum (DCS), 10% tryptose phosphate, L-
glutamine, penicillin, and streptomycin.  Murine myoblast C2C12 cells (ATCC) were 
grown in DMEM supplemented with 20% FBS, L-glutamine, penicillin, and 
streptomycin prior to differentiating. To differentiate cells into myotubes, confluent 
C2C12 cells were maintained in DMEM supplemented with 2% horse serum, L-
glutamine, penicillin, and streptomycin for 96 hours. Primary myoblasts from C57BL/6 
mice were harvested from limbs of 1-day old mice. Skeletal muscle was dissociated using 
type I collagenase (Worthington Biochemicals) and grown in DMEM supplemented with 
6% FBS, L-glutamine, penicillin, streptomycin, and gentamycin. To differentiate cells, 
the medium was replaced with DMEM containing 3% FBS.  
 
MBL deposition onto myotubes. Differentiated myotubes (either C2C12 or primary 
cells from C57BL/6 mice) cells either mock-infected or infected with RRV WT or RRV 
E2 DM at an approximate MOI of 20. At 18 hpi, culture medium was removed and cells 
were incubated in medium containing either 10% serum from WT or MBL-DKO mice 
for an additional 30 minutes. Cells were washed with PBS containing 400mM NaCl and 
harvested in RIPA lysis buffer. Cell lysates were analyzed by immunoblot analysis as 
described below. 
 
Immunoblot analysis. At indicated times post infection, mock-infected and RRV-
infected mice were sacrificed, and perfused with 1X PBS. Quadriceps muscles were 
removed and homogenized in radioimmunoprecipitation lysis buffer (RIPA; 50µM Tris 
pH 8.0, 150mM NaCl; 1% NP-40, 0.5% deoxycholate, 0.1% SDS and 1X complete 
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protease inhibitor cocktail (Roche)) by glass beads. Protein concentration was determined 
by Bradford protein assay and 25-30µg of protein was run onto a 10% SDS-PAGE gel. 
Protein was transferred onto a PVDF membrane, and membranes were blocked in 5% 
milk, 0.1% Tween-20 in PBS. Membranes were probed with goat anti-mouse MBL-A 
(1:1000 R&D Systems), goat anti-mouse MBL-C (1:1000 R&D Systems), goat anti-
mouse C3 polyclonal antibody (1:1000 Cappel), mouse anti-RRV (1:1000 ATCC), or 
goat anti-mouse actin polyclonal antibody (1:500 SCBT), washed with PBS containing 
0.1% Tween-20 and incubated with rabbit anti-goat antibody or sheep anti-mouse 
antibody conjugated to horseradish peroxidase (1: 10, 000 Sigma). Membranes were 
washed again and protein visualized by ECL (Amersham) according to manufacturer’s 
instructions. Densitometry was performed using ImageJ software (NIH).  
 
Immunofluorescence. BHK-21 cells were seeded at 1 x 104 cells/well into an 8-well 
chamber slide. Cells were infected at MOI of 1 with either diluent alone (mock), RRV 
WT or RRV E2 DM. At 12 hpi medium was removed and cells were incubated in HBSS 
with 5mM CaCl2 with or without 10ug/ml rhMBL (R&D Systems) for 30 minutes at 
37°C. Cells were washed 3-4 times with PBS, fixed in 1.5% PFA for 15 minutes, washed 
and incubated in PBS containing 100mM glycine, followed by incubation in 3% BSA in 
PBS with 0.05% Tween 20 containing 10% normal donkey serum. The primary antibody 
incubation with anti-MBL-C (SCBT 1:50) and anti-RRV (ATCC 1:1000) for 1 hour at 
RT. Wells were washed 3 times with PBS with 0.05% Tween 20 and incubated in 
secondary antibody (Alexa Fluor 488-anti mouse 1:1000; Alexa Fluor 594 anti-rabbit 
1:1000). Wells were washed in PBS with 0.05% Tween 20 three times and mounted 
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(ProLong Gold with DAPI, Invitrogen) and imaged by fluorescence microscopy 
(Olympus BX61). Images were processed using ImageJ (NIH).  
 
Mice. All mice used in this study were maintained and bred in house at the University of 
North Carolina (UNC) in accordance with UNC Institutional Animal Care and Use 
Committee guidelines. Mouse studies were performed in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health.  All mouse studies were performed at the University of 
North Carolina (Animal Welfare Assurance # A3410-01) using protocols approved by the 
UNC Institutional Animal Care and Use Committee (IACUC).  All studies were 
performed in a manner designed to minimize pain and suffering in infected animals, and 
any animals that exhibited severe disease signs was euthanized immediately in 
accordance with IACUC approved endpoints. C57BL/6 mice were purchased from The 
Jackson Laboratories (Bar Harbor, ME) and bred at UNC.  
 
Infection of mice with RRV. While RRV is classified as a biosafety level-2 agent, due 
to the exotic nature of the virus, all animal studies were performed in a biosafety level-3 
facility. Twenty-four day old mice were inoculated with 103 PFU of RRV strain in 
diluent (phosphate buffered saline supplemented with 1% DCS) into the left rear footpad. 
Mice were weighed daily and assigned a clinical score based on hind limb weakness and 
altered gait on the following scale: 0= no disease; 1=mild loss of hind limb grip; 
2=moderate loss of hind limb grip; 3=severe loss of hind limb grip; 4= no hind limb grip 
and mild inability to right; 5=no hind limb grip and complete inability to right; 
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6=moribund. 
  
Viral burden analysis. Mice were infected with RRV as described above, and at 
indicated times post infection mice were sacrificed, perfused with 1X PBS, and indicated 
tissues were dissected and removed, weighed, and homogenized with glass beads in 
diluent. Viral titer within infected tissues were determined by plaque assay on BHK-21 
cells from tissue homogenates. 
 
Quantitation of RRV genomes. Mice were infected with RRV as described above, and 
at indicated times post infection, mice were sacrificed, perfused with 1X PBS, and the 
quadriceps muscle were dissected and removed, and homogenized with glass beads in 
Trizol (Invitrogen). Total RNA was extracted using Pure Link RNA purification kit 
(Invitrogen), and cDNA was generated from 1µg of RNA using Superscript III reverse 
transcriptase. RRV genomes were amplified using a tagged RRV specific primer by 
quantitative RT-PCR, and absolute numbers of RRV genomes were determined using a 
standard curve of serial dilutions ranging from 108 to 100 copies of RRV genomes.  
 
Histological analysis. At desired times post infection, mice were sacrificed and perfused 
with 4% paraformaldehyde (PFA), pH 7.3. Tissues were paraffin embedded and 5µm 
sections were generated and stained with hematoxylin and eosin (H&E) to examine tissue 
pathology and inflammation. Sections were visualized by bright field light microscopy 
(Olympus BX61).  
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Evans blue dye uptake analysis. At 10 days post infection mice were injected with 1% 
Evans blue dye in PBS into the peritoneal cavity (50µl/10g mouse weight). At 6 hours 
post injection, mice were sacrificed and perfused with 4% PFA. Quadriceps muscle 
tissues were embedded in optimal cutting temperature compound (OCT) and frozen in an 
isopentane histobath, 5µm sections were generated, mounted with ProLong Gold with 
DAPI (Invitrogen) and sections were analyzed by fluorescence microscopy (Olympus 
BX61).  
 
Immunohistochemistry. At 7 dpi, mice were sacrificed and perfused with 4% PFA. 
Quadriceps muscles were removed, paraffin embedded, and 5µm sections were generated. 
Sections were deparaffinized in xylene, rehydrated through an ethanol gradient, and 
probed with a goat anti-mouse C3 polyclonal antibody (1:500 Cappel) using the 
Vectastain ABC-AP kit (Vector Labs, CA) and Vector Blue Alkaline phosphatase 
substrate kit (Vector Labs, CA) according to the manufacturers’ instructions. Sections 
were counterstained with Gill’s hematoxylin.  
 
Analysis of infiltrating inflammatory cells by flow cytometry. To determine the 
composition of the inflammatory cell infiltrates within the quadriceps muscle, at 
indicated times post infection mice were sacrificed and perfused with 1X PBS. Both 
quadriceps muscles were removed, minced, and digested with RPMI containing 10% 
fetal bovine serum (FBS), 15mM HEPES, 2.5mg/ml collagenase A (Roche), 1.7mg 
DNase I (Roche) for 2 hours at 37ºC with shaking. Cells were strained through a 40µm 
strainer and washed twice with wash buffer (HBSS containing 1% sodium azide and 1% 
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FBS) and total viable cells were determined by trypan blue exclusion. To stain cells for 
flow cytometry, cells were incubated with anti-mouse FcγRII/III (2.4G2; BD 
Pharmingen) and stained with combinations of the following antibodies:  fluorescein 
isothiocyanate (FITC)-conjugated anti-mouse CD3, phycoerythrin (PE)-conjugated anti-
NK1.1, PE-Cy5 anti-CD45 (leukocyte common antigen), PE-Cy7 anti-F4/80, 
Allophycocyanin (APC)-conjugated anti-CD49b, eF450-conjugated anti-CD11b, APC 
anti-major histocompatibility complex class II antigens (MHC II), and eF780-conjugated 
anti-CD45 (B220) (eBiosciences, San Diego, CA), FITC anti-Ly-6G, and PE anti-
SigLecF (BD-Pharmingen, San Diego, CA), and PE-Texas Red-conjugated anti-CD45 
(B220), and PE-Texas Red anti-CD11c (Molecular Bioprobes, Invitrogen). Cells were 
fixed with 2% PFA (pH 7.3) and analyzed on a CyAn flow cytometer (Becton Dickinson), 
and data was analyzed using Summit software.  
 
Gene expression. At 7 dpi following RRV infection, mice were sacrificed and perfused 
with 1X PBS. Quadriceps muscles were removed and homogenized in Trizol (Invitrogen) 
using glass beads. RNA was extracted using Invitrogen PureLink RNA purification kit, 
and cDNA was generated using Superscript III reverse transcriptase. Expression of 
indicated genes was measured by quantitative real-time PCR. Raw data values were 
normalized to 18S rRNA levels.  
 
Statistical analysis. Clinical scores and percent of starting weight at 10 dpi between WT 
RRV and the glycan mutants were analyzed for statistically significant differences by 
Mann-Whitney analysis. Viral burden, total number of infiltrating cells, and gene 
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expression data at each time point between the different virus strains was analyzed for 
statistically significant differences either Mann-Whiney analysis, one-way ANOVA, or t-
test (p<0.05 is considered significant). Statistical analyses were performed using 
GraphPad Prism 5.  
 
3.4 Results 
RRV E2 N-linked glycans contribute to MBL deposition onto infected cells.  
We have previously shown that MBL deposition is enhanced on cells following 
RRV infection, suggesting that some aspect of viral infection induces MBL binding to 
infected cells (79). Given the ligand specificity of MBL, we hypothesized that the RRV 
E2 N-linked glycans mediate MBL binding to infected cells, resulting in MBL deposition 
and subsequent complement activation. Although MBL did not directly bind to RRV 
virion particles, we reasoned that the glycoproteins might be in a slightly different 
conformation when they were displayed on the cell surface compared to the virion, and 
that this might allow MBL to bind the N-linked glycans on the viral glycoproteins located 
on the surface of infected cells. While both E1 and E2 contain N-linked glycosylation 
sites, we were primarily interested in evaluating the role of the E2 N-linked glycans due 
to their highly exposed location on the glycoprotein spike.  
To test whether the RRV E2 N-linked glycans contributed to binding of MBL to 
infected cells, we used a previously generated panel of mutant viruses lacking one or both 
of the E2 glycans: RRV E2 N200Q, E2 N262Q, and E2 N200;262Q (E2 DM) (210). 
Differentiated C2C12 myotubes or primary C57BL/6 murine myotubes, which are 
derived from skeletal muscle, were infected with either wild-type RRV (RRV WT) or the 
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glycan mutants for 18 hours. Infected cells were then incubated in medium containing 
serum from either naïve C57BL/6 or MBL-DKO mice for 30 minutes as a source of MBL. 
Cells were then extensively washed to remove unbound MBL and free virus, and cell 
lysates were analyzed by immunoblot for levels of MBL. Consistent with our hypothesis, 
we observed a significant decrease in MBL deposition onto RRV E2 DM-infected C2C12 
cells compared to RRV WT-infected cells (Figure 3.1A), despite similar levels of viral 
replication (Figure 3.1B). Similar results were observed in primary C57BL/6 myotubes 
(Figure 3.1C-D). We did not observe MBL deposition in cells incubated with MBL-DKO 
serum, demonstrating both the specificity of the MBL western blots and indicating that 
we were detecting only exogenously added MBL in the assay, rather than modulation of 
MBL production by the different viruses within the infected cells. Interestingly, infection 
with the viruses lacking each glycan individually showed comparable MBL deposition 
levels to RRV WT (Figure 3.2A-B), indicating that both N-linked glycans contribute to 
MBL deposition onto RRV-infected cells.  To confirm the western blot analysis and 
demonstrate that MBL was binding to virally infected cells in a viral glycan dependent 
manner, we evaluated MBL deposition by fluorescence microscopy. BHK-21 cells were 
infected with either diluent alone (mock-infected), RRV WT or RRV E2 DM for 12 
hours, and subsequently incubated with 10µg/ml of recombinant human MBL for 30 
minutes. Cells were washed extensively, fixed, stained without permeabilization to only 
detect surface localization of MBL (Texas Red) and RRV structural proteins (FITC), and 
imaged by fluorescence microscopy. As shown in Figure 3.3, we observed enhanced 
deposition of MBL onto RRV-infected cells compared to mock-infected cells. Within the 
RRV WT-infected culture, we only observed deposition onto the infected cells and not 
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onto uninfected cells (indicated by white arrowhead), indicating that viral infection 
within the cell induces MBL deposition.  Levels of MBL were reduced on cells infected 
with E2 DM compared to WT, despite comparable levels of RRV antigen between WT 
and E2 DM infection. Taken together, these data support the hypothesis that MBL 
recognizes and binds to the E2 N-linked glycans on the surface of infected cells.  
 
The RRV E2 N-linked glycans contribute to severe disease.  
Given that the E2 N-linked glycans were required for MBL binding to infected 
cells, and since MBL is required for RRV-induced disease (79), we hypothesized that the 
E2 glycans were also required for development of RRV-induced disease. Wild-type 
C57BL/6 mice were infected with either RRV WT or the panel of glycan mutant viruses, 
and mice were weighed and assigned a clinical score as previously described (161). 
Consistent with our previous studies, RRV WT-infected mice began to develop severe 
disease characterized by hind-limb dysfunction by 5 dpi, with peak disease severity from 
7 to 10 dpi (Figure 3.4A), and had reduced weight gain compared to mock-infected mice 
(Figure 3.4B). Mice infected with viruses lacking either one of the E2 glycosylation sites 
(E2 N200Q Figure 3.4A, top; E2 N262Q Figure 3.4A, middle) developed hind-limb 
dysfunction with approximately the same kinetics as WT-infected mice, but the peak 
disease severity was reduced in these mice compared to WT-infected mice. In addition, 
these mice had reduced weight loss compared to WT-infected mice (Figure 3.4B). These 
data suggest that each individual E2 glycan contributes to the severity of RRV-induced 
disease. Interestingly, mice infected with the virus lacking both of the E2 glycans (RRV 
E2 DM) developed a very mild disease with little to no hind-limb dysfunction, and 
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continued to gain weight throughout the course of infection (Figure 3.4A-B, bottom). 
Notably, the disease in the E2 DM-infected mice was remarkably similar to the disease 
induced in MBL-DKO and complement deficient mice (79, 158). Taken together, these 
data indicate while each of the E2 glycans contribute to disease severity individually, 
both of the E2 N-linked glycans are required for development of maximal disease, and 
suggests that the N-linked glycans have a key role in mediating RRV pathogenesis.  
 
RRV lacking one or both E2 N-linked glycans are attenuated for inflammatory pathology 
and tissue damage within quadriceps muscle.  
Infiltration of inflammatory cells into the skeletal muscle is a characteristic of 
RRV-induced disease, and much of the disease observed following RRV infection is due 
to the pathology mediated by inflammatory infiltrates. To assess the role of the E2 
glycans in mediating inflammatory pathology following RRV infection, we analyzed 
H&E stained quadriceps muscle sections from mice infected with either RRV WT or the 
RRV glycan mutants at 10 days post infection. As expected, we observed severe 
inflammatory pathology in the quadriceps of RRV WT-infected mice, as evidenced by 
the destruction of the fibrous architecture of the skeletal muscle and the presence of 
infiltrating cells (Figure 3.5A). We observed the presence of infiltrating cells in the 
quadriceps muscle of mice infected with any of E2 glycan mutant viruses. However, 
consistent with the disease scores, the quadriceps muscles of mice infected with either E2 
N200Q or E2 N262Q had moderate tissue damage that was reduced compared to RRV 
WT-infected mice, as indicated by the presence of intact muscle fibers (Figure 3.5A). In 
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contrast, mice infected with RRV E2 DM had intact skeletal muscle fibers with minimal 
tissue damage despite the presence of infiltrating cells (Figure 3.5A).  
To further confirm that mice infected with the RRV glycan mutants had reduced 
tissue damage we administered Evans blue dye (EBD) into either RRV WT or glycan 
mutant-infected mice at 10 dpi to visualize damaged muscle fibers within the quadriceps 
muscle. EBD is excluded from healthy cells, but taken up by cells with permeabilized 
membranes and is easily visualized by fluorescent microscopy due to its’ fluorescent 
properties; thus, EBD positive tissues indicate tissue damage. As shown in Figure 3.5B, 
we observed abundant EBD positive muscle fibers in quadriceps muscle from RRV WT-
infected mice. Consistent with the reduced clinical scores and pathology in mice infected 
with the glycan mutants, there were fewer EBD positive fibers observed in mice infected 
with either of the single E2 glycans mutants compared to RRV WT-infected mice. 
Furthermore, EBD positive muscle fibers were rare in mice infected with E2 DM, 
suggesting that both glycans are required for tissue damage.  
 
RRV glycan mutants retain ability to replicate in vivo.  
Although the RRV E2 N-linked glycans are dispensable for replication in cell 
culture (210), it is possible that the glycans might be required for efficient viral 
replication and dissemination in vivo. Therefore, we evaluated the viral titer within the 
quadriceps muscle and the ankle joints from either RRV WT, or glycan mutant-infected 
mice at multiple times points post-infection by plaque assay. There was no difference in 
viral titer within the quadriceps and ankle joints at 1 dpi between any of the viruses, 
suggesting that the E2 glycans are not required for initial dissemination to and replication 
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within target tissues (Figure 3.6 A-B). Overall, all of the glycan mutant viruses replicated 
at or near to wild-type levels in target tissues, although there were some differences in 
titer observed at intermediate time points. At 3 dpi, we observed reduced viral titer within 
the quadriceps muscle in mice infected with E2 N200Q and E2 DM compared to WT 
(Figure 3.6A). The E2 N262Q virus did not show any difference in titer compared to 
RRV WT at any time post-infection in either the ankle or the quadriceps muscle. At 5 dpi, 
only the RRV E2 DM titer is reduced in the quadriceps muscle compared to RRV WT, 
but importantly, at time points of severe disease, 7 and 10 dpi, no difference was 
observed in the quadriceps muscle between any of the viruses (Figure 3.6A). Similar 
results were observed in the ankle joints, although there were significant differences in 
titer at day 5 in the ankle joint between RRV E2 DM and RRV WT, but these differences 
were not sustained at time points of peak disease severity (7 or 10 dpi) (Figure 3.6B).  
In order to confirm the plaque assay results, we also performed quantitative real 
time RT-PCR to determine the absolute numbers of RRV genomes per µg of RNA within 
the quadriceps muscle between WT and E2 DM virus at 3 and 5 dpi. We did not observe 
any differences in the number of RRV genomes between the two viruses at 3 dpi (Figure 
3.7A).  This suggests that the overall levels of viral replication within the tissues are 
equivalent between the wild type and mutant virus at this time point. However, consistent 
with reduced viral titer at 5 dpi, we observed a similar decrease in viral RNA at 5 dpi in 
the quadriceps muscle between WT and E2 DM (Figure 3.7B). Taken together, these data 
indicate that the loss of the glycans does not overall affect the ability of the virus 
disseminate to and replicate within target tissues, however the E2 DM does show reduced 
replication at intermediate times in the infection process.    
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The RRV E2 glycan mutants and WT RRV induce equivalent inflammatory responses. 
RRV infection induces an inflammatory response that results in infiltration of 
inflammatory cells into target tissues such as the quadriceps muscle, subsequently leading 
to tissue damage (161). Prior studies demonstrated that even though RRV-infected C3-/- 
and MBL-DKO mice were resistant to virus-induced disease, virus induced inflammatory 
cell recruitment was unaffected in these mice (79, 158).  Therefore, we evaluated the E2 
glycan mutants to determine whether the virus induced disease process was similar to that 
observed in C3 or MBL deficient animals by quantifying and characterized inflammatory 
cell populations from quadriceps muscle of mice infected with the wild type or each of 
the mutant viruses by flow cytometry. At 10 dpi, which is a time point of peak 
inflammation within tissues, we did not observe any differences in the total magnitude 
nor the composition of the inflammatory cell population between RRV WT and the 
glycan mutants (Figure 3.8). Total numbers of leukocytes (as defined by LCA+ staining) 
in the quadriceps muscle were equivalent between mice in all groups (Figure 3.8), 
indicating that the E2 N-linked glycans do not affect infiltration of inflammatory cells 
into skeletal muscle. Furthermore, the numbers of inflammatory macrophage, which are 
thought to drive much of the tissue damage during RRV infection (135), and other cell 
types including CD4+ and CD8+ T cells, NK cells, and neutrophils, were equivalent 
between WT and the glycan mutants (Figure 3.8). These data suggest that loss of the E2 
glycans does not significantly affect the induction of the infiltration or composition of the 
inflammatory cells into the quadriceps muscle following RRV infection.  
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The RRV E2 N-linked glycans contribute to complement activation in quadriceps muscle.  
We have previously shown that complement activation following RRV infection 
is mediated primarily through MBL (79). Given that we observed a decrease in MBL 
deposition within RRV E2 DM-infected cultures, and since the disease phenotype 
induced by E2 DM in WT mice was strikingly similar to the disease induced by WT RRV 
in MBL-DKO mice, we hypothesized that the presence of the E2 glycans contribute to 
MBL deposition and complement activation in the quadriceps muscle following infection. 
MBL-mediated complement activation is initiated by the recognition of terminal sugars 
on glycosylated proteins by the CRD of MBL. Binding of MBL to the ligand leads to 
formation of the C3 convertase C2a4b by the MASPs, resulting in localized C3 
deposition. The C3 convertase cleaves and processes C3 into smaller components, and is 
indicative of complement activation. One such component is iC3b, which opsonizes 
targeted cells and interacts with CR3 to mediate phagocytic uptake by CR3-bearing cells 
(50).  
MBL levels are elevated within quadriceps muscle of RRV-infected mice at 7 dpi 
compared to mock-infected mice (79) and MBL deposition onto infected cells is 
dependent on the E2 glycans (Figures 3.1 and 3.3). Thus, if the RRV E2 glycans mediate 
complement activation through interactions with MBL, we would expect to see reduced 
amounts of MBL in mice infected with RRV E2 DM compared to RRV WT-infected 
mice. To test this, we infected mice with either RRV WT or RRV E2 DM and harvested 
quadriceps muscle at 7 dpi and analyzed the muscle homogenates by western blot for 
MBL-C levels. As shown in Figure 3.9A, RRV WT-infected mice had elevated levels of 
MBL-C in the quadriceps at 7 dpi compared to mock-infected mice, and importantly, we 
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observed reduced levels of MBL in RRV E2 DM-infected mice compared to RRV WT-
infected mice, suggesting that the RRV E2 glycans are required for MBL deposition 
within infected tissues.  
To determine if the reduced levels of MBL within the quadriceps muscle of RRV 
E2 DM infected mice correlated with reduced complement activation, we analyzed 
quadriceps muscle homogenates from RRV WT or RRV E2 DM-infected mice for levels 
of C3 cleavage products by western blot. Consistent with our hypothesis, we observed 
reduced levels of both the alpha and beta chain of C3 in E2 DM-infected mice compared 
to RRV WT-infected mice (Figure 3.9B), indicating that the E2 glycans are required for 
C3 deposition onto infected tissues. Furthermore, the levels of the C3 cleavage product 
iC3b was significantly reduced in E2 DM-infected mice compared to WT-infected mice 
(Figure 3.9B), indicating that the RRV E2 glycans are also required for complement 
activation following RRV infection.   
As western blot analysis of C3 present in quadriceps muscle tissue does not 
distinguish between C3 produced by infiltrating inflammatory monocytes and C3 that is 
deposited onto infected tissues, we wanted to further confirm that the RRV E2 glycans 
are required for C3 deposition onto skeletal muscle following infection by IHC staining 
of C3 on skeletal muscle sections. We infected mice with either RRV WT or E2 DM, and 
generated sections of the quadriceps muscle at 7 dpi. Consistent with results in Figure 
3.9B, we observed a reduction in C3 deposition onto the skeletal muscle from mice 
infected with RRV E2 DM compared to RRV WT (Figure 3.10). 
Prior studies indicate that MBL and the complement system induce expression of 
a subset of inflammatory mediators commonly associated with inflammatory arthritis 
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following RRV infection through CR3 dependent signaling (79, 160). Given that the 
RRV E2 N-linked glycans contribute to complement activation, we hypothesized that 
expression of these inflammatory mediators is also dependent on the glycans. To test this, 
we infected mice with either RRV WT or RRV E2 DM, harvested quadriceps muscles at 
7 dpi, and analyzed mRNA expression of various genes by quantitative real-time PCR. 
Expression of the pro-inflammatory calgranulin proteins S100A8 and S100A9 was 
diminished in MBL-DKO, C3-/-, and CR3-/- mice following RRV infection (79, 160). As 
shown in Figure 3.11, we observed significantly higher expression of S100A8 and 
S100A9 in the quadriceps muscle of RRV WT-infected mice compared to RRV E2 DM-
infected mice at 7 dpi, suggesting that expression of these genes was also dependent on 
the RRV glycans. Furthermore, expression of Arginase I and IL-6, whose expression is 
complement dependent, was also dependent on the E2 glycans (Figure 3.11). These data 
are consistent with the hypothesis that the RRV E2 N-linked glycans contribute for 
complement activation following infection, as they are required for expression of the 
same subset of genes that are complement dependent.  
Expression of the pro-inflammatory cytokine TNFα that is MBL, C3, and CR3-
independent following infection was unchanged between RRV WT and RRV E2 DM-
infected mice (Figure 3.11). However, expression of other C3-independent cytokines IL-
1β and IL-10 was dependent on the presence of the viral N-linked glycans. IL-1β 
expression is induced upon Toll-like receptor engagement (44), and may suggest that the 
viral N-linked glycans are interacting with TLRs to mediate IL-1β induction. 
Interestingly, IL-10 expression was dependent on MBL following RRV infection (79), 
further supporting the hypothesis that the E2 glycans interact with MBL. Taken together, 
	   125	  
these data suggest that the RRV E2 N-linked glycans regulate expression of a similar 
subset of pro-inflammatory genes as MBL, C3, and CR3, and further supporting the 
hypothesis that the RRV E2 glycans activate the host complement system through MBL.  
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3.5 Discussion 
Mosquito-borne alphaviruses such as RRV and CHIKV are emerging viruses that 
are a significant cause of explosive outbreaks of infectious arthritis in humans. The host 
complement system through the mannose binding lectin pathway plays a critical role in 
mediating development of disease and tissue damage through activation of inflammatory 
cells that infiltrate into the muscle and joints following infection (158, 160).  In this study, 
we demonstrate that the RRV envelope N-linked glycans are a viral ligand for MBL, and 
that this interaction contributes to activation of complement and induction of severe 
virus-induced disease.  
The N-linked glycans on the alphavirus glycoproteins have been implicated in a 
number of viral processes. The E1 glycan is embedded and the E1 glycoproteins mediates 
membrane fusion of the alphaviruses (125, 174), and loss of any of these sites has been 
shown to attenuate both Sindbis virus and Ross River virus replication in mammalian 
cells (174, 210).  Therefore, given the impact of the RRV E1 mutation on viral replication, 
which would have affected our ability to interpret results in vivo, we did not evaluate this 
virus within our study. The E2 glycans, on the other hand, are relatively surface exposed 
and in the case of RRV, do not significantly affect replication within cell culture (174, 
210). The alphavirus E2 glycoprotein is thought to be involved in receptor binding, but 
there has been no direct evidence to suggest that the N-linked glycans mediate receptor 
interaction (125). Studies using glycan mutants of a cell-culture adapted SINV found that 
loss of the SINV E2 glycans actually enhanced binding of virus to mammalian cells, due 
to a loss of negative charge of sialic acid, which is the terminal carbohydrate of complex 
glycans, allowing for tighter binding to heparan sulfate (122). Consequently, SINV 
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lacking either of the E2 glycans displayed enhanced virulence, disease, and viral titer in a 
mouse model of encephalomyelitis (122).  The fact that we did not see a corresponding 
enhancement of virulence with the RRV N-linked glycan mutants likely reflects the 
central role that virus-induced MBL binding and complement activation plays in the 
pathogenesis of RRV-induced disease (79, 158, 160).  Furthermore, unlike the TE12 
strain of Sindbis, which binds heparin sulfate and where the enhanced virulence of N-
linked glycan mutants has been linked to effects on heparin sulfate binding, the wild type 
T48 strain of RRV used in our studies does not efficiently use heparan sulfate as an 
attachment factor to bind to mammalian cells (92).   
The results presented in this study clearly demonstrate that viral N-linked glycans 
promote MBL binding to RRV infected cells and that MBL deposition and subsequent 
complement activation is reduced in tissues from animal infected with the N-linked 
glycan double mutant (Figures 3.1, 3.3 and 3.10).  Given the central role that MBL, 
complement activation, and subsequent inflammatory cell activation plays in the 
pathogenesis of RRV-induced disease (79), it is likely that the major mechanism of 
attenuation for the E2 DM virus is through the lack of MBL activation.  However, given 
that the E2 DM virus did show reduced levels of replication at intermediate times post 
infection (Figure 3.6), we cannot rule out the possibility that at least some of the impact 
on virus-induced disease with the E2 DM virus is due to this transient reduction in viral 
load.  However, it is important to point out that the decrease in viral load on days 3 and 5 
post infection did not affect the recruitment of inflammatory cells into the sites of viral 
replication (Figure 3.8), and that viral loads were indistinguishable on day 7 post 
infection, which is a time when severe disease is readily apparent with the wild type virus 
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(Figure 3.6).  It is also possible that in addition to their effects on MBL, which are crucial 
for disease, that the viral N-linked glycans are also regulating other aspects of the disease 
process.  This possibility is supported by the fact that both of the single mutant viruses, 
which are still capable of promoting MBL binding, were partially attenuated for virus-
induced disease.  Therefore it will be important to evaluate whether one or both of the 
viral N-linked glycans is mediating other interactions, such as interactions with C-type 
lectin receptors, that might also affect virus-induced disease.   
The interaction between MBL and viral N-linked glycans has been demonstrated 
in a number of other virus systems including HIV, SARS-CoV, and WNV (54, 61, 90, 
107, 257). In these systems, MBL recognizes and binds to high mannose glycans on the 
envelope glycoproteins, and leads either to direct neutralization of virus, or aids in 
inhibiting virus infection by prevent or abrogating attachment and entrance into entering 
host cells. In contrast to the protective role of MBL for other viruses, MBL clearly plays 
a pathologic role during RRV infection and these studies provide new insights into the 
role of viral N-linked glycans in driving this pathologic process. Furthermore, studies 
with other viruses have demonstrated that the interaction between MBL and the virus 
particle is important for MBL-mediated neutralization (61, 111, 257). In contrast to those 
studies, we have several lines of evidence that demonstrate MBL interacts with RRV-
infected cells through the E2 N-linked glycans on the surface of the infected cell rather 
than with the virion particle. First, MBL deposition onto infected cells in vitro and within 
infected tissues in vivo are elevated compared to mock-infected (79). Second, MBL 
deposition is reduced in cells and tissues infected with E2 DM RRV compared to WT 
RRV independent of viral replication, indicating that the E2 glycans mediate MBL 
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binding. Finally, we observed MBL deposition onto RRV-infected cell only, which was 
reduced in RRV E2 DM-infected cells. To our knowledge, this is the first demonstration 
where the interaction between the viral N-linked glycans and MBL on the surface of 
infected cells contributes to pathology and disease.  
In addition to providing new insights into the pathogenesis of alphavirus-induced 
arthritis, these findings suggest that targeting interactions between the viral N-linked 
glycans and MBL may have therapeutic potential for treating RRV induced arthritis.  
Blocking the ability of MBL to interact with the viral N-linked glycans or inhibiting 
downstream proteases, such as MASP proteins that mediate subsequent complement 
activation, could prevent the severe pathology associated with RRV induced disease and 
other arthralgia associated alphaviruses, while keeping the protective aspects of the host 
innate immune response intact. Furthermore, given that the viral N-linked glycan mutants 
are attenuated for disease, but not replication, it may be possible to incorporate N-linked 
glycan mutants into live attenuated alphavirus vaccines.  
In summary, we have demonstrated that the interaction between the host innate 
immune protein MBL and the RRV E2 N-linked glycans contribute to the pathogenesis 
of RRV-induced arthritis and myositis through activation of the host complement system. 
Our data suggests that specifically targeting the interaction between the RRV E2 N-
linked glycans and MBL through the use of MBL inhibitors may be an effective 
therapeutic strategy in the treatment of RRV and other virus-induced inflammatory 
diseases.   
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Figure 3.1: The RRV E2 N-linked glycans contribute to MBL deposition onto 
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Figure 3.1: The RRV E2 N-linked glycans contribute to MBL deposition onto 
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Figure 3.1 The RRV E2 N-linked glycans contribute to MBL deposition onto 
infected cells.  
(A) To determine if the RRV E2 N-linked glycans were required for MBL deposition 
onto infected cells, C2C12 myotubes were infected with either RRV WT or RRV E2 DM 
at an MOI of 20 for 18 hours, and subsequently incubated with either serum from a WT 
or MBL-DKO mouse for 30 minutes prior to harvesting. Cells were washed, harvested, 
and lysates were analyzed by immunoblot analysis using anti-mouse MBL-C, or anti-
mouse actin antibodies. Western blots of MBL-C and actin are shown.  
(B) Infected cell culture supernatants from (A) were assayed to determine viral titer at 18 
hpi between RRV WT (solid bar) and RRV E2 DM (open bar). Viral titer was determined 
by plaque assay on BHK-21 cells, and the bar represents the arithmetic mean ± SD of 
three replicates.  
(C) Primary C57BL/6 myotube cultures were infected with either RRV WT or RRV E2 
DM at an MOI of 20 for 18 hours, and subsequently incubated with either serum from a 
WT or MBL-DKO mouse for 30 minutes prior to harvesting. Cells were washed, 
harvested, and lysates were analyzed by immunoblot analysis using anti-mouse MBL-C, 
or anti-mouse actin antibodies. Western blots of MBL-C and actin are shown.  
(D) Infected cell culture supernatants from (C) were assayed to determine viral titer at 18 
hpi between RRV WT (solid bar) and RRV E2 DM (open bar). Viral titer was determined 
by plaque assay on BHK-21 cells, and the bar represents the arithmetic mean ± SD of 
three replicates.  
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Figure 3.2: Each E2 glycan contributes to MBL deposition onto infected cells 
(A-B) To determine if each individual E2 N-linked glycan was required for MBL 
deposition onto infected cells, C2C12 myotubes were infected with either RRV WT, E2 
N200Q, or E2 N262Q  at an MOI of 20 for 18 hours, and subsequently incubated with 
either serum from a WT or MBL-DKO mouse for 30 minutes prior to harvesting. Cells 
were washed, harvested, and lysates were analyzed by immunoblot analysis using anti-
mouse MBL-C, or anti-mouse actin antibodies. Western blots of MBL-C and actin are 
shown (A) and densitometry measurements of bands in immunoblot from three different 
experiments are graphically depicted as arbitrary units normalized to actin (B).  
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Figure 3.3: RRV E2 glycans contribute to MBL deposition onto infected cells.  
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Figure 3.3: RRV E2 glycans contribute to MBL deposition onto infected cells.  
To determine if the E2 glycans regulated MBL deposition onto RRV-infected cells, 
immunofluorescence staining of BHK-21 cells infected with either diluent (mock, top 
row), RRV WT (middle row) or RRV E2 DM (bottom row) at an MOI of 1 for 12 hours. 
Cells were subsequently incubated with 10µg/ml rhMBL-C for 30 minutes, washed, fixed, 
and stained for MBL-C, RRV antigen, and DAPI. Individual panels from left: DIC, 
MBL-C (red), RRV antigen (green), DAPI (blue), and merge. White arrow indicated 
uninfected cell. No MBL-C binding was observed in cells incubated without 10µg/ml of 
MBL-C (data not shown).  
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Figure 3.4: The RRV E2 N-linked glycans contribute to severe disease.  
(A-B) Twenty-four day old C57BL/6 were either mock-infected, or infected with either 
RRV WT or a RRV glycan mutant. Mice were assigned a clinical score (A) and assessed 
for weight loss (B) as described in the Materials and Methods.  Mice infected with RRV 
WT were compared directly to mice infected with E2 N200Q (top graphs), E2 N262Q 
(middle graphs) or E2 DM (bottom graphs). Each data point represents the arithmetic 
mean ± SD and is representative of at least three independent experiments.  
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Figure 3.5: The RRV E2 N-linked glycans contribute to pathology and tissue 
damage.  
(A-B) Twenty-four day old WT C57BL/6 mice were infected with either RRV WT, E2 
N200Q, E2 N262Q, or E2 DM.  
(A) Tissue pathology and inflammation was examined at 10 dpi by H&E staining of 
paraffin embedded sections of quadriceps muscle from either RRV WT or the glycn 
mutants. A representative section from mice infected with each virus strain is shown.  
(B) To assess damage within the muscle, mice infected with either RRV WT or the RRV 
glycan mutants were injected with EBD at 10 dpi, and frozen sections were generated. 
EBD positive muscle fibers were identified by fluorescence microscopy. Representative 
sections of each virus strain are shown.  
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Figure 3.6: RRV lacking E2 N-linked glycans retain ability to replicate in vivo 
Quadriceps muscle (A) and ankle joints (B) from mice infected with RRV WT (solid 
circles, n=4-15/time point), RRV E2 N200Q (open circles, n=3-6/time point), RRV E2 
N262Q (solid squares, n=3-5/time point) or RRV E2 DM (open square, n=3-8/time point) 
were assayed to determine viral titer at various times post infection. Viral titer was 
determined by plaque assay on BHK-21 cells. **p<0.01 ***p<0.005 as determined by 
one-way ANOVA analysis  with Bonferroni’s Multiple Comparison test of glycan mutant 
compared to RRV WT.  
	   145	  
Figure 3.7: Amounts of RRV genomes in quadriceps muscle are equivalent at 3 dpi 
but not 5 dpi between RRV WT and E2 DM.   
 
A.  
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Figure 3.7: Amounts of RRV genomes in quadriceps muscle are equivalent at 3 dpi 
but not 5 dpi between RRV WT and E2 DM.  
(A-B) Mice were infected with either RRV WT or E2 DM to determine absolute numbers 
of RRV genomes per µg of RNA between RRV WT and E2 DM at 3 dpi (A) and 5 dpi 
(B). At indicated times post infection, quadriceps muscle were harvested, RNA was 
isolated and absolute numbers of RRV genomes between RRV WT (solid circles) or E2 
DM (open squares) were quantified by quantitative RT-PCR. **p<0.01 by t-test.  
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Figure 3.8: The RRV E2 glycan mutants and WT RRV induce equivalent 
inflammatory responses. 
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Figure 3.8: The RRV E2 glycan mutants and WT RRV induce equivalent 
inflammatory responses. 
 Leukocytes were isolated from the quadriceps muscle of mice infected with either RRV 
WT (solid circles, n=8-16), RRV E2 N200Q (open circles, n=8), RRV E2 N262Q (solid 
square, n=8) or RRV E2 DM (open square, n=8-16) mice at 10 dpi. Cells were 
characterized and quantified by flow cytometry using the markers described in the 
Materials and Methods. Total numbers of leukocytes, inflammatory macrophage and 
other inflammatory cell types are shown. Each data point represents a single animal, and 
data presented in the figure are combined from three independent experiments. *p<0.05 
by one-way ANOVA with Bonferroni’s Multiple Comparison post-test.  
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Figure 3.9: The RRV E2 N-linked glycans contribute to MBL deposition and 
complement activation in quadriceps muscle. 
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Figure 3.9: The RRV E2 N-linked glycans contribute to MBL deposition and 
complement activation in quadriceps muscle. 
(A) Quadriceps muscle homogenates from mock-infected mice or mice infected with 
either RRV WT or RRV E2 DM were analyzed by immunoblot analysis at 7 dpi to 
determine relative levels of MBL. Each lane represents an individual mouse.  
(B) To determine if complement activation differed between mice infected with RRV WT 
or RRV E2 DM, we analyzed homogenized quadriceps muscles from either mock-
infected or infected mice at 7 dpi by immunoblot analysis using an anti-mouse C3 or anti-
mouse actin antibody. C3 cleavage products are indicated with solid arrowheads. Each 
lane represents an individual mouse.  
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Figure 3.10: The RRV E2 glycans contribute to complement deposition in 
quadriceps muscle  
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Figure 3.10: The RRV E2 glycans contribute to complement deposition in 
quadriceps muscle  
C3 deposition was assessed by IHC using an anti-mouse C3 antibody on quadriceps 
muscle sections from mock-infected mice or mice infected with either RRV WT or RRV 
E2 DM at 7 dpi. C3 positive areas are stained in blue. A representative section from each 
strain is shown.  
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Figure 3.11:  RRV E2 glycans contriute to expression of complement dependent pro-
inflammatory genes 
Relative mRNA expression of C3-dependent inflammatory mediators and cytokines 
S100A9, S100A8, Arginase I, and IL-6, and C3-independent cytokines TNFα, IL-1β, and 
IL-10 from quadriceps muscle from mice infected with either RRV WT (solid bar, n=7) 
or E2 DM (open bar, n=8) mice by quantitative real-time PCR. Raw data values were 
normalized to 18S rRNA levels, log-transformed, and are graphically depicted as fold 
expression over mock-infected mice. Data from a single experiment is shown, but is 





CHAPTER FOUR: 	  
DISCUSSION AND FUTURE DIRECTIONS 
 
Arthritic alphaviruses such as Ross River virus and chikungunya virus are a 
significant cause of epidemics of infectious arthritis in various areas around the world. 
Patients infected with these viruses experience debilitating polyarthritis, arthalgia and 
myalgia in peripheral joints that can last from weeks to months. Studies in a mouse model 
of RRV-induced disease have demonstrated the central role of the host inflammatory 
response in mediating disease following viral infection. In particular, inflammatory 
macrophages and macrophage products are thought to drive disease through direct 
damage to inflamed tissues. The host complement system, which is a component of the 
innate immune system, plays a critical role in regulating activation of the inflammatory 
cells through CR3-dependent mechanisms (158, 160). However, the precise mechanisms 
and viral ligands that activate complement following RRV infection are not known.  
 
4.1 MBL and the RRV E2 N-linked glycans contribute to RRV-induced disease 
through activation of the host complement system.  
MBL contributes to development of severe RRV-induced disease  
To further investigate how RRV activated the complement system, we first sought 
to determine which activation pathway(s) are involved in complement activation 
following RRV infection using mice deficient in the different initiator molecules of the 
	   156	  
three main complement activation pathways. We found that the lectin pathway of 
complement, specifically mediated by mannose binding lectin, was the activation 
pathway required for development of RRV-induced disease (Figure 2.1, (79)), and mice 
deficient in the classical pathway initiator molecule C1q or the alternative pathway 
molecule factor B developed disease similar to WT mice, indicating that neither the 
classical or alternative pathways were involved in development of disease. Interestingly, 
these results are consistent with human data that failed to find evidence of immune 
complexes, which activate complement through the classical pathway, in the synovial 
fluid of patients suffering from RRV-induced polyarthritis (57, 58).  
We characterized the disease in mice deficient in both mouse isoforms of MBL 
(MBL-DKO) and found that the disease was very similar to both C3 and CR3 deficient 
mice. Viral burden within the ankle joints and skeletal muscle did not differ between WT 
and MBL-DKO mice (Figure 2.7), indicating that similar to C3, MBL is not required for 
infection or clearance of virus. This is in contrast to the role that MBL has in other 
arboviral systems where MBL contributes to direct neutralization of virions (7, 61). 
Virus-induced inflammation is equivalent between MBL-DKO and WT mice, suggesting 
that MBL does not regulate infiltration of cells into the skeletal muscle (Figure 2.8).  
To determine if MBL regulated complement activation following RRV infection, 
we analyzed deposition of C3 onto quadriceps muscle from WT or MBL-DKO mice. 
Consistent with our hypothesis, MBL-DKO mice had dramatically reduced amounts of 
C3 within the inflamed skeletal muscle compared to WT mice, and consequently had 
decreased levels of C3 cleavage products such as iC3b. Analysis of complement 
dependent expression of pro-inflammatory genes such as the calgranulins S100A8 and 
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S100A9 also showed dependence on MBL, as their expression was reduced in MBL-
DKO mice following RRV infection. 
The C3 cleavage product C3a was found to be elevated in RRV patients compared 
to osteoarthritis patients, suggesting that complement was activated following RRV 
infection in humans (158). We observed elevated levels of MBL within the quadriceps 
muscle as well as in the serum of RRV-infected mice (79). Similarly, we found elevated 
levels of MBL in the serum of RRV patients compared to healthy controls (79), 
suggesting that MBL may have a role in human RRV-induced disease. Circulating levels 
of MBL with the serum levels can rise following bacterial or viral infection since MBL is 
an acute phase protein (53), and thus might be up-regulated following RRV infection. 
 The results presented in this study demonstrate a pathologic role for MBL in 
RRV-induced disease and presents a possible avenue for therapeutic intervention for 
patients suffering from RRV-induced disease. Current treatment of RRV-induced disease 
is merely palliative and patients are often prescribed NSAIDS and rest. A therapeutic that 
that specifically targets the lectin pathway of complement may be an effective approach 
to limit disease pathology and alleviate symptoms caused by RRV infection. 
Pharmacological inhibitors of the lectin pathway, which primarily target and inhibit 
MASP activity, are currently in development, and may be of some use in treatment of 
RRV-induced disease in humans (14). 
 
The role of MBL polymorphisms in severity of RRV-induced disease.   
MBL is a highly polymorphic protein in the human population and 
polymorphisms in the promoter region of the human Mbl2 gene affect expression and 
	   158	  
production of MBL, leading to a wide range of “normal” baseline MBL levels across the 
human population (47). Given that elevated levels of MBL correlated with severity of 
RRV-induced polyarthritis in humans, it is tempting to speculate that people with MBL 
polymorphisms conferring higher levels of circulating MBL may be at greater risk of 
developing more severe disease in response to RRV infection. Conversely, humans with 
MBL polymorphisms conferring lower levels of MBL may be protected from developing 
severe RRV-induced disease. A small subset of nine patients suffering from RRV-
induced disease has been genotyped to determine if any MBL polymorphism associated 
with severity of disease. Overall, there was no association within this very small subset of 
patients with severity of polyarthritis (79). However, there was a significant association 
with the polymorphism at -550 in the Mbl2 promoter region, which confers higher levels 
of circulating MBL with neurocognitive impairment (S. Mahalingam, B. Piraino, B. 
Cameron, L. Herrero, and A. Lloyd, unpublished data). While we cannot draw any 
concrete conclusions from such a small data set, the implications from these data is 
people with genotypes conferring higher levels of MBL might be at greater risk for 
developing severe atypical symptoms of RRV-induced disease. Additional studies that 
include a larger cohort of patients are really needed to further address the role of MBL 
polymorphisms in determining severity of RRV-induced disease in humans. Ideally, such 
a study would include patients exhibiting a wide range of disease severity, including 
those who are asymptomatic but have serological evidence of RRV infection.  
Another possible approach to studying the role of MBL polymorphisms in 
determining severity of RRV-induced disease may be to use a panel of genetically 
diverse mice called the Collaborative Cross (CC). The CC is composed of a panel of 
	   159	  
recombinant inbred mouse lines that have been generated through interbreeding of eight 
different mouse lines (C57BL/6J, A/J, 129s1/SvImJ, NZO/HILtJ, NOD/ShiLtJ, WSB/EiJ, 
PWK/PhJ, and CAST/EiJ) (37). The genotypes and single nucleotide polymorphisms 
present in the CC lines that have been generated through this system represent greater 
than 90% of common mouse genetic diversity, and is currently being used to model 
genetic variation in the human population (186). In particular, our lab has been involved 
in initial studies evaluating the effect of host genetics on susceptibility or protection to 
infectious diseases (Ferris MT et al, manuscript under review). Furthermore, the CC 
provides a powerful tool to be able to evaluate the role of host genetics on viral 
pathogenesis (21, 170). Given the single nucleotide polymorphisms found specifically in 
Mbl2 and expression differences across the CC founder lines, it is likely that this system 
will better allow us to understand the role of MBL polymorphisms in mediating disease 
(118).   
 Liu et al determined the baseline circulating MBL levels in various commonly 
used laboratory mouse strains including some of the founder lines of the CC, and found 
that levels of MBL-A ranged from 5.7µg/ml to 9.4µg/ml and levels of MBL-C ranged 
from 25µg/ml to 91µg/ml (138). The range in MBL levels between the different mouse 
strains suggests that there may be some genetic basis conferring differential MBL 
expression and production. However, not much, if anything, is known about the MBL 
polymorphisms in mice or if they are similar to the human Mbl2 polymorphisms. 
As a preliminary foray into exploring the possibility of using the CC to evaluate 
the role of host genetics, particularly MBL, on RRV pathogenesis, we were interested in 
determining if levels of MBL differed within the founder lines of CC. We performed a 
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western blot analysis of relative amounts of MBL-C present in the serum of both male 
and female naïve mice from each of the founder lines (Figure 4.1). Interestingly, we 
observed a wide range of MBL-C levels across the founder lines as well as between 
males and females within some of the lines. Of note, C57BL/6J mice, which we have 
used as our standard model to study RRV pathogenesis, appeared to have moderate to 
high levels of MBL and develop severe RRV disease, whereas other mouse lines, such as 
the 129s1/SvImJ line, had very low levels of MBL, and develop very mild RRV-induced 
disease, despite similar viral burden within target tissues (Gunn BM, Lotstein AR, and 
Heise MT, unpublished data). However, other strains of mice such as PWK/PhJ, who 
appear to have comparable levels of MBL to the C57BL/6J mice, developed mild disease, 
and suggests that levels of MBL is unlikely to be the sole determinant of disease severity 
following RRV infection. However, while these data are by no means conclusive or 
indicative of the role of lower levels of MBL protecting from disease, they suggest that 
the CC may be a useful tool to experimentally address questions relating to 
polymorphisms of MBL as well as the role of host genetics on RRV pathogenesis.  
 
The RRV E2 N-linked glycans contribute to severe RRV-induced disease through 
activation of the host complement system. 
Since MBL recognizes high mannose carbohydrates, we hypothesized that MBL 
may be recognizing the viral N-linked glycans present on the surface of infected cells. 
MBL does not bind directly to SINV or CHIKV virion particles (61), and we were unable 
to demonstrate direct interaction between either mammalian-derived or mosquito-derived 
RRV virions (79). However, since alphaviruses bud from the plasma membrane of 
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infected cells and the N-linked glycans are also present on the mature RRV glycoprotein 
spikes, we reasoned that it might be possible that MBL was recognizing the arrays of E2 
glycans on the infected cell rather than on the virion. In support of this hypothesis, RRV 
infection resulted in elevated levels of MBL within the quadriceps muscles of infected 
mice as well as onto infected cells (Figure 2.3, (79)). To determine if the E2 glycans 
regulated MBL deposition onto infected cells, we used a virus that had been genetically 
mutated to lack the E2 glycosylation sites and evaluate deposition of MBL onto infected 
cells between the E2 glycan mutant and WT virus. Consistent with our hypothesis, the E2 
glycan mutant-infected cells had reduced MBL deposition compared to WT virus as 
determined by western blot as well as by immunofluorescence despite similar levels of 
virus replication and output in both assays. These data together indicate that the E2 
glycans present on the infected cell regulate extracellular deposition of MBL onto 
infected cells.  
We next evaluated the role of the RRV N-linked glycans in RRV pathogenesis. 
Interestingly, mice infected with viruses that lacked either of the two E2 glycans showed 
reduced disease compared to WT virus; however, the single E2 glycan mutant-infected 
mice still exhibited some level of disease. In contrast, mice infected with a virus that 
lacks both of the E2 glycans E2 N200;262Q (E2 DM), exhibited dramatically reduced 
disease compared to WT mice. Further analysis of the pathology induced by RRV E2 
DM compared to RRV WT showed striking similarity to the disease induced in MBL-
DKO, C3-/-, and CR3-/- following RRV infection. Furthermore, RRV E2 DM-infected 
mice had reduced levels of MBL within the quadriceps muscle as well as reduced C3 
deposition and cleavage products compared to RRV WT-infected mice. Together, these 
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data suggest that the E2 glycans regulate MBL-dependent complement activation leading 
to disease.  
 
Glycans on infected cells versus on the virion.  
 The finding that MBL does not bind to the RRV virion particles, but does appear 
to bind to the E2 glycans on the infected cell, is intriguing in that the glycans should be 
the same on the infected cell and on the virion itself since the glycoproteins at the plasma 
membrane of the infected cell are incorporated into the virion particle. The three CRDs 
that make up each subunit of MBL are separated by a constant distance of 45Å, and thus 
require distinct spacing of carbohydrate ligands to efficiently bind and activate 
complement (211). Thus, one possible explanation for why MBL may recognize the 
infected cell rather than the virion is that the array of viral glycoproteins lying on the 
plasma membrane may provide the particular spacing and repeating array of carbohydrate 
ligands needed to efficiently bind MBL and activate complement whereas the glycans on 
the spherical virion particle may not. Structural analysis of the positions and spacing of 
the glycans on the surface of the infected cell compared to the virus would be needed to 
determine the spacing of the glycans are different between the two scenarios.  
 Recognition of the RRV N-linked glycans on the plasma membrane of the 
infected cell rather than the virion may also partially explain why MBL is pathologic in 
RRV-induced disease but protective in other virus systems. Since alphaviruses bud from 
the plasma membrane, the glycoproteins are prominently displayed on the cell surface, 
and allow for MBL deposition and complement activation directly on the infected host 
cell. Flaviviruses, such a WNV and DENV, bud from the ER and thus the glycoproteins 
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are only ever presented to MBL in virion form (136). Similarly, SARS-CoV forms 
virions within the cytoplasm of infected cells and mature virions are released by 
exocytosis (129). Thus, the interaction of flaviviruses and SARS-CoV with MBL may 
occur outside and away from host cells, and allow for complement activation and 
neutralization only on the virus. In contrast, recognition of the RRV E2 glycans on the 
infected cell by MBL may lead to complement activation on the infected cell, resulting in 
opsonization for killing and/or clearance by monocytes and macrophages.  
 
Other possible ligands that could induce MBL-dependent complement activation 
following RRV infection. 
Our work suggests that the RRV E2 N-linked glycans present on the surface of 
the infected cell act as a ligand for MBL binding and subsequent complement activation. 
However, MBL can bind to carbohydrate ligands that are not necessarily foreign in origin, 
such as N-linked glycans on receptors as well as other host proteins (223). Altered 
glycosylation of self-proteins has been demonstrated in tumor cells and in cells 
undergoing stress, leading to presentation of aberrantly glycosylated proteins on the 
surface of the cell (177, 229). Furthermore, alteration or loss of glycosyltransferase or 
glycosidase expression may lead to incomplete processing of the glycans resulting in 
hybrid or high mannose glycans on proteins being transported to the cell surface.  
Alphaviruses induce host cell transcriptional shutoff, and thus it is possible that 
any proteins undergoing glycosylation at the time of shutoff may be aberrantly 
glycosylated. Some of these proteins may include surface proteins that are still 
transported to the surface of cell and could therefore be able to interact with MBL and 
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other carbohydrate binding proteins. Thus, in addition to recognition of the RRV 
glycoproteins on the surface of the infected cell, it is possible that MBL may also 
recognize aberrantly glycosylated host cell proteins. One possible experiment to address 
this possibility would be to generate the E2 glycan mutations in the context of a virus that 
is unable to induce host transcriptional shutoff, and determine the ability of these viruses 
to induce MBL deposition onto infected cells. Gorchakov et al. described an nsP2 mutant 
of SINV that is defective in its ability to induce shutoff, and a similar mutation could be 
made in RRV (60, 75).  If the shutoff defective mutant virus with the WT glycans is still 
able to induce MBL deposition, while the mutant virus lacking the E2 glycans is not, this 
would provide strong evidence that the E2 glycans themselves are regulating MBL 
deposition onto infected cells.  
 
4.2 Future Directions 
Direct interaction between E2 glycans and MBL 
We have developed two assays to determine if the E2 glycans contribute to MBL 
deposition on the surface of infected cells: western blot analysis of levels of MBL present 
with skeletal muscle cultures infected with either RRV WT or RRV E2 DM, as well as a 
visual analysis by immunofluorescence assay. In these assays, MBL is added 
exogenously to infected cells for 30 minutes to mimic in vivo conditions where MBL 
would interact with extracellular components of infected cells. Results from both assays 
indicate that the E2 glycans contribute to MBL deposition onto infected cells, despite 
similar levels of viral replication and/or viral antigen (Figures 3.1-3.3).  
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While these results indicate the E2 glycans regulate MBL deposition onto infected 
cells, we have not demonstrated a direct interaction between the RRV E2 glycans on the 
surface of the infected cell and MBL. Several additional experiments may be able to help 
determine if there is direct interaction between the glycans and MBL. Co-
immunoprecipitation of the E2 glycoproteins and MBL from cells infected with either 
RRV WT or RRV E2 DM and incubated with exogenously added MBL would determine 
if a direct interaction between the RRV glycoproteins and MBL is dependent on the E2 
glycans in the context of the infection.  
Another approach would be to express either the WT or E2 DM glycoproteins 
from a plasmid and determine MBL deposition in the same assays described above. The 
advantage of this approach would be that the assay evaluates the contribution of the 
glycoproteins alone rather than in the context of viral infection. If MBL deposition occurs 
only onto the cells expressing the WT glycoproteins and not onto the cells expressing the 
E2 DM glycoproteins, it would suggest that the E2 glycans are indeed regulating MBL 
deposition onto the surface of cells. However, it is currently unclear if stable expression 
of the glycoproteins and maintenance of the mature glycoprotein spikes on the plasma 
membrane is feasible. An early study of SFV budding demonstrated that the 
glycoproteins at the plasma membrane do not accumulate in the absence of nucleocapsid 
interactions (256), and if this is the case, negative results would be difficult to interpret, 
since no binding of MBL to even WT glycoproteins could mean either that MBL binds to 
something else on the infected cell, or that the glycoproteins are not being maintained at 
the plasma membrane. IFA staining of unpermeabilized transfected cells for the RRV 
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structural proteins may be able to help determine if the glycoproteins are present on the 
surface of the cell.  
 
MBL crosstalk with toll-like receptor pathways 
The complement system has been recently shown to be involved in crosstalk with 
other innate immune pathways such as the toll-like receptor (TLR) family of receptors 
(82). MBL in particular appears to play a role in modulating signaling from various 
receptors. MBL bound to S. aureus bacteria enhanced signaling by TLR2 and TLR6 to 
generate a specific and robust response to S. aureus infection (108). MBL has also been 
reported to bind to TLR4 through the N-linked glycans on the receptor (212), and one 
study suggests that MBL binding to TLR4 can suppress LPS-induced pro-inflammatory 
responses (239). Intriguingly, TLR4 has a role in mediating RRV-induced disease 
(Neighbours L.M., Long K.M., and Heise M.T., unpublished data), thus it will be 
interesting to determine if MBL-TLR4 interactions contribute to RRV-induced disease.  
 
Role of the complement system in pathogenesis of other arthritic alphaviruses.  
The complement system appears to contribute to protection from encephalitic 
alphavirus infection yet enhances pathology following RRV infection (24, 79, 97, 98). 
However, the role of complement in the pathogenesis other arthritic alphaviruses, such as 
CHIKV, is currently unknown. Preliminary studies analyzing levels of circulating MBL 
in the serum of human CHIKV patients show elevated levels of MBL compared to 
uninfected healthy controls (Herrero, L. and Mahalingham, S., unpublished data). While 
additional studies in both mice and humans are needed to determine if there is a role for 
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MBL and complement in CHIKV pathogenesis, this preliminary data indicating that 
elevated levels of MBL are associated with CHIKV-associated polyarthritis suggest that 
MBL may play a role in other arthritic alphavirus infections.   
Based on the results of the studies of this dissertation indicating a role for the 
RRV E2 glycans in mediating disease, similar mutations in the E2 glycans were 
generated in CHIKV in order to evaluate their potential role in CHIKV pathogenesis. 
Interestingly, the CHIKV mutant virus that lacks both of the E2 glycans (E2 N263; 
345Q) induces a mild disease compared to CHIKV WT in mice, suggesting that the E2 
glycans modulate CHIKV pathogenesis (McGee, C.E. and Heise, M.T., unpublished 
data). Whether the CHIKV E2 glycans regulate complement activation similar to the 
RRV E2 glycans remains to be seen; however this data highlights the importance of the 
viral N-linked glycans in arthritic alphavirus pathogenesis.  
 
4.3 Conclusions and working model 
 The work described in this dissertation has identified critical pathologic roles for 
the host innate immune protein mannose binding lectin and the viral N-linked glycans in 
RRV pathogenesis. In this model, the E2 N-linked glycans on the surface of the infected 
cell induce MBL-dependent complement activation leading to development of RRV-
induced disease. In addition to advancing our understanding of the molecular 
mechanisms that regulate RRV pathogenesis and identifying potential therapeutic targets, 
we have described novel pathologic roles for both MBL and viral N-linked glycans in 
viral pathogenesis.  
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Our current working model of how the interaction between the viral N-linked 
glycans and MBL contributes to RRV-induced disease is outlined in Figure 4.2 and is 
discussed below. As RRV replicates in host cells and tissues, the glycosylated envelope 
glycoproteins are expressed on the plasma membrane of the infected cell. Circulating 
MBL in the serum recognizes and binds to the E2 N-linked glycans that are present on 
the surface of infected cells to activate the complement cascade. Activation of 
complement produces the iC3b cleavage product that serves as a ligand to activate 
infiltrating inflammatory cells through CR3. Activation through CR3 initiates pro-
inflammatory signaling that ultimately results in production of effector molecules and 
proteins that damage and kill iC3b-opsonized cells and tissues, resulting in the 
immunopathology that causes clinical disease.  
Finally, arthritic alphaviruses are an important cause of infectious arthritis in 
many areas around the world, and have the potential to cause explosive epidemics of 
debilitating disease in millions of people. The work presented here advances our 
understanding of the mechanisms that contribute to development of RRV-induced disease, 
and suggest that targeting of MBL and the host complement system may be an effective 
therapeutic target for treatment of RRV and other arthritic alphaviruses.  
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Figure 4.1:  MBL levels vary between Collaborative Cross founder strains.  
To determine if baseline MBL levels varies between the founder mouse lines of the 
Collaborative Cross, western blot analysis using anti-mouse MBL-C antibodies was 
performed on equal volumes of serum from naïve male (M) and female (F) mice from 
each founder line.  
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Figure 4.2: Current model of how viral N-linked glycans and MBL contribute to 
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Figure 4.2: Current model of how viral N-linked glycans and MBL contribute to 
RRV-induced disease.   
As RRV replicates in host cells and tissues, the glycosylated envelope glycoproteins are 
expressed on the plasma membrane of the infected cell (Step 1). Circulating MBL in the 
serum recognizes and binds to the E2 N-linked glycans present on the surface of infected 
cells to activate the complement system (Steps 2-3). Activation of complement produces 
the iC3b cleavage product that serves as a ligand to activate infiltrating inflammatory 
cells through CR3 (Step 3-4). Activation of the cells, indicated by lightening bolts, 
through CR3 initiates pro-inflammatory signaling that ultimately results in production of 
effector molecules and proteins that damage and kill iC3b-opsonized cells and tissues, 
resulting in the immunopathology that causes clinical disease (Step 5). Figure adapted 
from Li et al. with permission from Nature Publishing Group (133).   
APPENDIX: 
 
MECHANISMS OF TYPE I IFN INDUCTION IN MYELOID DENDRITIC 
CELLS BY MAMMALIAN CELL-DERIVED ROSS RIVER VIRUS.  	  
A1.1 Introduction 
 Arthritic alphaviruses such as Ross River virus and chikungunya viruses are 
mosquito borne viruses that cause explosive epidemics of infectious arthritis in many 
areas around the world. These viruses are transmitted to humans by a mosquito vector 
and thus the virus is capable of infecting and replicating in both vertebrate and mosquito 
cells. The viruses that emerge from each of these different hosts have properties of the 
host cell, and one major difference between vertebrate and invertebrate cells is the 
glycosylation of proteins. As discussed in the introduction of this dissertation, asparagine 
(N)-linked glycosylation of viral proteins varies between mosquito and mammalian cells 
due to the lack of certain glycosidases in mosquito cells. Mosquito and other invertebrate 
cells produce high mannose glycans with mannose as the terminal residue, whereas 
vertebrate cells typically glycosylate proteins with complex or hybrid glycans, which 
have terminal sialic acid (215).  
Early induction of type I interferon (IFN) is important for control of alphavirus 
replication (reviewed in (196)), and one of the major immune cell types capable of 
secreting large amounts of IFN is the dendritic cell (DC) population. DCs in the skin, 
such as Langerhan cells, are thought to be some of the first cells that come into contact 
with alphaviruses following infection by an infected mosquito (141). Prior studies 
demonstrated that mammalian cell-derived alphaviruses induce robust amounts of type I 
IFN from myeloid dendritic cells whereas mosquito cell-derived alphaviruses fail to 	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induce much IFN at all (209). The failure to induce IFN from dendritic cells by the 
mosquito-derived virus was independent of viral replication, and did not appear to occur 
through active suppression of type I IFN induction (209, 210). Rather, the mosquito-
derived virus simply failed to activate IFN induction, whereas the mammalian-derived 
virus did. Additional studies indicated that the N-linked glycans on the mammalian-
derived virus glycoproteins mediate IFN induction from mDCs (210). In particular, the 
two E2 N-linked glycans (E2 N200, N262) together were required for IFN production 
from mDCs. Analysis of the types of glycans that are typically glycosylated at the two 
sites revealed that the glycan at E2 N200 is typically a high mannose glycan, whereas the 
E2 N262 is predominantly a complex or hybrid glycan when produced in a mammalian 
cell (210). Together, this data suggests that the combination of the high mannose glycan 
and the complex glycan together induced IFN from mDCs. However, the mechanism by 
which the viral glycans induce type I IFN is unclear.  
 There are several classes of innate immune receptors that are present on DCs that 
mediate type I IFN production from DCs: the toll-like receptors (TLRs), C-type lectin 
receptors (CLRs), and the RIG-I like receptors (RLRs). These receptors are present either 
on the plasma membrane, within the endosome, or cytoplasmic and are involved in 
pathogen sensing. TLRs are present on the cell membrane as well as in the endosomes 
and engage a diverse set of bacterial, viral, and fungal ligands to induce the type I IFN 
system and NF-kB signaling pathways that initiate pro-inflammatory programs (reviewed 
in REF). While the list of ligands for the various TLRs is constantly growing, it is clear 
that some of the TLRs are activated by carbohydrate ligands. Viral glycoproteins from 
	   174	  
several different viruses such as respiratory syncytial virus, measles, and human 
cytomegalovirus have been shown to activate TLR2 or TLR4 (15, 16, 36, 127).  
CLRs are an emerging class of innate immune receptors that are typically found 
on the plasma membrane of immune cells and specifically recognize carbohydrate 
structures.  DC-SIGN, CLEC5A, CLEC4A (DCIR) have been shown to interact with 
arboviruses, both flaviviruses and alphaviruses, to modulate pathogenesis (Long, K.M., 
and Heise M.T. manuscript under revision, (30, 31, 120)). Signaling from these receptors 
results in production of cytokines that regulate adaptive immunity (71). In addition, 
activation of certain CLRs leads to modulation of signaling pathways induced by other 
PRRs, such as TLRs (reviewed in (71)).  
RLRs are cytoplasmic sensors that recognize nucleic acid within the cytoplasm 
and are required for type I IFN induction in response to many different viruses (reviewed 
in (139)). While RLRs do not directly recognize carbohydrate and protein structures, 
there is increasing evidence that the there is crosstalk between the RLRs and other PRR 
signaling pathways (179), and thus RLRs may play a secondary role in induction of type I 
IFN as a result of activation through other pathways.  
 In this study, we wanted to identify potential host sensors that recognized the viral 
N-linked glycans, leading to the production of type I IFN from mDCs. Given the 
localization and ligand specificity of the TLRs and CLRs, we hypothesized that these 
families of receptors may be recognizing the N-linked glycans on mammalian derived 
RRV. To determine if any of these sensors had a role in type I IFN induction, we took 
advantage of the availability of mice that are genetically deficient in the several different 
receptors: TLR2, TLR4, MyD88, DC-SIGN, and SIGN-R3. We derived mDCs from 
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these various mouse lines, and infected them with mammalian derived RRV and analyzed 
type I IFN production in the culture supernatant. However, we have not yet identified any 
particular receptor that mediates type I IFN production from mDCs in response to RRV 
infection.  
 
A1.2 Materials and Methods 
Viruses and cells. The viral stocks used in this study were generated from the infectious 
clone of the T48 strain of RRV (pRR64), kindly provided by Richard Kuhn (Purdue 
University) as described in (161). Briefly, viral RNA was generated through in vitro 
transcription of SacI-linearized pRR64 using the mMessage mMachine SP6 kit (Ambion) 
and electroportated into mammalian BHK-21 cells (ATCC). Viral titer was determined 
by plaque assay on BHK-21 cells.  BHK-21 cells were grown in α-MEM (Gibco) 
supplemented with 10% donor calf serum (DCS), 10% tryptose phosphate, L-glutamine, 
penicillin, and streptomycin. C6/36 mosquito cells were grown in. L929 cells were grown 
in α-MEM (Gibco) supplemented with 10% donor calf serum (DCS), 10% tryptose 
phosphate, L-glutamine, penicillin, and streptomycin.  
 
Generation of bone marrow derived dendritic cells (BMDCs). To generate BMDCs, 
bone marrow was extracted from the femurs and tibias of 8-10 week old mice, and 
cultured in low cluster 6-well plates in RPMI-10 (RPMI-1640 with 10% FBS, L-
glutamine, b-mercaptoethanol, gentamicin, and penicillin, and streptomycin). To 
differentiate cells into BMDCs, cells were incubated in varying concentrations of GM-
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CSF and IL-4 for 7 days as described in (209). Cells were either cryo-preserved or used 
immediately for experiments.  
 
Infection of BMDC with RRV. BMDCs were plated at a density of 6 x 105 cells/well in 
RPMI-10 with GM-CSF and IL-4. Cells were infected either with diluent alone (mock) or 
with mammalian-derived RRV (mam-RRV) at an MOI of 10 or 20 for 2 hours in a 600µl 
volume. An addition 400µl of RPMI-10 with GM-CSF and IL-4 was added, and cells 
were incubated an additional 10 or 22 hours at 37C 5% CO2. At indicated time points (12 
hpi or 24 hpi), culture supernatant was harvested by pelleting cells at 13000 RPM for 5 
minutes, and transferring supernatant to a sterile eppendorf tube and stored at -80C until 
ready to assay.  
 
Inhibition of endocytosis using dynasore. To inhibit endocytosis, differentiated 
BMDCs were incubated in RPMI-10 with GM-CSF and IL-4 containing either 80 µM of 
dynasore (Sigma Aldrich, St. Louis, MO) or DMSO vehicle for 30 minutes prior to 
infection with virus, and were maintained in the inhibitor following infection.  
 
Type I IFN bioassay. Interferon bioassay was used to determine amounts of type I IFN 
as described in (209). Briefly, culture supernatants and interferon standards (NIH) were 
acidified to pH<2 with HCl overnight, and pH brought back to a neutral pH of 7-8 by 
NaOH. Samples were then UV-treated for 10 minutes to inactivate any residual virus. 
Samples were titrated by two-fold serial dilution onto L929 cells seeded in 96 well plates 
at a density of 8 x 103 cells/well, and incubated overnight. Following overnight 
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incubation, cells were challenged with EMCV at an MOI of 5 for 24 hours. Cell viability 
was determined by incubation in 6mg/ml of MTT (Sigma) for 3 hours. Residual MTT 
was removed, and the cells were dissolved in 0.4M HCl in isopropanol, and the 
absorbance 570nm of each well was measured on a microplate reader. To determine total 
amounts of IFN in each well, the well number at which had 50% cell viability was 
compared to the IFN standard and converted to international units (IU/ml).   
 
Analysis of percent infection of BMDCs by RRV. Differentiated BMDCs were infected 
as above with either diluent, mam-RRVgfp or mos-RRVgfp at MOI 10. At 12 hpi, cells 
were harvested by pelleting and were fixed in 2% PFA overnight. Cells were analyzed for 
GFP expression on a CyAn flow cytometer (Becton Dickinson), and data was analyzed 
using Summit software.  
 
Statistical analyses. Amounts of type I IFN production were analyzed for statistically 
significant differences by one-way ANOVA or students two tailed t-test between the 
various knockout lines and treatments (p<0.05 is considered significant). Statistical 
analyses were performed using GraphPad Prism 5.  
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A1.3 Results 
Endocytosis of virus is required for type I IFN induction from BMDCs following mam-
RRV infection.  
Active viral replication by mammalian derived RRV was not required for 
induction of type I IFN from mDCs (209), suggesting that a cellular receptor is being 
activated during the entry stage of viral infection. This implies that the virus is interacting 
with the receptor during receptor binding and entry or during the internalization and 
fusion step. Both TLR2 and TLR4 are located at the plasma membrane as well as in the 
endosome and phagosome, where as CLRs are typically found at the plasma membrane. 
Furthermore, signaling through activation of RLRs required viral entry and release of 
viral RNA into the cytoplasm. To determine if type I IFN induction by mam-RRV 
required viral entry into the cell, we used a pharmacological inhibitor of dynamin, 
dynasore, to block clathrin-mediated endocytosis and entry of virus into the cell (142). 
Murine BMDCs were incubated in either 80µM of dynasore or DMSO vehicle prior to 
infection with mam-RRV, and type I IFN production was measured by type I IFN 
bioassay at 12 hpi. As shown in Figure A1.1, we observed a significant decrease in the 
amount of type I IFN production in cells treated with dynasore compared to vehicle 
treatment, indicating that endocytosis and/or viral entry is required for IFN induction 
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TLR2 and TLR4 do not contribute to type I IFN induction from mDCs in response to 
mam-RRV.  
 Given that TLR2 and TLR4 can recognize to viral glycoproteins to initiate pro-
inflammatory signaling as well as type I IFN production, we generated BMDCs from 
mice genetically deficient in either TLR2 or TLR4. To determine if either of the receptors 
mediated type I IFN induction from mDCs following mam-RRV infection, we infected 
either WT, TLR2-/- or TLR4-/- BMDCs with mam-RRV and measured type I IFN 
production at 12 hpi by type I IFN bioassay. Consistent with previous studies, mamRRV 
induced robust amounts of type I IFN from WT BMDCs (Figure A1.2). However, the 
induction of type I IFN was not dependent on either TLR2 or TLR4 as both TLR2-/- and 
TLR4-/- BMDCs produced comparable amounts of IFN to WT BMDCs (Figure A1.2).  
 While the results above indicated that neither TLR2 or TLR4 were required for 
IFN induction from mam-RRV infected BMDCs, it is possible that both receptors are 
capable of recognizing the N-linked glycans, and thus could compensate for each other.  
Multiple TLRs, including TLR2 and TLR4, signal through the adaptor protein MyD88, 
and thus we evaluated the production of type I IFN by mam-RRV in MyD88-/- BMDCs. 
As shown in Figure A1.2, MyD88-/- and WT BMDCs induced equivalent amounts of type 
I IFN following mam-RRV infection, suggesting that TLR signaling through MyD88 
does not contribute to type I IFN induction in BMDCs. In addition to ruling out the role 
for TLR2 in IFN induction following mam-RRV infection, the use of MyD88-/- BMDCs 
also ruled out possible roles for TLR7, TLR9, TLR5, and TLR6 in mediating IFN 
induction by mam-RRV, since those receptors signal exclusively through MyD88 (117). 
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DC-SIGN and SIGN-R3 are not required for type I IFN induction from BMDCs following 
mam-RRV infection.  
 Type I IFN induction from mamRRV-infected BMDCs appears to require 
endocytosis and/or viral entry, yet neither TLR2 nor TLR4 mediated IFN induction 
following mamRRV infection, we next evaluated the role of CLRs in type I IFN 
induction. The CLRs DC-SIGN and SIGN-R3 can recognize and bind to high mannose 
glycans, and DC-SIGN has been reported to be an attachment factor for mosquito-derived 
alphaviruses that aids in viral entry into DCs (66, 71, 120). Thus, we hypothesized that 
DC-SIGN or SIGN-R3 mediated type IFN induction from BMDCs following mamRRV 
infection. To test this, we generated BMDCs from WT, DC-SIGN-/-, or SIGN-R3-/- mice, 
and measured type I IFN induction following mam-RRV infection. As shown in Figure 
A1.3A, we did not observe any difference in type I IFN induction between WT, DC-
SIGN-/- or SIGN-R3-/-, suggesting that these receptors do not mediate IFN induction 
following mamRRV infection.  
Mosquito cell-derived RRV infects BMDCs at a much higher efficiency than 
mammalian-cell derived RRV (209), and Klimstra et al. demonstrated that DC-SIGN and 
L-SIGN can act as dendritic cell attachment factors for mosquito cell-derived SINV (120). 
Therefore, we hypothesized that DC-SIGN might mediate efficient entry of mosRRV into 
BMDCs. To test this, we infected WT or DC-SIGN-/- BMDCs with a GFP-expressing 
mosRRV and determined percentage of viral infection by flow cytometry. Consistent 
with prior studies, we observed a significant increase in the number of cells infected with 
mosRRV compared to mamRRV in both the WT and DC-SIGN-/- BMDCs (Figure 
A1.2B). However, we did not observe any difference in the numbers of cells infected 
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with mos-RRV between WT and DC-SIGN-/- BMDCs, suggesting that DC-SIGN does 
not mediate efficient entry of mos-RRV into BMDCs (Figure A1.3B).   
 
A1.4 Discussion and Future Directions 
 Early induction of type I IFN is critical in the control of alphavirus infection. 
Interestingly, mosquito and mammalian cell-derived RRV differentially induce type I 
IFN from myloid dendritic cells, and in particular, the RRV N-linked glycans on 
mammalian cell-derived RRV appear to be responsible for the differential type I IFN 
induction (209, 210). The mechanisms and/or host sensors that drive N-linked glycan 
mediated type I IFN induction are currently unknown. Innate immune pattern recognition 
receptors such as TLRs and CLRs can recognize carbohydrate structures on pathogens to 
activate host immune pathways. In this study we evaluated the role of these receptors in 
mediating type I IFN induction from BMDCs following infection with mam-RRV.  
 Prior studies indicated that viral replication was not necessarily required for IFN 
induction from mDCs (209), and suggests that the receptor involved in N-linked glycan 
recognition was either at the plasma membrane or located within endosomes. To 
distinguish between these two possibilities we used dynasore, which is an inhibitor of 
dynamin and clathrin mediated endocytosis. Our results indicated that endocytosis was 
required for IFN induction from mDCs following RRV infection. Both TLR2 and TLR4, 
which have been shown to recognize viral glycoproteins, can signal from the endosome 
and phagosomes (12). Therefore, we evaluated the role of TLR2 and TLR4 in type I IFN 
induction from mDCs. Surprisingly, neither receptor was required for type I IFN 
induction following mamRRV infection. Similar results were found with MyD88-/- mDCs, 
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suggesting that the MyD88-dependent TLRs do not mediate type I IFN from mDCs, 
definitively ruling out TLR2. While TLR4 signals through MyD88 at the plasma 
membrane, MyD88-independent TLR4 signaling can occur through the adaptor TRIF in 
the phagosome to mediate type I IFN induction (12, 252). We did not evaluate the role of 
TRIF-dependent TLRs in mediating type I IFN from mDCs in this study and needs to be 
tested, but our results with TLR4-/- BMDCs suggests that TLR4, regardless of whether it 
is at the plasma membrane or within phagosomes or endosomes, does not mediate N-
linked glycan dependent type I IFN induction.  
 Since CLRs recognize glycan structures and the CLR DC-SIGN has been shown 
to interact with SINV, we next evaluated the role of DC-SIGN and one of its homologues 
SIGN-R3 in type I IFN from mDCs (120). However, neither DC-SIGN nor SIGN-R3 
mediated type I IFN induction (Figure A1.3A). Furthermore, while DC-SIGN has been 
reported to be an attachment factor that enhances mosquito-derived SINV entry into DCs 
(120), DC-SIGN was not required for mos-RRV entry into DCs (Figure A1.3B). There 
are five mouse homologues to the human DC-SIGN (mouse DC-SIGN, SIGN-R1, SIGN-
R2, SIGN-R3, and SIGN-R4) and while the SIGN-R3 is thought to be the one most 
closely related in carbohydrate binding specificity to the human DC-SIGN (169, 176), it 
is possible that one of the other DC-SIGN homologues can compensate in the absence of 
DC-SIGN in mouse cells and may partially explain our results.  
 RLRs such as RIG-I and MDA-5 contribute to type I IFN induction by 
alphaviruses (Cruz, CC and Heise MT unpublished data, (246, 248)) in fibroblasts. While 
RLRs are activated by RNA ligands and are unlikely to be directly activated by N-linked 
glycans on mamRRV, there is increasing evidence of cross-talk between RLRs and other 
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PRR families such as the NOD-like receptors, who can cross-talk with TLRs (179). 
Given that type I IFN from mDCs by mam-RRV required endocytosis, but not active 
viral replication, it is possible that RLRs may mediate some aspect of type I IFN 
induction by the N-linked glycans through cross talk with another PRR that does engage 
carbohydrates. In this scenario, a two-step induction process is required for type I IFN 
production: initial detection of viral N-linked glycans on incoming viruses by a CLR or 
TLR, subsequent recognition of viral RNA by the RLR, and synergy between the two 
pathways to produce robust amounts of type I IFN. We have not directly evaluated the 
role of IPS-1 or any of the RLRs in this study, and those experiments will need to be 
performed to determine the role of RLRs in mediating type I IFN production in mDCs 
following mam-RRV infection. Additional studies using BMDCs from mice deficient in 
both IPS-1 and various TLRs/CLRs may be useful in determining if there is synergy or 




In this study we have evaluated the role of several of the most likely innate 
immune receptors capable of recognizing viral glycoproteins in mediating type I IFN 
production from mDCs by the N-linked glycans on mamRRV. This has not been an 
exhaustive study by any means, and there are many more candidate receptors that may 
mediate IFN production from mDCs in response to mamRRV. In particular, other CLRs 
are attractive candidates to evaluate for their role in IFN production as well as a potential 
role in viral pathogenesis. For example, Langerin (CLEC4K), which is present on dermal 
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DCs called Langerhan cells that are in the skin, is an attractive candidate because of 
Langerhan cells are likely to be among the first cells to come into contact with mosRRV. 
Other receptors such as CLEC5A and CLEC4A (DCIR) have been shown to either 
interact with arboviruses or play a critical role in inflammatory diseases similar to 
alphavirus-induced arthritic diseases (30, 31, 114).  
Rather than generating BMDCs from mice deficient in all of the different CLRs to 
evaluate their role in IFN induction, an alternative approach to determining if there is a 
role for any given CLR in IFN induction is to first determine if RRV interacts directly 
with candidate CLRs. Chen et al. have described a method to determine direct interaction 
between the carbohydrate recognition domains (CRDs) of various CLRs and viruses 
through expression of the CLR CRD fused to the Fc region of a human IgG and then 
performing an ELISA to determine if the virus bound to the CRD (30). We have taken a 
similar approach and generated constructs containing the CRDs of the CLRs outlined in 
Table A1.1. To produce the CLR.Fc fusion proteins, we transfected the constructs into 
HEK293T cells, and collected the supernatant 72 hours post transfection, and 
subsequently purified the CLR.Fc using a protein G column. The ELISA assay is 
currently undergoing optimization, and thus we do not have any interaction data so far; 
however, this panel of CLR.Fc fusion proteins provides us with a set of reagents to 
explore the roles of CLRs in alphavirus pathogenesis.  
 
In summary, interactions between viral N-linked glycans and the innate immune 
system is an emerging field of study, and there is mounting evidence that these 
interactions play a critical role in modulating the host immune response and viral 
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pathogenesis. Dissecting these interactions by first identifying the host innate immune 
sensors involved in recognition and signaling will help further our understanding of how 
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Figure A1.1: Endocytosis of virus is required for type I IFN induction from BMDCs 






Figure A1.1 Endocytosis of virus is required for type I IFN induction from BMDCs 
following mamRRV infection.  
To determine if endocytosis was required for induction of type I IFN from mam-RRV, 
murine C57BL/6 BMDCs were incubated in 80µM dynasore (solid bars) or DMSO 
vehicle (open bars) and then either mock infected or infected with mam-RRV for 12 
hours.  Amounts of type I IFN in the culture supernatant at 12 hpi were determined by 
type I IFN bioassay on L929 cells. The bar represents the arithmetic mean ± SD of 
triplicate wells and is representative of at least two independent experiments.  
***p<0.0001 by students t-test.  
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Figure A1.2: TLR2 and TLR4 do not contribute to type I IFN induction from mDCs 








Figure A1.2 TLR2 and TLR4 do not contribute to type I IFN induction from mDCs 
in response to mam-RRV.  
BMDCs derived from C57BL/6 WT (black bar), TLR2-/- (open bar), TLR4-/- (light grey 
bar), or MyD88-/- (dark grey bar) were infected with mam-RRV at MOI 20. Amounts of 
type I IFN in the culture supernatant at 12 hpi were determined by type I IFN bioassay on 
L929 cells. n.s. by one-way ANOVA analysis with Bonferroni’s muliple comparisons 
post-test. The bar represents the arithmetic mean ± SD of triplicate wells, and is 
representative of two independent experiments.  
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Figure A1.3: DC-SIGN and SIGN-R3 are not required for type I IFN induction 
from BMDCs following mamRRV infection.  
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Figure A1.3: DC-SIGN and SIGN-R3 are not required for type I IFN induction 
from BMDCs following mamRRV infection.  
(A) BMDCs from C57BL/6 WT (black bar), DC-SIGN-/- (blue bar), or SIGN-R3-/- 
(grey bar) were infected with mam-RRV at MOI 20. Amounts of type I IFN in the 
culture supernatant at 24 hpi were determined by interferon bioassay on L929 cells. 
The bar represents the arithmetic mean ± SD of triplicate wells. 
(B) BMDCs from C57BL/6 WT, DC-SIGN-/-, or SIGN-R3-/- were infected with 
diluent alone (mock; open bar), mam-RRVgfp (light blue bar) or mos-RRVgfp 
(dark blue bar) at MOI 10. Percent GFP+ cells were determined by flow cytometry. 
The bar represents the arithmetic mean ± SD of triplicate wells.  
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Table A1.1: CLR.Fc fusion constructs.  
C-type Lectin receptor Function Ref. 
CLEC5A/MDL-1 Pro-inflammatory cytokine induction; 
expressed on monocytes/macrophages; roles 
in DENV and JEV pathogenesis, 
inflammatory arthritis 
 
(30, 31, 114) 
CLEC4A/DCIR ITIM containing CLR; expressed on DCs; 
role in CHIKV pathogenesis 





CLEC4E/Mincle Pro-inflammatory cytokine induction; 
expressed on neutrophils and macrophages 
 
(253) 
DC-SIGN Expressed on DCs, macrophages; attachment 
factor for SINV, HIV, DENV 
 
(72, 120, 224) 
CLEC4M/L-SIGN Expressed on endothelial cells; attachment 
factor for SINV 
 
(120) 




CLEC4D/MCL Expressed on monocytes/macrophages; pro-
inflammatory cytokine production 
 
(77) 




DCAR ITAM containing CLR; pro-inflammatory 
cytokine induction; pairs with DCIR 
(115, 116) 
 
Table A1.1 CLR.Fc fusions constructs.  
Initial panel of CLRs that we will evaluate for potential interaction with alphaviruses.  
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